	
The	O
psychiatric	B
symptoms	I
in	O
the	O
vast	O
majority	O
of	O
patients	O
in	O
both	O
controlled	O
and	O
open-label	O
trials	O
resolved	O
within	O
7	O
days	O
of	O
discontinuation	O
of	O
POTIGA	O
.	O
	
Chickenpox	B
and	O
measles	B
,	O
for	O
example	O
,	O
can	O
have	O
a	O
more	O
serious	O
or	O
even	O
fatal	B
course	O
in	O
susceptible	O
children	O
or	O
adults	O
using	O
corticosteroids	O
.	O
	
The	O
risk	O
of	O
thromboembolic	B
disease	I
due	O
to	O
oral	O
contraceptives	O
gradually	O
disappears	O
after	O
COC	O
use	O
is	O
discontinued	O
.	O
	
b	O
includes	O
neuropathy	B
peripheral	I
,	O
neuropathy	B
,	O
peripheral	B
motor	I
neuropathy	I
,	O
polyneuropathy	B
,	O
peripheral	B
sensoryneuropathy	I
,	O
and	O
paraesthesia	B
.	O
	
Grade	O
3-4	O
cardiac	B
failure	I
occurred	O
in	O
1.6	O
%	O
of	O
patients	O
taking	O
ZYTIGA	O
and	O
led	O
to	O
5	O
treatment	O
discontinuations	O
and	O
2	O
deaths	B
.	O
	
Monitor	O
liver	O
laboratory	O
tests	O
at	O
least	O
monthly	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
for	O
MTC	O
with	O
the	O
use	O
of	O
TRULICITY	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g	O
.	O
	
The	O
effect	O
that	O
symptomatic	O
suppression	O
has	O
upon	O
the	O
long-term	O
course	O
of	O
the	O
syndrome	O
is	O
unknown	O
.	O
	
In	O
addition	O
,	O
beta-agonists	O
have	O
been	O
reported	O
to	O
produce	O
electrocardiographic	B
changes	I
,	O
such	O
as	O
flattening	B
of	I
the	I
T	I
wave	I
,	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
and	O
ST	B
segment	I
depression	I
,	O
although	O
the	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O
	
Samples	O
from	O
6	O
patients	O
with	O
confirmed	O
binding	O
activity	O
to	O
the	O
modified	O
cytotoxic	O
T-lymphocyte-associated	O
antigen	O
4	O
(	O
CTLA-4	O
)	O
region	O
of	O
the	O
belatacept	O
molecule	O
were	O
assessed	O
by	O
an	O
in	O
vitro	O
bioassay	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
Consider	O
other	O
antidiabetic	O
therapies	O
in	O
patients	O
with	O
history	O
of	O
pancreatitis	O
(	O
5.2	O
)	O
.	O
	
Because	O
FANAPT	O
was	O
not	O
marketed	O
at	O
the	O
time	O
these	O
studies	O
were	O
performed	O
,	O
it	O
is	O
not	O
known	O
if	O
FANAPT	O
is	O
associated	O
with	O
this	O
increased	O
risk	O
.	O
	
TRULICITY	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
gastrointestinal	O
disease	O
,	O
including	O
severe	O
gastroparesis	O
,	O
and	O
is	O
therefore	O
not	O
recommended	O
in	O
these	O
patients	O
.	O
	
Hemorrhage	B
:	O
Severe	O
,	O
sometimes	O
fatal	B
,	O
hemorrhage	B
including	O
hemoptysis	B
and	O
gastrointestinal	B
hemorrhage	I
occurred	O
in	O
3	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Tendon	B
rupture	I
or	O
serious	O
injury	B
to	I
the	I
injected	I
finger	I
:	O
Avoid	O
injecting	O
XIAFLEX	O
into	O
tendons	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
or	O
other	O
collagen-containing	O
structure	O
of	O
the	O
hand	O
.	O
	
The	O
most	O
frequent	O
reactions	O
were	O
hypotension	B
and	O
hypertension	B
.	O
	
Sinus	B
tachycardia	I
was	O
reported	O
in	O
3.0	O
%	O
,	O
2.8	O
%	O
,	O
and	O
5.6	O
%	O
of	O
patient	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
elevations	B
in	I
triglycerides	I
>	O
=200	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
13.2	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
10.5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Restart	O
treatment	O
based	O
on	O
ANC	O
and	O
platelet	O
count	O
recovery	O
.	O
	
5.4	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
with	O
Insulin	O
and	O
Insulin	O
Secretagogues	O
Insulin	O
and	O
insulin	O
secretagogues	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
Vimizim	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Monitor	O
patients	O
with	O
skin	O
reactions	O
closely	O
.	O
	
Genital	O
Mycotic	O
Infections	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
clinical	O
trials	O
,	O
female	B
genital	I
mycotic	I
infections	I
(	O
e.g.	O
,	O
vulvovaginal	B
mycotic	I
infection	I
,	O
vulvovaginal	B
candidiasis	I
,	O
and	O
vulvovaginitis	B
)	O
occurred	O
in	O
3.2	O
%	O
,	O
10.4	O
%	O
,	O
and	O
11.4	O
%	O
of	O
females	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
*	O
140	O
patients	O
with	O
advanced	O
phase	O
CML	O
including	O
76	O
patients	O
with	O
AP	O
CML	O
and	O
64	O
patients	O
with	O
BP	O
CML	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
from	O
the	O
short-term	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
*	O
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
DOTAREM	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
safety	O
of	O
conjugated	O
estrogens/bazedoxifene	O
was	O
evaluated	O
in	O
four	O
Phase	O
3	O
clinical	O
trials	O
ranging	O
from	O
12	O
weeks	O
to	O
24	O
months	O
in	O
duration	O
and	O
enrolling	O
6,210	O
postmenopausal	O
women	O
age	O
40	O
to	O
75	O
years	O
(	O
mean	O
age	O
55	O
years	O
)	O
.	O
	
Of	O
the	O
patients	O
in	O
those	O
trials	O
,	O
95	O
%	O
were	O
between	O
18	O
and	O
65	O
years	O
old	O
;	O
48	O
%	O
were	O
male	O
,	O
and	O
84	O
%	O
were	O
Caucasian	O
.	O
	
Other	O
adverse	O
reactions	O
reported	O
included	O
rash	B
,	O
nausea	B
,	O
and	O
headache	B
in	O
patients	O
exposed	O
to	O
FIRAZYR	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
2	O
times	O
the	O
rate	O
of	O
placebo	O
)	O
in	O
these	O
trials	O
for	O
the	O
600	O
mg	O
dose	O
of	O
HORIZANT	O
were	O
somnolence/sedation	O
and	O
dizziness	B
(	O
see	O
Table	O
4	O
)	O
.	O
	
Laboratory	O
abnormalities	O
are	O
described	O
separately	O
in	O
Table	O
9	O
.	O
	
(	O
5.1	O
)	O
*	O
Administer	O
a	O
thyroid-blocking	O
agent	O
before	O
DaTscan	O
administration	O
.	O
	
5.5	O
Beta-Blocker	O
Withdrawal	O
Cleviprex	O
is	O
not	O
a	O
beta-blocker	O
,	O
does	O
not	O
reduce	O
heart	O
rate	O
,	O
and	O
gives	O
no	O
protection	O
against	O
the	O
effects	O
of	O
abrupt	O
beta-blocker	O
withdrawal	O
.	O
	
In	O
some	O
instances	O
,	O
HBV	B
reactivation	I
occurring	O
in	O
conjunction	O
with	O
TNF-blocker	O
therapy	O
has	O
been	O
fatal	B
.	O
	
No	O
serious	O
adverse	O
reactions	O
related	O
to	O
Neuraceq	O
administration	O
have	O
been	O
reported	O
.	O
	
Caution	O
is	O
recommended	O
in	O
patients	O
with	O
hemoglobin	O
<	O
10	O
g/dl	O
.	O
	
The	O
etiology	O
of	O
hepatocellular	B
injury	I
was	O
possibly	O
related	O
to	O
TANZEUM	O
but	O
direct	O
attribution	O
to	O
TANZEUM	O
was	O
confounded	O
by	O
the	O
presence	O
of	O
gallstone	O
disease	O
diagnosed	O
on	O
ultrasound	O
3	O
weeks	O
after	O
the	O
event	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
the	O
insulin	O
secretagogue	O
or	O
insulin	O
may	O
be	O
required	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
used	O
in	O
combination	O
with	O
JARDIANCE	O
.	O
	
A	O
total	O
of	O
9	O
serious	O
adverse	O
reactions	O
were	O
reported	O
for	O
CAPS	O
patients	O
.	O
	
The	O
most	O
common	O
related	O
adverse	O
reactions	O
that	O
were	O
not	O
hematologic	O
,	O
hepatic	O
or	O
renal	O
events	O
were	O
paresthesia	B
,	O
flushing	B
,	O
and	O
nausea	B
and/or	O
vomiting	B
,	O
which	O
each	O
occurred	O
in	O
2	O
%	O
of	O
patients	O
(	O
Table	O
1	O
)	O
.	O
	
ADCETRIS-induced	O
peripheral	B
neuropathy	I
is	O
cumulative	O
.	O
	
*	O
viral	B
,	I
and	I
other	I
infections	I
.	O
	
No	O
patients	O
treated	O
with	O
SAPHRIS	O
experienced	O
QTc	B
increases	I
>	O
=60	O
msec	O
from	O
baseline	O
measurements	O
,	O
nor	O
did	O
any	O
patient	O
experience	O
a	O
QTc	B
of	I
>	I
=500	I
msec	I
.	O
	
In	O
most	O
cases	O
,	O
these	O
effects	O
appear	O
to	O
be	O
reversible	O
upon	O
drug	O
discontinuation	O
and	O
with	O
appropriate	O
medical	O
treatment	O
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
,	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
,	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
Many	O
of	O
the	O
drugs	O
metabolized	O
by	O
CYP2D6	O
can	O
prolong	O
the	O
QT	O
interval	O
and	O
should	O
not	O
be	O
administered	O
with	O
Coartem	O
Tablets	O
due	O
to	O
the	O
potential	O
additive	O
effect	O
on	O
the	O
QT	O
interval	O
(	O
e.g.	O
,	O
flecainide	O
,	O
imipramine	O
,	O
amitriptyline	O
,	O
clomipramine	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.6	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
CIMZIA	O
should	O
be	O
carefully	O
considered	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
chronic	O
or	O
recurrent	O
infection	O
.	O
	
(	O
5.3	O
)	O
*	O
Worsening	B
of	I
urinary	I
retention	I
may	O
occur	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
the	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
,	O
dizziness	B
,	O
rash	B
,	O
pruritis	B
,	O
flushing	B
,	O
headache	B
,	O
and	O
injection	B
site	I
hemorrhage	I
occurred	O
in	O
<	O
1.3	O
%	O
of	O
patients	O
.	O
	
Death	B
related	O
to	O
diarrhea	B
and	O
electrolyte	B
imbalance	I
occurred	O
in	O
the	O
randomized	O
clinical	O
trial	O
.	O
	
*	O
viral	B
and	I
other	I
infections	I
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Biotech	O
,	O
Inc.	O
at	O
1-800-526-7736	O
(	O
1-800-JANSSEN	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
1	O
presents	O
the	O
adverse	O
reactions	O
reported	O
when	O
STENDRA	O
was	O
taken	O
as	O
recommended	O
(	O
on	O
an	O
as-needed	O
basis	O
)	O
from	O
these	O
3	O
clinical	O
trials	O
.	O
	
While	O
this	O
normally	O
would	O
be	O
expected	O
to	O
be	O
of	O
little	O
consequence	O
in	O
most	O
patients	O
,	O
prior	O
to	O
prescribing	O
STENDRA	O
,	O
physicians	O
should	O
carefully	O
consider	O
whether	O
patients	O
with	O
underlying	O
cardiovascular	O
disease	O
could	O
be	O
affected	O
adversely	O
by	O
such	O
vasodilatory	O
effects	O
,	O
especially	O
in	O
combination	O
with	O
sexual	O
activity	O
.	O
	
5.3	O
Spinal/Epidural	O
Anesthesia	O
or	O
Puncture	O
When	O
neuraxial	O
anesthesia	O
(	O
spinal/epidural	O
anesthesia	O
)	O
or	O
spinal/epidural	O
puncture	O
is	O
employed	O
,	O
patients	O
treated	O
with	O
antithrombotic	O
agents	O
for	O
prevention	O
of	O
thromboembolic	O
complications	O
are	O
at	O
risk	O
of	O
developing	O
an	O
spinal	B
hematoma	I
which	O
can	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
Onset	O
of	O
dyspnea	O
or	O
non-productive	O
cough	O
may	O
be	O
related	O
to	O
pulmonary	O
toxicity	O
and	O
patients	O
should	O
be	O
carefully	O
evaluated	O
clinically	O
.	O
	
Thromboembolic	O
events	O
have	O
been	O
associated	O
with	O
ESA	O
use	O
in	O
other	O
disease	O
states	O
;	O
and	O
have	O
also	O
been	O
reported	O
with	O
peginterferon	O
alfa	O
use	O
in	O
hepatitis	O
C	O
patients	O
.	O
	
c	O
Includes	O
skin	B
papilloma	I
and	O
papilloma	B
.	O
	
The	O
incidence	O
in	O
the	O
DME	O
studies	O
from	O
baseline	O
to	O
week	O
52	O
was	O
3.3	O
%	O
(	O
19	O
out	O
of	O
578	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
compared	O
with	O
2.8	O
%	O
(	O
8	O
out	O
of	O
287	O
)	O
in	O
the	O
control	O
group	O
;	O
from	O
baseline	O
to	O
week	O
100	O
,	O
the	O
incidence	O
was	O
6.4	O
%	O
(	O
37	O
out	O
of	O
578	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
compared	O
with	O
4.2	O
%	O
(	O
12	O
out	O
of	O
287	O
)	O
in	O
the	O
control	O
group	O
.	O
	
Increase	B
in	I
Hematocrit	I
In	O
a	O
pool	O
of	O
four	O
placebo-controlled	O
studies	O
,	O
median	O
hematocrit	B
decreased	I
by	O
2.8	O
%	O
in	O
JARDIANCE	O
10	O
mg	O
and	O
2.8	O
%	O
in	O
JARDIANCE	O
25	O
mg	O
treated	O
patients	O
.	O
	
Sixty-two	O
patients	O
were	O
exposed	O
to	O
ILARIS	O
for	O
at	O
least	O
6	O
months	O
,	O
56	O
for	O
at	O
least	O
1	O
year	O
and	O
4	O
for	O
at	O
least	O
3	O
years	O
.	O
	
*	O
Serious	O
dermatologic	B
reactions	I
:	O
Discontinue	O
if	O
Stevens-Johnson	O
syndrome	O
or	O
toxic	O
epidermal	O
necrolysis	O
occurs	O
(	O
5.10	O
)	O
.	O
	
(	O
5.5	O
)	O
*	O
Seizures	B
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
lower	O
seizure	O
threshold	O
.	O
	
*	O
No	O
dosing	O
adjustments	O
are	O
recommended	O
in	O
the	O
presence	O
of	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
erythromycin	O
,	O
fluconazole	O
,	O
diltiazem	O
,	O
verapamil	O
and	O
grapefruit	O
juice	O
)	O
.	O
	
Increased	O
Mortality	O
In	O
the	O
cIAI	O
trials	O
(	O
Phase	O
2	O
and	O
3	O
)	O
,	O
death	B
occurred	O
in	O
2.5	O
%	O
(	O
14/564	O
)	O
of	O
patients	O
receiving	O
ZERBAXA	O
and	O
in	O
1.5	O
%	O
(	O
8/536	O
)	O
of	O
patients	O
receiving	O
meropenem	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Table	O
1	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
the	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
806	O
)	O
for	O
12	O
months	O
included	O
back	B
pain	I
,	O
pneumonia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
,	O
bronchitis	B
,	O
sinusitis	B
,	O
cough	B
,	O
oropharyngeal	B
pain	I
,	O
arthralgia	B
,	O
influenza	B
,	O
pharyngitis	B
,	O
and	O
pyrexia	B
.	O
	
The	O
safety	O
of	O
self-administration	O
was	O
evaluated	O
in	O
a	O
separate	O
,	O
open-label	O
trial	O
in	O
56	O
patients	O
with	O
HAE	O
.	O
	
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.2	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
The	O
potency	O
Units	O
of	O
XEOMIN	O
are	O
specific	O
to	O
the	O
preparation	O
and	O
assay	O
method	O
utilized	O
.	O
	
Table	O
8	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
6-Week	O
Schizophrenia	O
Trials	O
*	O
Akathisia	B
includes	O
:	O
akathisia	B
and	O
hyperkinesia	B
.	O
	
Table	O
2	O
presents	O
the	O
most	O
common	O
laboratory	O
abnormalities	O
reported	O
in	O
>	O
=10	O
%	O
patients	O
who	O
received	O
INLYTA	O
or	O
sorafenib	O
.	O
	
DUAVEE	O
is	O
used	O
after	O
menopause	O
for	O
women	O
with	O
a	O
uterus	O
to	O
:	O
*	O
reduce	O
moderate	O
to	O
severe	O
hot	O
flushesEstrogens	O
are	O
hormones	O
made	O
by	O
a	O
woman	O
's	O
ovaries	O
.	O
	
Glabellar	O
Lines	O
Testing	O
for	O
antibodies	O
to	O
DYSPORT	O
(	O
r	O
)	O
was	O
performed	O
for	O
1554	O
subjects	O
who	O
had	O
up	O
to	O
nine	O
cycles	O
of	O
treatment	O
.	O
	
This	O
information	O
does	O
not	O
take	O
the	O
place	O
of	O
talking	O
to	O
your	O
healthcare	O
provider	O
about	O
your	O
medical	O
condition	O
or	O
your	O
treatment	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
:	O
Adults	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Dermatologic	O
Reactions	O
A	O
significantly	O
higher	O
number	O
of	O
patients	O
treated	O
with	O
Prolia	O
developed	O
dermal	B
adverse	I
events	I
(	O
such	O
as	O
dermatitis	B
,	O
eczema	B
,	O
and	O
rashes	B
)	O
,	O
with	O
these	O
events	O
reported	O
in	O
8.2	O
%	O
of	O
the	O
placebo	O
and	O
10.8	O
%	O
of	O
the	O
Prolia	O
groups	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
This	O
finding	O
of	O
an	O
increased	O
risk	O
of	O
asthma-related	O
death	B
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
If	O
signs	O
and	O
symptoms	O
of	O
TD	O
appear	O
in	O
a	O
patient	O
on	O
SAPHRIS	O
,	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
Where	O
skin	B
reactions	I
occur	O
,	O
they	O
may	O
be	O
progressive	O
and	O
increase	O
in	O
severity	O
with	O
further	O
treatment	O
.	O
	
However	O
,	O
there	O
may	O
be	O
an	O
increased	O
risk	O
of	O
severe	O
skin	B
toxicity	I
when	O
TREANDA	O
and	O
allopurinol	O
are	O
administered	O
concomitantly	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
INVOKANA	O
,	O
assess	O
volume	O
status	O
and	O
correct	O
hypovolemia	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
,	O
or	O
if	O
on	O
diuretics	O
,	O
ACEi	O
,	O
or	O
ARB	O
.	O
	
Amylase	O
and	O
Lipase	O
Increase	O
Patients	O
exposed	O
to	O
TRULICITY	O
had	O
mean	O
increases	B
from	I
baseline	I
in	I
lipase	I
of	O
14	O
%	O
to	O
20	O
%	O
,	O
while	O
placebo-treated	O
patients	O
had	O
mean	O
increases	O
of	O
up	O
to	O
3	O
%	O
.	O
	
Patients	O
with	O
an	O
established	O
diagnosis	O
of	O
diabetes	O
mellitus	O
who	O
are	O
started	O
on	O
atypical	O
antipsychotics	O
should	O
be	O
monitored	O
regularly	O
for	O
worsening	O
of	O
glucose	O
control	O
.	O
	
*	O
Myelosuppression	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Fatalities	B
have	O
been	O
reported	O
in	O
association	O
with	O
excessive	O
use	O
of	O
inhaled	O
sympathomimetic	O
drugs	O
.	O
	
Do	O
not	O
restart	O
if	O
pancreatitis	O
is	O
confirmed	O
.	O
	
There	O
were	O
7	O
(	O
0.5	O
%	O
)	O
deaths	B
due	O
to	O
cardiorespiratory	B
arrest	I
in	O
the	O
ZYTIGA	O
arms	O
and	O
3	O
(	O
0.3	O
%	O
)	O
deaths	B
in	O
the	O
placebo	O
arms	O
.	O
	
*	O
Concomitant	O
colchicine	O
or	O
androgen-deprivation	O
therapeutic	O
drugs	O
(	O
such	O
as	O
luteinizing	O
hormone-releasing	O
analogs	O
and	O
anti-androgen	O
drugs	O
)	O
may	O
interfere	O
with	O
11	O
C-choline	O
PET	O
imaging	O
.	O
	
(	O
6.1	O
)	O
*	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C-associated	O
thrombocytopenia	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
:	O
anemia	B
,	O
pyrexia	B
,	O
fatigue	B
,	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
decreased	B
appetite	I
,	O
influenza-like	B
illness	I
,	O
asthenia	B
,	O
insomnia	B
,	O
cough	B
,	O
pruritus	B
,	O
chills	B
,	O
myalgia	B
,	O
alopecia	B
,	O
and	O
peripheral	B
edema	I
.	O
	
5.5	O
Imaging	O
Errors	O
due	O
to	O
Conditions	O
that	O
Affect	O
the	O
Sympathetic	O
Nervous	O
System	O
Individuals	O
with	O
conditions	O
that	O
affect	O
the	O
sympathetic	O
nervous	O
system	O
,	O
e.g.	O
,	O
Parkinsonian	O
syndromes	O
such	O
as	O
Parkinson	O
's	O
disease	O
or	O
multiple	O
system	O
atrophy	O
,	O
may	O
show	O
decreased	O
cardiac	O
uptake	O
of	O
AdreView	O
independent	O
of	O
heart	O
disease	O
.	O
	
*	O
Fatal	B
and/or	O
serious	O
and	O
severe	O
diarrhea	B
or	O
colitis	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
The	O
majority	O
of	O
Peyronie	O
's	O
patients	O
experienced	O
at	O
least	O
one	O
adverse	O
reaction	O
(	O
92	O
%	O
XIAFLEX-treated	O
patients	O
,	O
61	O
%	O
placebo-treated	O
)	O
.	O
	
3-Month	O
and	O
6-Month	O
Trials	O
TUDORZA	O
PRESSAIR	O
was	O
studied	O
in	O
two	O
3-month	O
(	O
Trials	O
B	O
and	O
C	O
)	O
and	O
one	O
6-month	O
(	O
Trial	O
D	O
)	O
placebo-controlled	O
trials	O
in	O
patients	O
with	O
COPD	O
.	O
	
5.6	O
Immunosuppression	O
Persons	O
who	O
are	O
using	O
drugs	O
that	O
suppress	O
the	O
immune	O
system	O
are	O
more	O
susceptible	O
to	O
infections	B
than	O
healthy	O
individuals	O
.	O
	
Approximately	O
two-thirds	O
of	O
patients	O
with	O
psychosis	B
in	O
controlled	O
trials	O
had	O
no	O
prior	O
psychiatric	O
history	O
.	O
	
(	O
2.2	O
,	O
5.4	O
)	O
*	O
Hyperglycemia	B
:	O
ZYKADIA	O
can	O
cause	O
hyperglycemia	B
.	O
	
Serious	O
Adverse	O
Reactions	O
and	O
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
In	O
the	O
four	O
pooled	O
Phase	O
3	O
clinical	O
trials	O
,	O
serious	O
adverse	O
reactions	O
(	O
SARs	O
)	O
occurred	O
in	O
98/1300	O
(	O
7.5	O
%	O
)	O
of	O
patients	O
receiving	O
Teflaro	O
and	O
100/1297	O
(	O
7.7	O
%	O
)	O
of	O
patients	O
receiving	O
comparator	O
drugs	O
.	O
	
Initiate	O
or	O
optimize	O
anti-hyperglycemic	O
medications	O
as	O
indicated	O
.	O
	
Vascular	O
disorders	O
:	O
hypotension	B
,	O
hypertension	B
.	O
	
These	O
effects	O
were	O
dose-related	O
and	O
generally	O
appeared	O
within	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
.	O
	
The	O
population	O
had	O
a	O
mean	O
age	O
of	O
64	O
years	O
(	O
ranging	O
from	O
40	O
to	O
89	O
years	O
)	O
,	O
with	O
58	O
%	O
males	O
,	O
94	O
%	O
Caucasian	O
,	O
and	O
had	O
COPD	O
with	O
a	O
mean	O
pre-bronchodilator	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
percent	O
predicted	O
of	O
48	O
%	O
.	O
	
Clinical	O
status	O
including	O
liver	O
transaminases	O
should	O
be	O
monitored	O
and	O
appropriate	O
therapy	O
initiated	O
.	O
	
Because	O
of	O
the	O
possibility	O
of	O
significant	O
systemic	O
absorption	O
of	O
inhaled	O
corticosteroids	O
in	O
sensitive	O
patients	O
,	O
patients	O
treated	O
with	O
BREO	O
ELLIPTA	O
should	O
be	O
observed	O
carefully	O
for	O
any	O
evidence	O
of	O
systemic	O
corticosteroid	O
effects	O
.	O
	
*	O
Blood	O
PSA	O
levels	O
<	O
2	O
ng/mL	O
have	O
been	O
associated	O
with	O
poor	O
performance	O
of	O
11	O
C-choline	O
PET	O
imaging	O
(	O
higher	O
numbers	O
of	O
false	O
positive	O
and	O
false	O
negative	O
results	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
In	O
Study	O
1	O
and	O
2	O
,	O
the	O
majority	O
of	O
arrhythmias	B
were	O
grade	O
1	O
or	O
2	O
.	O
	
Interrupt	O
and	O
then	O
reduce	O
or	O
discontinue	O
Zydelig	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	O
Trials	O
(	O
N=555	O
patients	O
)	O
a	O
Includes	O
the	O
terms	O
blood	B
pressure	I
increased	I
and	O
hypertension	B
.	O
	
5.17	O
Effect	O
on	O
Growth	O
Orally	O
inhaled	O
corticosteroids	O
may	O
cause	O
a	O
reduction	B
in	I
growth	I
velocity	I
when	O
administered	O
to	O
children	O
and	O
adolescents	O
.	O
	
Any	O
patient	O
treated	O
with	O
atypical	O
antipsychotics	O
should	O
be	O
monitored	O
for	O
symptoms	O
of	O
hyperglycemia	O
including	O
polydipsia	O
,	O
polyuria	O
,	O
polyphagia	O
,	O
and	O
weakness	O
.	O
	
(	O
5.1	O
)	O
	
Immune	O
system	O
disorders	O
:	O
Alopecia	B
totalis	I
.	O
	
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thrombotic	B
Events	I
:	O
Discontinue	O
COMETRIQ	O
for	O
myocardial	O
infarction	O
,	O
cerebral	O
infarction	O
,	O
or	O
other	O
serious	O
arterial	O
thromboembolic	O
events	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
PERFORATIONS	B
AND	O
FISTULAS	B
,	O
andHEMORRHAGE	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
as	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
*	O
Infections	B
:	O
Monitor	O
patients	O
for	O
fever	O
and	O
infections	O
and	O
evaluate	O
promptly	O
(	O
5.2	O
)	O
.	O
	
Dose	O
modifications	O
or	O
temporary	O
delay	O
of	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
occurred	O
in	O
199/359	O
patients	O
(	O
55	O
%	O
)	O
receiving	O
INLYTA	O
and	O
220/355	O
patients	O
(	O
62	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
(	O
5.2	O
)	O
*	O
Anaphylaxis	B
and	O
Infusion	B
Reactions	I
:	O
Severe	O
and	O
anaphylactic	B
reactions	I
have	O
occurred	O
;	O
monitor	O
clinically	O
and	O
discontinue	O
TREANDA	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
in	O
Study	O
1	O
and	O
2	O
reported	O
for	O
TECFIDERA	O
240	O
mg	O
BID	O
at	O
>	O
=	O
2	O
%	O
higher	O
incidence	O
than	O
placebo	O
TECFIDERA	O
N=769	O
%	O
Placebo	O
N=771	O
%	O
Flushing	B
40	O
6	O
Abdominal	B
pain	I
18	O
10	O
Diarrhea	B
14	O
11	O
Nausea	B
12	O
9	O
Vomiting	B
9	O
5	O
Pruritus	B
8	O
4	O
Rash	B
8	O
3	O
Albumin	B
urine	I
present	I
6	O
4	O
Erythema	B
5	O
1	O
Dyspepsia	B
5	O
3	O
Aspartate	B
aminotransferase	I
increased	I
4	O
2	O
Lymphopenia	B
2	O
<	O
1	O
Gastrointestinal	O
TECFIDERA	O
caused	O
GI	B
events	I
(	O
e.g.	O
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
abdominal	B
pain	I
,	O
and	O
dyspepsia	B
)	O
.	O
	
Adverse	O
reactions	O
from	O
the	O
MCL	O
trial	O
(	O
N=111	O
)	O
using	O
single	O
agent	O
IMBRUVICA	O
560	O
mg	O
daily	O
occurring	O
at	O
a	O
rate	O
of	O
>	O
=	O
10	O
%	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
JEVTANA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
The	O
association	O
with	O
TREANDA	O
therapy	O
has	O
not	O
been	O
determined	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatotoxicity	B
may	O
occur	O
with	O
use	O
of	O
SIRTURO	O
.	O
	
Table	O
3	O
identifies	O
adverse	O
reactions	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
for	O
all	O
grades	O
and	O
grades	O
3	O
or	O
4	O
for	O
the	O
Phase	O
1/2	O
CML	O
safety	O
population	O
.	O
	
A	O
total	O
of	O
62	O
%	O
of	O
patients	O
were	O
female	O
and	O
46	O
%	O
were	O
Asian	O
.	O
	
Osteonecrosis	B
of	I
the	I
Jaw	I
ONJ	B
has	O
been	O
reported	O
in	O
the	O
osteoporosis	O
clinical	O
trial	O
program	O
in	O
patients	O
treated	O
with	O
Prolia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
DUAVEE	O
is	O
a	O
prescription	O
medicine	O
that	O
contains	O
a	O
mixture	O
of	O
estrogens	O
and	O
bazedoxifene	O
.	O
	
The	O
commonly	O
reported	O
adverse	O
events	O
were	O
falls	B
(	O
24	O
%	O
)	O
,	O
urinary	B
tract	I
infections	I
(	O
15	O
%	O
)	O
,	O
headache	B
(	O
13	O
%	O
)	O
,	O
syncope	B
(	O
13	O
%	O
)	O
,	O
and	O
dizziness	B
(	O
10	O
%	O
)	O
.	O
	
Table	O
6	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=1	O
%	O
of	O
Patients	O
Treated	O
for	O
DVT	O
and	O
PE	O
in	O
the	O
AMPLIFY	O
Study	O
ELIQUISN=2676n	O
(	O
%	O
)	O
Enoxaparin/WarfarinN=2689n	O
(	O
%	O
)	O
Epistaxis	B
77	O
(	O
2.9	O
)	O
146	O
(	O
5.4	O
)	O
Contusion	B
49	O
(	O
1.8	O
)	O
97	O
(	O
3.6	O
)	O
Hematuria	B
46	O
(	O
1.7	O
)	O
102	O
(	O
3.8	O
)	O
Menorrhagia	B
38	O
(	O
1.4	O
)	O
30	O
(	O
1.1	O
)	O
Hematoma	B
35	O
(	O
1.3	O
)	O
76	O
(	O
2.8	O
)	O
Hemoptysis	B
32	O
(	O
1.2	O
)	O
31	O
(	O
1.2	O
)	O
Rectal	B
hemorrhage	I
26	O
(	O
1.0	O
)	O
39	O
(	O
1.5	O
)	O
Gingival	B
bleeding	I
26	O
(	O
1.0	O
)	O
50	O
(	O
1.9	O
)	O
AMPLIFY-EXT	O
Study	O
The	O
mean	O
duration	O
of	O
exposure	O
to	O
ELIQUIS	O
was	O
approximately	O
330	O
days	O
and	O
to	O
placebo	O
was	O
312	O
days	O
in	O
the	O
AMPLIFY-EXT	O
study	O
.	O
	
In	O
Trial	O
2	O
,	O
cardiomyopathy	B
occurred	O
in	O
9	O
%	O
(	O
5/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
in	O
none	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
Injection	B
site	I
pain	I
has	O
also	O
been	O
reported	O
.	O
	
Evaluate	O
patients	O
for	O
tuberculosis	O
risk	O
factors	O
and	O
test	O
for	O
latent	O
infection	O
prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
and	O
periodically	O
during	O
therapy	O
.	O
	
In	O
Trial	O
2	O
,	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
deep	B
venous	I
thrombosis	I
(	O
DVT	B
)	O
and	O
pulmonary	B
embolism	I
(	O
PE	B
)	O
:	O
7	O
%	O
(	O
4/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
none	O
of	O
the	O
53	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
Manage	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
until	O
symptoms	O
resolve	O
,	O
and	O
consider	O
use	O
of	O
corticosteroids	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
JARDIANCE	O
assess	O
and	O
correct	O
volume	O
status	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
,	O
and	O
in	O
patients	O
on	O
diuretics	O
.	O
	
Cases	O
of	O
peripheral	B
motor	I
neuropathy	I
have	O
also	O
been	O
reported	O
.	O
	
In	O
Trial	O
1	O
,	O
the	O
incidence	O
of	O
fever	B
(	O
serious	O
and	O
non-serious	O
)	O
was	O
28	O
%	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
10	O
%	O
in	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
Indwelling	O
epidural	O
or	O
intrathecal	O
catheters	O
should	O
not	O
be	O
removed	O
earlier	O
than	O
24	O
hours	O
after	O
the	O
last	O
administration	O
of	O
ELIQUIS	O
.	O
	
Consider	O
empiric	O
anti-fungal	O
therapy	O
in	O
patients	O
at	O
risk	O
for	O
invasive	O
fungal	O
infections	O
who	O
develop	O
severe	O
systemic	O
illness	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
report	O
any	O
symptoms	O
suggestive	O
of	O
endophthalmitis	O
or	O
retinal	O
detachment	O
without	O
delay	O
and	O
should	O
be	O
managed	O
appropriately	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
resulting	O
in	O
permanent	O
discontinuation	O
was	O
pyrexia	B
(	O
4	O
%	O
)	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
treatment	O
discontinuation	O
in	O
2	O
or	O
more	O
patients	O
with	O
classical	O
HL	O
or	O
sALCL	O
were	O
peripheral	B
sensory	I
neuropathy	I
(	O
8	O
%	O
)	O
and	O
peripheral	B
motor	I
neuropathy	I
(	O
3	O
%	O
)	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
greater	O
than	O
35	O
%	O
of	O
subjects	O
)	O
in	O
clinical	O
trials	O
in	O
adult	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
and	O
REBETOL	O
were	O
fatigue	B
,	O
anemia	B
,	O
nausea	B
,	O
headache	B
and	O
dysgeusia	B
.	O
	
Evaluate	O
abnormal	O
serum	O
liver	O
tests	O
with	O
repeat	O
testing	O
within	O
3	O
to	O
5	O
days	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Among	O
the	O
712	O
patients	O
who	O
participated	O
in	O
this	O
open-label	O
extension	O
study	O
,	O
the	O
mean	O
age	O
of	O
the	O
population	O
was	O
56.4	O
years	O
(	O
range	O
from	O
23	O
to	O
88	O
years	O
)	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
20	O
%	O
)	O
are	O
anemia	B
,	O
elevated	B
alkaline	I
phosphatase	I
,	O
hypertriglyceridemia	B
,	O
lymphopenia	B
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
elevated	B
AST	I
,	O
hypophosphatemia	B
,	O
elevated	B
ALT	I
and	O
hypokalemia	B
.	O
	
(	O
5.1	O
)	O
*	O
Paradoxical	B
bronchospasm	I
:	O
Discontinue	O
TUDORZA	O
PRESSAIR	O
and	O
consider	O
other	O
treatments	O
if	O
paradoxical	O
bronchospasm	O
occurs	O
.	O
	
Appropriate	O
empiric	O
antifungal	O
therapy	O
should	O
be	O
considered	O
while	O
a	O
diagnostic	O
workup	O
is	O
being	O
performed	O
.	O
	
(	O
2.2	O
)	O
(	O
4	O
)	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
Severe	O
hypersensitivity	B
reactions	I
can	O
occur	O
.	O
	
Table	O
5	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Patients	O
with	O
Proteinuria	B
in	O
the	O
Fixed-dose	O
Clinical	O
Studies	O
PRISTIQ	O
Placebo	O
50	O
mg	O
100	O
mg	O
200	O
mg	O
400	O
mg	O
Proteinuria	B
4	O
6	O
8	O
5	O
7	O
Vital	O
sign	O
changes	O
Table	O
6	O
summarizes	O
the	O
changes	O
that	O
were	O
observed	O
in	O
placebo-controlled	O
,	O
short-term	O
,	O
pre-marketing	O
studies	O
with	O
PRISTIQ	O
in	O
patients	O
with	O
MDD	O
(	O
doses	O
50	O
to	O
400	O
mg	O
)	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
therapy	O
with	O
TNF-blockers	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
tuberculosis	O
reactivation	O
during	O
therapy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
.	O
	
In	O
255	O
HAE	O
patients	O
treated	O
with	O
intravenous	O
or	O
subcutaneous	O
KALBITOR	O
in	O
clinical	O
studies	O
,	O
10	O
patients	O
(	O
4	O
%	O
)	O
experienced	O
anaphylaxis	B
.	O
	
EXCERPT	O
:	O
CAPS	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
greater	O
than	O
10	O
%	O
reported	O
by	O
patients	O
with	O
CAPS	O
treated	O
with	O
ILARIS	O
are	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
influenza	B
,	O
headache	B
and	O
nausea	B
.	O
	
There	O
were	O
no	O
deaths	B
in	O
the	O
ARCAPTA	O
NEOHALER	O
600	O
mcg	O
dose	O
group	O
or	O
in	O
the	O
salmeterol	O
active	O
control	O
group	O
.	O
	
Symptoms	O
include	O
fever	B
,	O
chills	B
,	O
arthralgia	B
,	O
myalgia	B
,	O
facial	B
flushing	I
,	O
facial	B
edema	I
,	O
vomiting	B
,	O
weakness	B
,	O
shortness	B
of	I
breath	I
,	O
hypotension	B
,	O
syncope	B
,	O
chest	B
tightness	I
,	O
or	O
angina	B
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
AFINITOR	O
dose	O
adjustment	O
was	O
stomatitis	B
.	O
	
(	O
2.2	O
,	O
5.4	O
)	O
*	O
Depression	B
:	O
Depression	B
and	O
suicidality	B
have	O
been	O
reported	O
in	O
trials	O
with	O
BENLYSTA	O
.	O
	
Subjects	O
received	O
1	O
inhalation	O
once	O
daily	O
of	O
the	O
following	O
:	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
,	O
or	O
vilanterol	O
25	O
mcg	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-experienced	O
Subjects	O
:	O
The	O
most	O
common	O
treatment-emergent	O
laboratory	O
abnormalities	O
(	O
greater	O
than	O
5	O
%	O
for	O
Grades	O
2	O
to	O
4	O
combined	O
)	O
observed	O
in	O
VIKING-3	O
at	O
Week	O
48	O
were	O
elevated	B
ALT	I
(	O
10	O
%	O
)	O
.	O
	
5.6	O
Human	O
Albumin	O
This	O
product	O
contains	O
albumin	O
,	O
a	O
derivative	O
of	O
human	O
blood	O
.	O
	
5.9	O
Myasthenia	O
Gravis	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
,	O
a	O
disease	O
characterized	O
by	O
decreased	O
cholinergic	O
activity	O
at	O
the	O
neuromuscular	O
junction	O
.	O
	
In	O
the	O
placebo	O
controlled	O
adjunctive	O
therapy	O
trials	O
in	O
patients	O
with	O
partial-onset	O
seizures	O
(	O
Study	O
3	O
,	O
Study	O
4	O
and	O
Study	O
5	O
)	O
,	O
1021	O
patients	O
received	O
APTIOM	O
.	O
	
The	O
other	O
cases	O
represented	O
a	O
variety	O
of	O
malignancies	B
,	O
including	O
rare	B
malignancies	I
that	O
are	O
usually	O
associated	O
with	O
immunosuppression	B
,	O
and	O
malignancies	O
that	O
are	O
not	O
usually	O
observed	O
in	O
children	O
and	O
adolescents	O
.	O
	
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
serious	O
breathing	B
difficulties	I
,	O
including	O
respiratory	B
failure	I
,	O
in	O
patients	O
with	O
cervical	O
dystonia	O
treated	O
with	O
botulinum	O
toxin	O
products	O
.	O
	
Evaluate	O
patients	O
with	O
symptoms	O
compatible	O
with	O
pancreatitis	O
to	O
establish	O
a	O
diagnosis	O
.	O
	
Most	O
adverse	O
events	O
were	O
mild	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
,	O
and	O
all	O
patients	O
recovered	O
without	O
treatment	O
.	O
	
There	O
may	O
be	O
new	O
information	O
.	O
	
Patients	O
with	O
New	O
York	O
Heart	O
Association	O
Class	O
III	O
and	O
IV	O
heart	O
failure	O
,	O
recent	O
myocardial	O
infarction	O
,	O
and	O
conduction	O
abnormalities	O
uncontrolled	O
by	O
medications	O
were	O
not	O
eligible	O
for	O
the	O
clinical	O
trials	O
.	O
	
None	O
of	O
the	O
subjects	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
.	O
	
Most	O
of	O
these	O
events	O
were	O
not	O
specific	O
to	O
the	O
injection	O
site	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
In	O
clinical	O
studies	O
,	O
subjects	O
with	O
impaired	O
renal	O
function	O
were	O
more	O
likely	O
to	O
have	O
greater	O
reductions	O
in	O
serum	O
calcium	O
levels	O
compared	O
to	O
subjects	O
with	O
normal	O
renal	O
function	O
.	O
	
Data	O
are	O
not	O
available	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
death	O
in	O
patients	O
with	O
COPD	O
is	O
increased	O
by	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonists	O
.	O
	
6.1	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Adverse	O
reactions	O
were	O
evaluated	O
for	O
1778	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
1224	O
patients	O
treated	O
with	O
comparator	O
antibacterial	O
drugs	O
in	O
seven	O
Phase	O
2	O
and	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
5.7	O
Extravasation	O
Injury	O
TREANDA	O
extravasations	B
have	O
been	O
reported	O
in	O
post	O
marketing	O
resulting	O
in	O
hospitalizations	O
from	O
erythema	B
,	O
marked	O
swelling	B
,	O
and	O
pain	B
.	O
	
On	O
average	O
,	O
pain	O
scores	O
returned	O
to	O
baseline	O
by	O
the	O
end	O
of	O
the	O
treatment	O
day	O
and	O
then	O
remained	O
at	O
or	O
below	O
baseline	O
levels	O
.	O
	
5.3	O
Lymphopenia	O
TECFIDERA	O
may	O
decrease	B
lymphocyte	I
counts	I
.	O
	
(	O
5.1	O
)	O
*	O
Infections	B
:	O
Monitor	O
for	O
fever	O
and	O
other	O
signs	O
of	O
infection	O
and	O
treat	O
promptly	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
insulin	O
or	O
insulin	O
secretagogue	O
may	O
be	O
required	O
to	O
minimize	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
used	O
in	O
combination	O
with	O
INVOKANA	O
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14	O
)	O
.	O
]	O
	
Do	O
not	O
administer	O
COMETRIQ	O
to	O
patients	O
with	O
severe	O
hemorrhage	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Patients	O
were	O
treated	O
with	O
pemetrexed	O
500	O
mg/m2	O
followed	O
after	O
30	O
minutes	O
by	O
cisplatin	O
75	O
mg/m2	O
every	O
three	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
treatment	O
courses	O
.	O
	
These	O
adverse	O
reactions	O
occurred	O
more	O
frequently	O
among	O
patients	O
with	O
a	O
baseline	O
history	O
of	O
hypertension	O
and	O
among	O
patients	O
receiving	O
concomitant	O
corticosteroids	O
and	O
non-steroidal	O
anti-inflammatory	O
drugs	O
.	O
	
Placebo-Controlled	O
Experience	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
those	O
occurring	O
at	O
an	O
incidence	O
of	O
greater	O
than	O
5	O
%	O
in	O
the	O
NORTHERA	O
group	O
and	O
with	O
at	O
least	O
a	O
3	O
%	O
greater	O
incidence	O
in	O
the	O
NORTHERA	O
group	O
than	O
in	O
the	O
placebo	O
group	O
)	O
in	O
NORTHERA-treated	O
patients	O
during	O
the	O
three	O
placebo-controlled	O
trials	O
were	O
headache	B
,	O
dizziness	B
,	O
nausea	B
,	O
hypertension	B
.	O
	
Patients	O
with	O
risk	O
factors	O
for	O
diabetes	O
mellitus	O
(	O
e.g.	O
,	O
obesity	O
,	O
family	O
history	O
of	O
diabetes	O
)	O
who	O
are	O
starting	O
treatment	O
with	O
atypical	O
antipsychotics	O
should	O
undergo	O
fasting	O
blood	O
glucose	O
testing	O
at	O
the	O
beginning	O
of	O
treatment	O
and	O
periodically	O
during	O
treatment	O
.	O
	
(	O
5.6	O
)	O
*	O
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Gastrointestinal	B
toxicity	I
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Hepatobiliary	O
disorders	O
:	O
jaundice	B
,	O
hepatomegaly	B
.	O
	
Grade	O
3-4	O
low	B
serum	I
phosphorus	I
(	O
7	O
%	O
)	O
and	O
low	B
potassium	I
(	O
5	O
%	O
)	O
occurred	O
at	O
a	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
rate	O
in	O
the	O
ZYTIGA	O
arm	O
.	O
	
Event	O
PRADAXA	O
150	O
mgN	O
=	O
6059n	O
(	O
%	O
/year	O
b	O
)	O
WarfarinN	O
=	O
5998n	O
(	O
%	O
/year	O
b	O
)	O
PRADAXA	O
150	O
mgvs	O
.	O
	
Information	O
on	O
the	O
consequences	O
,	O
reversibility	O
,	O
time	O
to	O
onset	O
,	O
and	O
pathophysiology	O
of	O
the	O
skin	B
abnormalities	I
remains	O
incomplete	O
.	O
	
(	O
2.2	O
,	O
5.6	O
)	O
*	O
Pancreatitis	B
:	O
Elevations	B
of	I
lipase	I
and	O
pancreatitis	B
can	O
occur	O
.	O
	
Treatment	O
discontinuation	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
35/1300	O
(	O
2.7	O
%	O
)	O
of	O
patients	O
receiving	O
Teflaro	O
and	O
48/1297	O
(	O
3.7	O
%	O
)	O
of	O
patients	O
receiving	O
comparator	O
drugs	O
with	O
the	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
being	O
hypersensitivity	B
for	O
both	O
treatment	O
groups	O
at	O
a	O
rate	O
of	O
0.3	O
%	O
in	O
the	O
Teflaro	O
group	O
and	O
0.5	O
%	O
in	O
comparator	O
group	O
.	O
	
Nervous	O
system	O
disorders	O
:	O
cerebellar	B
syndrome	I
,	O
cerebral	B
hemorrhage	I
,	O
convulsion	B
,	O
gait	B
disturbance	I
,	O
intracranial	B
pressure	I
increased	I
,	O
psychomotor	B
skills	I
impaired	I
,	O
pyramidal	B
tract	I
syndrome	I
,	O
somnolence	B
.	O
	
Patients	O
were	O
ineligible	O
if	O
AST	O
and/or	O
ALT	O
>	O
=2.5*	O
ULN	O
and	O
patients	O
were	O
excluded	O
if	O
they	O
had	O
liver	O
metastases	O
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
Table	O
2	O
were	O
identified	O
in	O
750	O
patients	O
treated	O
in	O
Study	O
1	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
(	O
4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Vascular	B
risks	I
:	I
Stop	I
Natazia	I
if	I
a	I
thrombotic	I
event	O
occurs	O
.	O
	
I	O
nfections	O
and	O
infestations	O
:	O
cryptococcal	B
cutaneous	I
infection	I
,	O
enteroviral	B
encephalitis	I
,	O
pharyngitis	B
,	O
pneumonia	B
,	O
sepsis	B
,	O
furuncle	B
,	O
infectious	B
hepatitis	I
,	O
rash	B
pustular	I
,	O
subcutaneous	B
abscess	I
.	O
	
It	O
is	O
predominantly	O
on	O
or	O
around	O
the	O
lips	O
or	O
in	O
the	O
nail	O
beds	O
of	O
the	O
fingers	O
or	O
toes	O
,	O
but	O
more	O
widespread	O
involvement	O
of	O
the	O
face	O
and	O
legs	O
has	O
also	O
been	O
reported	O
.	O
	
Inhaled	O
corticosteroids	O
should	O
be	O
used	O
with	O
caution	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
with	O
active	O
or	O
quiescent	O
tuberculosis	O
infections	O
of	O
the	O
respiratory	O
tract	O
;	O
systemic	O
fungal	O
,	O
bacterial	O
,	O
viral	O
,	O
or	O
parasitic	O
infections	O
;	O
or	O
ocular	O
herpes	O
simplex	O
.	O
	
Upper	B
respiratory	I
tract	I
infection	I
was	O
the	O
most	O
common	O
adverse	O
reaction	O
reported	O
in	O
the	O
trial	O
through	O
Week	O
24	O
occurring	O
in	O
6.5	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
as	O
compared	O
with	O
7.6	O
%	O
of	O
control-treated	O
patients	O
,	O
respectively	O
.	O
	
The	O
most	O
common	O
adverse	O
event	O
leading	O
to	O
discontinuation	O
,	O
hypotension/orthostatic	O
hypotension	B
,	O
was	O
reported	O
by	O
0.4	O
%	O
(	O
8/2146	O
)	O
patients	O
randomized	O
to	O
Edarbi	O
40	O
mg	O
or	O
80	O
mg	O
compared	O
to	O
0	O
%	O
(	O
0/801	O
)	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
If	O
a	O
patient	O
develops	O
skin	O
discoloration	O
,	O
serious	O
consideration	O
should	O
be	O
given	O
to	O
an	O
alternative	O
treatment	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
with	O
NORTHERA	O
are	O
included	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
*	O
Supine	B
Hypertension	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hyperpyrexia	B
and	O
Confusion	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
May	O
exacerbate	B
existing	I
ischemic	I
heart	I
disease	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
Headache	B
,	O
dizziness	B
,	O
nausea	B
,	O
hypertension	B
,	O
and	O
fatigue	B
(	O
greater	O
than	O
5	O
%	O
)	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Lundbeck	O
at	O
1-800-455-1141	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
major	O
risk	O
factors	O
for	O
decreased	O
bone	O
mineral	O
content	O
,	O
such	O
as	O
prolonged	O
immobilization	O
,	O
family	O
history	O
of	O
osteoporosis	O
,	O
postmenopausal	O
status	O
,	O
tobacco	O
use	O
,	O
advanced	O
age	O
,	O
poor	O
nutrition	O
,	O
or	O
chronic	O
use	O
of	O
drugs	O
that	O
can	O
reduce	O
bone	O
mass	O
(	O
e.g.	O
,	O
anticonvulsants	O
,	O
oral	O
corticosteroids	O
)	O
should	O
be	O
monitored	O
and	O
treated	O
with	O
established	O
standards	O
of	O
care	O
.	O
	
Forty	O
percent	O
of	O
patients	O
had	O
elevated	B
uric	I
acid	I
levels	I
on	O
study	O
including	O
13	O
%	O
with	O
values	O
above	O
10	O
mg/dL	O
.	O
	
Adverse	O
events	O
leading	O
to	O
dose	O
reduction	O
occurred	O
in	O
11	O
%	O
of	O
patients	O
.	O
	
The	O
safety	O
and	O
efficacy	O
of	O
ARCAPTA	O
NEOHALER	O
in	O
patients	O
with	O
asthma	O
have	O
not	O
been	O
established	O
.	O
	
Chemotherapy	O
was	O
given	O
by	O
intravenous	O
infusion	O
every	O
3	O
weeks	O
for	O
up	O
to	O
6	O
cycles	O
,	O
in	O
the	O
absence	O
of	O
dose-limiting	O
chemotherapy-related	O
toxicities	O
.	O
	
There	O
is	O
no	O
known	O
treatment	O
for	O
established	O
cases	O
of	O
TD	O
,	O
although	O
the	O
syndrome	O
may	O
remit	O
,	O
partially	O
or	O
completely	O
,	O
if	O
antipsychotic	O
treatment	O
is	O
withdrawn	O
.	O
	
(	O
5.4	O
)	O
*	O
Life-threatening	O
paradoxical	B
bronchospasm	I
can	O
occur	O
.	O
	
The	O
safety	O
of	O
resuming	O
TNF-blockers	O
after	O
HBV	O
reactivation	O
has	O
been	O
controlled	O
is	O
not	O
known	O
.	O
	
Women	O
enrolled	O
in	O
Studies	O
1	O
and	O
2	O
received	O
calcium	O
(	O
600-1200	O
mg	O
)	O
and	O
vitamin	O
D	O
(	O
200-400	O
IU	O
)	O
daily	O
,	O
while	O
women	O
in	O
Studies	O
3	O
and	O
4	O
received	O
no	O
calcium	O
and	O
vitamin	O
D	O
supplementation	O
as	O
part	O
of	O
the	O
protocol	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Because	O
adverse	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
changes	O
in	O
mean	O
serum	O
creatinine	O
were	O
similar	O
to	O
those	O
observed	O
in	O
adults	O
.	O
	
b	O
Of	O
the	O
reported	O
adverse	O
drug	O
reactions	O
none	O
were	O
serious	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
Kyprolis	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
PRES	O
is	O
not	O
known	O
.	O
	
*	O
Fatal	B
anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Proteinuria	B
(	O
all	O
grades	O
)	O
occurred	O
in	O
52	O
%	O
of	O
subjects	O
receiving	O
STRIBILD	O
,	O
41	O
%	O
of	O
subjects	O
receiving	O
ATRIPLA	O
,	O
and	O
42	O
%	O
of	O
subjects	O
receiving	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
.	O
	
A	O
total	O
of	O
225	O
patients	O
were	O
treated	O
with	O
1,076	O
doses	O
of	O
30	O
mg	O
FIRAZYR	O
for	O
987	O
attacks	O
of	O
acute	O
HAE	O
.	O
	
If	O
PML	O
is	O
confirmed	O
,	O
consider	O
discontinuation	O
of	O
immunosuppressant	O
therapy	O
,	O
including	O
BENLYSTA	O
.	O
	
(	O
5.2	O
)	O
*	O
Angioedema	B
:	O
Patients	O
taking	O
concomitant	O
ACE	O
inhibitor	O
therapy	O
may	O
be	O
at	O
increased	O
risk	O
for	O
angioedema	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Increased	O
Risk	O
of	O
Thrombotic	O
Events	O
after	O
Premature	O
Discontinuation	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
ELIQUIS	O
,	O
in	O
the	O
absence	O
of	O
adequate	O
alternative	O
anticoagulation	O
increases	O
the	O
risk	O
of	O
thrombotic	B
events	I
.	O
	
Renal	O
and	O
urinary	O
disorders	O
-	O
Urinary	B
retention	I
.	O
	
Study	O
2	O
enrolled	O
patients	O
with	O
a	O
median	O
age	O
of	O
17	O
years	O
(	O
6	O
months	O
to	O
85	O
years	O
)	O
;	O
64	O
%	O
were	O
male	O
,	O
and	O
the	O
underlying	O
malignancies	O
were	O
osteogenic	O
sarcoma	O
in	O
32	O
%	O
,	O
and	O
leukemia	O
or	O
lymphoma	O
in	O
62	O
%	O
of	O
patients	O
.	O
	
Some	O
of	O
these	O
infections	B
have	O
been	O
severe	O
(	O
e.g.	O
,	O
leading	O
to	O
sepsis	B
,	O
hepatic	B
failure	I
)	O
or	O
fatal	B
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
prostatic	O
hyperplasia	O
or	O
bladder-neck	O
obstruction	O
and	O
instruct	O
patients	O
to	O
consult	O
a	O
physician	O
immediately	O
if	O
this	O
occurs	O
.	O
	
Procedural	O
Complications	O
:	O
contusion	B
.	O
	
SPRINT-1	O
(	O
subjects	O
who	O
were	O
previously	O
untreated	O
)	O
evaluated	O
the	O
use	O
of	O
VICTRELIS	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
with	O
or	O
without	O
a	O
four-week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
PegIntron/REBETOL	O
alone	O
.	O
	
In	O
postmarketing	O
experience	O
with	O
TUDORZA	O
PRESSAIR	O
,	O
immediate	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
(	O
including	O
swelling	B
of	I
the	I
lips	I
)	O
,	O
urticaria	B
,	O
rash	B
,	O
bronchospasm	B
,	O
or	O
itching	B
have	O
been	O
reported	O
.	O
	
There	O
is	O
neither	O
scientific	O
rationale	O
for	O
reversal	O
nor	O
experience	O
with	O
systemic	O
hemostatics	O
(	O
desmopressin	O
and	O
aprotinin	O
)	O
in	O
individuals	O
receiving	O
apixaban	O
.	O
	
Hypophosphatemia	O
and	O
osteomalacia	O
secondary	O
to	O
proximal	O
renal	O
tubulopathy	O
should	O
be	O
considered	O
in	O
patients	O
at	O
risk	O
of	O
renal	O
dysfunction	O
who	O
present	O
with	O
persistent	O
or	O
worsening	O
bone	O
or	O
muscle	O
symptoms	O
while	O
receiving	O
products	O
containing	O
tenofovir	O
DF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
If	O
CDAD	O
is	O
suspected	O
or	O
confirmed	O
,	O
ongoing	O
antibacterial	O
use	O
not	O
directed	O
against	O
C.	O
difficile	O
should	O
be	O
discontinued	O
,	O
if	O
possible	O
.	O
	
Do	O
not	O
restart	O
MULTAQ	O
in	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
observed	O
liver	O
injury	O
.	O
	
Approximately	O
half	O
of	O
the	O
patients	O
(	O
54	O
%	O
)	O
were	O
male	O
.	O
	
JEVTANA	O
treatment	O
delay	O
or	O
discontinuation	O
may	O
be	O
necessary	O
.	O
	
Similar	O
SVR	O
rates	O
were	O
reported	O
in	O
subjects	O
who	O
were	O
randomized	O
to	O
receive	O
ribavirin	O
dose	O
reduction	O
compared	O
to	O
subjects	O
who	O
were	O
randomized	O
to	O
receive	O
an	O
ESA	O
.	O
	
The	O
safety	O
of	O
the	O
combination	O
of	O
VICTRELIS	O
800	O
mg	O
three	O
times	O
daily	O
with	O
PegIntron/REBETOL	O
was	O
assessed	O
in	O
2095	O
subjects	O
with	O
chronic	O
hepatitis	O
C	O
in	O
one	O
Phase	O
2	O
,	O
open-label	O
trial	O
and	O
two	O
Phase	O
3	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Prescribers	O
and	O
patients	O
should	O
be	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
acute	O
narrow-angle	O
glaucoma	O
(	O
e.g.	O
,	O
eye	O
pain	O
or	O
discomfort	O
,	O
blurred	O
vision	O
,	O
visual	O
halos	O
or	O
colored	O
images	O
in	O
association	O
with	O
red	O
eyes	O
from	O
conjunctival	O
congestion	O
and	O
corneal	O
edema	O
)	O
.	O
	
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
,	O
an	O
opportunistic	O
infection	O
,	O
or	O
sepsis	O
.	O
	
In	O
three	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
lasting	O
up	O
to	O
3	O
months	O
in	O
duration	O
,	O
the	O
mean	O
age	O
of	O
patients	O
was	O
56.4	O
years	O
(	O
range	O
from	O
23	O
to	O
88	O
years	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Thromboembolic	B
Complications	I
:	O
Portal	B
vein	I
thrombosis	I
has	O
been	O
reported	O
in	O
patients	O
with	O
chronic	O
liver	O
disease	O
receiving	O
PROMACTA	O
.	O
	
5.5	O
Hypersensitivity	O
Serious	O
acute	B
hypersensitivity	I
reactions	I
(	O
e.g.	O
,	O
urticaria	B
,	O
angioedema	B
)	O
have	O
been	O
observed	O
during	O
combination	O
therapy	O
with	O
VICTRELIS	O
,	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
DALVANCE	O
were	O
nausea	B
(	O
5.5	O
%	O
)	O
,	O
headache	B
(	O
4.7	O
%	O
)	O
,	O
and	O
diarrhea	B
(	O
4.4	O
%	O
)	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
and	O
resolved	O
spontaneously	O
.	O
	
In	O
one	O
of	O
the	O
3	O
cases	O
an	O
alternate	O
etiology	O
was	O
identified	O
to	O
explain	O
the	O
rise	B
in	I
liver	I
enzyme	I
(	O
acute	O
viral	O
hepatitis	O
)	O
.	O
	
Prosthetic	O
heart	O
valves	O
:	O
ELIQUIS	O
use	O
not	O
recommended	O
.	O
	
If	O
resolution	O
of	O
the	O
RPED	O
is	O
documented	O
on	O
repeat	O
ophthalmological	O
evaluation	O
within	O
3	O
weeks	O
,	O
resume	O
trametinib	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
(	O
5.3	O
)	O
*	O
Oral	B
ulceration	I
:	O
Mouth	B
ulcers	I
,	O
stomatitis	B
,	O
and	O
oral	B
mucositis	I
are	O
common	O
.	O
	
(	O
2.1	O
)	O
(	O
5.2	O
)	O
*	O
Contraindicated	O
if	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
JEVTANA	O
or	O
to	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
was	O
similar	O
to	O
that	O
for	O
adults	O
.	O
	
Consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
-	O
Cardiac	O
Toxicities	O
(	O
5.1	O
)	O
,	O
Pulmonary	O
Toxicity	O
(	O
5.4	O
)	O
,	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Dizziness	B
,	O
somnolence	B
,	O
fatigue	B
,	O
and	O
insomnia	B
appeared	O
to	O
show	O
a	O
dose	O
relationship	O
.	O
	
c	O
n	O
(	O
%	O
)	O
indicates	O
number	O
of	O
patients	O
and	O
percent	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
,	O
hypertriglyceridemia	B
,	O
and	O
anemia	B
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
DYSPORT	O
(	O
r	O
)	O
:	O
vertigo	B
,	O
photophobia	B
,	O
influenza-like	B
illness	I
,	O
amyotrophy	B
,	O
burning	B
sensation	I
,	O
facial	B
paresis	I
,	O
hypoesthesia	B
,	O
erythema	B
,	O
and	O
excessive	B
granulation	I
tissue	I
.	O
	
In	O
all	O
clinical	O
studies	O
,	O
including	O
uncontrolled	O
extension	O
studies	O
,	O
the	O
exposure	O
to	O
GILENYA	O
0.5	O
mg	O
was	O
approximately	O
4119	O
person-years	O
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
related	O
to	O
the	O
spread	B
of	I
toxin	I
effects	I
.	O
	
In	O
arriving	O
at	O
a	O
diagnosis	O
,	O
it	O
is	O
important	O
to	O
identify	O
cases	O
in	O
which	O
the	O
clinical	O
presentation	O
includes	O
both	O
serious	O
medical	O
illness	O
(	O
e.g.	O
,	O
pneumonia	O
,	O
systemic	O
infection	O
,	O
etc	O
.	O
)	O
	
After	O
6	O
cycles	O
,	O
patients	O
remained	O
on	O
study	O
with	O
no	O
additional	O
anticancer	O
treatment	O
,	O
and	O
tumor	O
assessments	O
continued	O
until	O
documented	O
disease	O
progression	O
.	O
	
Single	O
intraperitoneal	O
doses	O
of	O
bendamustine	O
in	O
mice	O
and	O
rats	O
administered	O
during	O
organogenesis	O
caused	O
an	O
increase	B
in	I
resorptions	I
,	O
visceral	B
malformations	I
,	O
and	O
decreased	B
fetal	I
body	I
weights	I
.	O
	
Monitor	O
serum	O
potassium	O
levels	O
periodically	O
after	O
initiating	O
INVOKANA	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
patients	O
predisposed	O
to	O
hyperkalemia	O
due	O
to	O
medications	O
or	O
other	O
medical	O
conditions	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
discontinue	O
TECFIDERA	O
and	O
seek	O
immediate	O
medical	O
care	O
should	O
they	O
experience	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
or	O
angioedema	O
.	O
	
Three	O
patients	O
(	O
2	O
%	O
)	O
died	B
from	O
myelosuppression-related	B
adverse	I
reactions	I
;	O
one	O
each	O
from	O
neutropenic	B
sepsis	I
,	O
diffuse	B
alveolar	I
hemorrhage	I
with	O
Grade	O
3	O
thrombocytopenia	B
,	O
and	O
pneumonia	B
from	O
an	O
infection	B
(	I
CMV	I
)	O
.	O
	
The	O
results	O
of	O
these	O
evaluations	O
were	O
consistent	O
with	O
a	O
retinal	B
dystrophy	I
,	O
including	O
abnormalities	B
in	I
the	I
electroretinogram	I
of	O
both	O
patients	O
,	O
with	O
abnormal	B
fluorescein	I
angiography	I
and	O
diminished	B
sensitivity	I
on	I
visual	I
field	I
testing	O
in	O
one	O
patient	O
.	O
	
5.5	O
Metabolic	O
Changes	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	O
changes	O
that	O
may	O
increase	B
cardiovascular/cerebrovascular	I
risk	I
.	O
	
The	O
majority	O
of	O
events	O
resolved	O
following	O
interruption	O
of	O
BLINCYTO	O
,	O
but	O
some	O
resulted	O
in	O
treatment	O
discontinuation	O
.	O
	
In	O
acute	O
purulent	O
conditions	O
,	O
steroids	O
may	O
mask	O
infection	O
or	O
enhance	O
existing	O
infection	O
.	O
	
*	O
Fluid	B
retention	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Generally	O
,	O
adverse	O
reactions	O
were	O
mild	O
,	O
not	O
dose	O
related	O
,	O
and	O
similar	O
regardless	O
of	O
age	O
,	O
gender	O
,	O
and	O
race	O
.	O
	
In	O
such	O
children	O
or	O
adults	O
who	O
have	O
not	O
had	O
these	O
diseases	O
or	O
been	O
properly	O
immunized	O
,	O
particular	O
care	O
should	O
be	O
taken	O
to	O
avoid	O
exposure	O
.	O
	
Patients	O
experiencing	O
new	O
,	O
worsening	O
,	O
or	O
recurrent	O
hepatotoxicity	O
may	O
require	O
a	O
delay	O
,	O
change	O
in	O
dose	O
,	O
or	O
discontinuation	O
of	O
ADCETRIS	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
receiving	O
the	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
5.12	O
Cardiovascular	O
Effects	O
Vilanterol	O
,	O
like	O
other	O
beta2-agonists	O
,	O
can	O
produce	O
a	O
clinically	O
significant	O
cardiovascular	O
effect	O
in	O
some	O
patients	O
as	O
measured	O
by	O
increases	B
in	I
pulse	I
rate	I
,	O
and	O
also	O
cardiac	B
arrhythmias	I
,	O
such	O
as	O
supraventricular	B
tachycardia	I
and	O
extrasystoles	B
.	O
	
These	O
risks	O
importantly	O
may	O
limit	O
the	O
role	O
of	O
AdreView	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
patients	O
with	O
severe	O
renal	O
impairment	O
.	O
	
Fifty	O
percent	O
(	O
50	O
%	O
)	O
of	O
the	O
population	O
were	O
male	O
;	O
81	O
%	O
were	O
White	O
,	O
14	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
After	O
initiation	O
of	O
TRULICITY	O
,	O
observe	O
patients	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
,	O
including	O
persistent	O
severe	O
abdominal	O
pain	O
.	O
	
(	O
4	O
)	O
*	O
Cigarette	O
smoking	O
increases	O
the	O
risk	O
of	O
serious	O
cardiovascular	B
events	I
from	O
combination	O
oral	O
contraceptive	O
(	O
COC	O
)	O
use	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
1	O
%	O
of	O
XIAFLEX-Treated	O
Patients	O
with	O
Peyronie	O
's	O
disease	O
and	O
at	O
a	O
Greater	O
Incidence	O
than	O
Placebo	O
After	O
Up	O
to	O
Four	O
Treatment	O
Cycles	O
in	O
Studies	O
1	O
and	O
2	O
Combined	O
a	O
Includes	O
:	O
injection	B
site	I
hematoma	I
and	O
penile	B
hematoma	I
were	O
reported	O
with	O
the	O
verbatim	O
term	O
of	O
penile	B
bruising	I
or	O
injection	B
site	I
bruising	I
in	O
87	O
%	O
of	O
subjects	O
.	O
	
There	O
were	O
no	O
clinically	O
meaningful	O
differences	O
in	O
the	O
incidence	O
of	O
adverse	O
events	O
following	O
treatment	O
with	O
XIAFLEX	O
based	O
on	O
the	O
severity	O
of	O
baseline	O
erectile	O
dysfunction	O
or	O
concomitant	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
inhibitor	O
use	O
.	O
	
The	O
impact	O
of	O
discontinuation	O
of	O
androgen-deprivation	O
therapy	O
upon	O
11	O
C-choline	O
PET	O
imaging	O
has	O
not	O
been	O
established	O
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
The	O
average	O
age	O
was	O
57	O
years	O
(	O
age	O
range	O
from	O
19	O
to	O
84	O
years	O
)	O
.	O
	
Table	O
5	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
of	O
XIAFLEX-treated	O
patients	O
and	O
at	O
a	O
frequency	O
greater	O
than	O
placebo-treated	O
patients	O
after	O
up	O
to	O
8	O
injections	O
in	O
the	O
pooled	O
placebo-controlled	O
trials	O
through	O
Day	O
365	O
.	O
	
Treatment	O
and	O
Reduction	O
in	O
the	O
Risk	O
of	O
Recurrence	O
of	O
Deep	O
Venous	O
Thrombosis	O
and	O
Pulmonary	O
Embolism	O
PRADAXA	O
was	O
studied	O
in	O
4387	O
patients	O
in	O
4	O
pivotal	O
,	O
parallel	O
,	O
randomized	O
,	O
double-blind	O
trials	O
.	O
	
The	O
risk	O
of	O
VTE	B
in	O
women	O
using	O
COCs	O
has	O
been	O
estimated	O
to	O
be	O
3	O
to	O
9	O
per	O
10,000	O
woman-years	O
.	O
	
Because	O
these	O
reactions	O
may	O
worsen	O
renal	O
function	O
,	O
use	O
caution	O
when	O
initiating	O
or	O
escalating	O
doses	O
of	O
TRULICITY	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
5.8	O
Leukopenia	O
,	O
Neutropenia	O
and	O
Agranulocytosis	O
In	O
clinical	O
trial	O
and	O
postmarketing	O
experience	O
,	O
events	O
of	O
leukopenia/neutropenia	O
have	O
been	O
reported	O
temporally	O
related	O
to	O
antipsychotic	O
agents	O
.	O
	
When	O
injecting	O
a	O
cord	O
affecting	O
a	O
PIP	O
joint	O
of	O
the	O
fifth	O
finger	O
,	O
the	O
needle	O
insertion	O
should	O
not	O
be	O
more	O
than	O
2	O
to	O
3	O
mm	O
in	O
depth	O
and	O
avoid	O
injecting	O
more	O
than	O
4	O
mm	O
distal	O
to	O
the	O
palmar	O
digital	O
crease	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
For	O
these	O
events	O
,	O
the	O
median	O
time	O
to	O
onset	O
was	O
15	O
days	O
.	O
	
If	O
signs	O
and	O
symptoms	O
of	O
tardive	O
dyskinesia	O
appear	O
in	O
a	O
patient	O
on	O
FANAPT	O
,	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
Although	O
some	O
of	O
the	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
been	O
found	O
to	O
have	O
abnormal	B
visual	I
acuity	I
,	O
it	O
is	O
not	O
possible	O
to	O
assess	O
whether	O
POTIGA	O
caused	O
their	O
decreased	B
visual	I
acuity	I
,	O
as	O
baseline	O
assessments	O
are	O
not	O
available	O
for	O
these	O
patients	O
.	O
	
(	O
5.2	O
)	O
*	O
POTIGA	O
can	O
cause	O
skin	B
discoloration	I
.	O
	
Assessment	O
of	O
the	O
relationship	O
between	O
atypical	O
antipsychotic	O
use	O
and	O
glucose	O
abnormalities	O
is	O
complicated	O
by	O
the	O
possibility	O
of	O
an	O
increased	O
background	O
risk	O
of	O
diabetes	O
mellitus	O
in	O
patients	O
with	O
schizophrenia	O
and	O
the	O
increasing	O
incidence	O
of	O
diabetes	O
mellitus	O
in	O
the	O
general	O
population	O
.	O
	
The	O
initial	O
prescription	O
and	O
renewal	O
of	O
the	O
medication	O
order	O
beyond	O
28	O
days	O
should	O
be	O
made	O
by	O
a	O
physician	O
only	O
after	O
examination	O
of	O
the	O
patient	O
with	O
the	O
aid	O
of	O
magnification	O
such	O
as	O
slit	O
lamp	O
biomicroscopy	O
and	O
,	O
where	O
appropriate	O
,	O
fluorescein	O
staining	O
.	O
	
peri-infusional	B
reactions	I
consistent	O
with	O
hypersensitivity	B
or	O
anaphylaxis	B
were	O
not	O
reported	O
in	O
these	O
11	O
patients	O
nor	O
were	O
neutralizing	O
antibodies	O
against	O
ipilimumab	O
detected	O
.	O
	
Binding	O
to	O
this	O
receptor	O
is	O
required	O
for	O
Vimizim	O
to	O
be	O
taken	O
into	O
cells	O
where	O
it	O
is	O
active	O
.	O
	
Adverse	O
reaction	O
of	O
hyperuricemia	B
was	O
reported	O
for	O
15	O
%	O
of	O
patients	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
anaphylaxis	B
;	O
and	O
infusion	B
site	I
reactions	I
;	O
pneumocystis	B
jiroveci	I
pneumonia	I
and	O
pneumonitis	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Ophthalmic	B
Adverse	I
Reaction	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
local	B
skin	I
reactions	I
,	O
application	B
site	I
pain	I
,	O
application	B
site	I
pruritus	I
,	O
application	B
site	I
irritation	I
,	O
application	B
site	I
infection	I
,	O
periorbital	B
edema	I
,	O
nasopharyngitis	B
and	O
headache	B
.	O
	
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.1	O
%	O
subjects	O
who	O
received	O
Gadavist	O
.	O
	
Provide	O
supportive	O
medical	O
care	O
if	O
shortness	O
of	O
breath	O
develops	O
.	O
	
In	O
a	O
study	O
of	O
TREANDA	O
(	O
90	O
mg/m	O
2	O
)	O
in	O
combination	O
with	O
rituximab	O
,	O
one	O
case	O
of	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
occurred	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Durata	O
Therapeutics	O
,	O
Inc.	O
at	O
1-855-387-2825	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov	O
/medwatch	O
.	O
	
Hypoglycemia	O
In	O
all	O
clinical	O
trials	O
,	O
hypoglycemia	O
was	O
defined	O
as	O
any	O
event	O
regardless	O
of	O
symptoms	O
,	O
where	O
biochemical	O
hypoglycemia	O
was	O
documented	O
(	O
any	O
glucose	O
value	O
below	O
or	O
equal	O
to	O
70	O
mg/dL	O
)	O
.	O
	
Given	O
these	O
considerations	O
,	O
SAPHRIS	O
should	O
be	O
prescribed	O
in	O
a	O
manner	O
that	O
is	O
most	O
likely	O
to	O
minimize	O
the	O
occurrence	O
of	O
TD	O
.	O
	
Concomitant	O
short-acting	O
beta2-agonists	O
can	O
be	O
used	O
as	O
needed	O
for	O
acute	O
relief	O
(	O
5.2	O
)	O
*	O
Do	O
not	O
exceed	O
the	O
recommended	O
dose	O
.	O
	
A	O
majority	O
of	O
Qutenza-treated	O
patients	O
in	O
clinical	O
studies	O
had	O
adverse	O
reactions	O
with	O
a	O
maximum	O
intensity	O
of	O
``	O
mild	O
''	O
or	O
``	O
moderate	O
''	O
.	O
	
(	O
5.11	O
)	O
*	O
The	O
starting	O
dose	O
of	O
INLYTA	O
should	O
be	O
decreased	O
if	O
used	O
in	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
.	O
	
5.3	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
A	O
case	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
and	O
a	O
case	O
of	O
probable	O
PML	B
occurred	O
in	O
patients	O
with	O
MS	O
who	O
received	O
GILENYA	O
in	O
the	O
post	O
marketing	O
setting	O
.	O
	
Adequate	O
data	O
are	O
not	O
available	O
on	O
whether	O
anti-viral	O
therapy	O
can	O
reduce	O
the	O
risk	O
of	O
HBV	O
reactivation	O
in	O
HBV	O
carriers	O
who	O
are	O
treated	O
with	O
TNF-blockers	O
.	O
	
Additional	O
signs	O
may	O
include	O
elevated	B
creatine	I
phosphokinase	I
,	O
myoglobinuria	B
(	O
rhabdomyolysis	B
)	O
,	O
and	O
acute	B
renal	I
failure	I
.	O
	
Overall	O
,	O
3.9	O
%	O
of	O
patients	O
reported	O
at	O
least	O
one	O
adverse	O
reaction	O
,	O
primarily	O
occurring	O
immediately	O
or	O
several	O
days	O
following	O
DOTAREM	O
administration	O
.	O
	
Serious	O
infections	B
occurred	O
at	O
a	O
rate	O
of	O
2.3	O
%	O
in	O
the	O
GILENYA	O
group	O
versus	O
1.6	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
The	O
route	O
of	O
administration	O
was	O
intramuscular	O
n=852	O
,	O
intravenous	O
n=29	O
,	O
other	O
or	O
unknown	O
n=59	O
.	O
	
*	O
Report	O
any	O
unusual	O
vaginal	O
bleeding	O
right	O
away	O
while	O
you	O
are	O
taking	O
DUAVEE	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
31	O
years	O
(	O
range	O
18	O
to	O
61	O
years	O
)	O
,	O
89	O
%	O
were	O
Caucasian	O
,	O
and	O
34	O
%	O
were	O
male	O
.	O
	
Delay	O
in	O
stopping	O
treatment	O
with	O
TIVICAY	O
or	O
other	O
suspect	O
agents	O
after	O
the	O
onset	O
of	O
hypersensitivity	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
(	O
5.2	O
)	O
*	O
Progressive	B
Multifocal	I
Leukoencephalopathy	I
(	O
PML	B
)	O
:	O
Patients	O
presenting	O
with	O
new-onset	O
or	O
deteriorating	O
neurological	O
signs	O
and	O
symptoms	O
should	O
be	O
evaluated	O
for	O
PML	O
by	O
an	O
appropriate	O
specialist	O
.	O
	
Trials	O
3	O
and	O
4	O
included	O
3,255	O
subjects	O
,	O
of	O
which	O
57	O
%	O
were	O
male	O
and	O
85	O
%	O
were	O
white	O
.	O
	
Based	O
on	O
effective	O
donor	O
screening	O
and	O
product	O
manufacturing	O
processes	O
,	O
it	O
carries	O
an	O
extremely	O
remote	O
risk	O
for	O
transmission	O
of	O
viral	B
diseases	I
.	O
	
The	O
risk	O
of	O
impaired	B
renal	I
function	I
with	O
JARDIANCE	O
is	O
increased	O
in	O
elderly	O
patients	O
and	O
patients	O
with	O
moderate	O
renal	O
impairment	O
.	O
	
Human	O
relevance	O
of	O
GLP-1	O
receptor	O
agonist	O
induced	O
C-cell	B
tumors	I
in	O
rodents	O
has	O
not	O
been	O
determined	O
.	O
	
5.4	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
Progressive	O
multifocal	O
leukoencephalopathy	O
(	O
PML	O
)	O
is	O
an	O
often	O
rapidly	O
progressive	O
and	O
fatal	O
opportunistic	O
infection	O
of	O
the	O
CNS	O
that	O
is	O
caused	O
by	O
the	O
JC	O
virus	O
,	O
a	O
human	O
polyoma	O
virus	O
.	O
	
Twenty-one	O
of	O
290	O
patients	O
(	O
7	O
%	O
)	O
experienced	O
adverse	O
reactions	O
that	O
were	O
assessed	O
as	O
related	O
to	O
VORAXAZE	O
.	O
	
Patients	O
experiencing	O
new	O
or	O
worsening	O
peripheral	O
neuropathy	O
may	O
require	O
a	O
delay	O
,	O
change	O
in	O
dose	O
,	O
or	O
discontinuation	O
of	O
ADCETRIS	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
To	O
avoid	O
transfer	O
of	O
the	O
drug	O
into	O
the	O
eyes	O
and	O
to	O
the	O
periocular	O
area	O
during	O
and	O
after	O
application	O
,	O
patients	O
should	O
wash	O
hands	O
well	O
after	O
applying	O
Picato	O
(	O
r	O
)	O
gel	O
.	O
	
The	O
reactions	O
generally	O
related	O
to	O
rash	B
and	O
pruritis	B
within	O
minutes	O
of	O
DaTscan	O
administration	O
.	O
	
(	O
5.7	O
)	O
(	O
8.1	O
)	O
5.1	O
Bone	O
Marrow	O
Suppression	O
Bone	B
marrow	I
suppression	I
manifested	O
as	O
neutropenia	B
,	O
anemia	B
,	O
thrombocytopenia	B
and/or	O
pancytopenia	B
may	O
occur	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Three	O
hundred	O
ninety-five	O
patients	O
,	O
including	O
approximately	O
250	O
children	O
(	O
aged	O
2	O
to	O
17	O
years	O
)	O
have	O
been	O
treated	O
with	O
ILARIS	O
in	O
interventional	O
trials	O
in	O
CAPS	O
or	O
SJIA	O
.	O
	
Overall	O
,	O
177	O
patients	O
were	O
enrolled	O
into	O
the	O
study	O
and	O
received	O
ILARIS	O
4	O
mg/kg	O
(	O
up	O
to	O
300	O
mg	O
maximum	O
)	O
in	O
Part	O
I	O
,	O
and	O
100	O
patients	O
received	O
ILARIS	O
4	O
mg/kg	O
(	O
up	O
to	O
300	O
mg	O
maximum	O
)	O
every	O
4	O
weeks	O
or	O
placebo	O
in	O
Part	O
II	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
for	O
patients	O
treated	O
with	O
STENDRA	O
(	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
)	O
was	O
2.8	O
%	O
.	O
	
Cases	O
of	O
pulmonary	B
toxicity	I
have	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Not	O
for	O
Acute	O
Use	O
TUDORZA	O
PRESSAIR	O
is	O
intended	O
as	O
a	O
twice-daily	O
maintenance	O
treatment	O
for	O
COPD	O
and	O
is	O
not	O
indicated	O
for	O
the	O
initial	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
(	O
i.e.	O
,	O
rescue	O
therapy	O
)	O
.	O
	
Intraocular	O
pressure	O
and	O
the	O
perfusion	O
of	O
the	O
optic	O
nerve	O
head	O
should	O
be	O
monitored	O
and	O
managed	O
appropriately	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.7	O
)	O
]	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
,	O
to	O
the	O
patient	O
's	O
underlying	O
vascular	O
risk	O
factors	O
or	O
anatomical	O
defects	O
,	O
to	O
a	O
combination	O
of	O
these	O
factors	O
,	O
or	O
to	O
other	O
factors	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
andPatient	O
Counseling	O
Information	O
(	O
17.6	O
)	O
]	O
.	O
	
If	O
bone	O
abnormalities	O
are	O
suspected	O
,	O
then	O
appropriate	O
consultation	O
should	O
be	O
obtained	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
ribavirin	O
for	O
additional	O
information	O
regarding	O
dose	O
reduction	O
and/or	O
discontinuation	O
.	O
	
Perform	O
a	O
baseline	O
ocular	O
examination	O
prior	O
to	O
administration	O
of	O
PROMACTA	O
and	O
,	O
during	O
therapy	O
with	O
PROMACTA	O
,	O
regularly	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
cataracts	O
.	O
	
Among	O
these	O
202	O
patients	O
,	O
66	O
(	O
33	O
%	O
)	O
were	O
exposed	O
to	O
TAFINLAR	O
and	O
68	O
(	O
34	O
%	O
)	O
were	O
exposed	O
to	O
trametinib	O
for	O
greater	O
than	O
6	O
to	O
12	O
months	O
while	O
40	O
(	O
20	O
%	O
)	O
were	O
exposed	O
to	O
TAFINLAR	O
and	O
36	O
(	O
18	O
%	O
)	O
were	O
exposed	O
to	O
trametinib	O
for	O
greater	O
than	O
one	O
year	O
.	O
	
Among	O
the	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
for	O
NSF	O
are	O
repeated	O
or	O
higher	O
than	O
recommended	O
doses	O
of	O
a	O
GBCA	O
and	O
degree	O
of	O
renal	O
impairment	O
at	O
the	O
time	O
of	O
exposure	O
.	O
	
Clinical	O
Trials	O
in	O
Infantile-Onset	O
and	O
Juvenile-Onset	O
Pompe	O
Disease	O
Two	O
multicenter	O
,	O
open-label	O
clinical	O
trials	O
were	O
conducted	O
in	O
39	O
infantile-onset	O
Pompe	O
disease	O
patients	O
,	O
ages	O
1	O
month	O
to	O
3.5	O
years	O
old	O
.	O
	
Subgroup	O
analyses	O
of	O
women	O
50	O
to	O
59	O
years	O
of	O
age	O
suggest	O
no	O
increased	O
risk	O
of	O
stroke	B
for	O
those	O
women	O
receiving	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
versus	O
those	O
receiving	O
placebo	O
(	O
18	O
versus	O
21	O
per	O
10,000	O
women-years	O
)	O
.	O
	
Although	O
the	O
effect	O
of	O
supplementation	O
with	O
calcium	O
and	O
vitamin	O
D	O
was	O
not	O
studied	O
,	O
such	O
supplementation	O
may	O
be	O
beneficial	O
in	O
all	O
patients	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Deaths	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
any	O
therapy	O
in	O
the	O
KRd	O
arm	O
occurred	O
in	O
27/392	O
(	O
7	O
%	O
)	O
patients	O
compared	O
with	O
27/389	O
(	O
7	O
%	O
)	O
patients	O
who	O
died	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
any	O
Rd	O
therapy	O
.	O
	
*	O
Store	O
DUAVEE	O
at	O
room	O
temperature	O
between	O
68	O
degrees	O
F	O
to	O
77	O
degrees	O
F	O
(	O
20	O
degrees	O
C	O
to	O
25	O
degrees	O
C	O
)	O
.	O
	
b	O
Grade	O
4	O
adverse	O
reactions	O
limited	O
to	O
hyperkeratosis	B
(	O
n	O
=	O
1	O
)	O
and	O
constipation	B
(	O
n	O
=	O
1	O
)	O
.	O
	
Management	O
includes	O
mouthwashes	O
and	O
topical	O
treatments	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
-	O
Stevens-Johnson	B
syndrome	I
.	O
	
More	O
frequent	O
monitoring	O
of	O
renal	O
function	O
is	O
recommended	O
in	O
these	O
patients	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
(	O
5.4	O
)	O
5	O
.	O
	
Discontinue	O
infusion	O
immediately	O
if	O
hypersensitivity	O
is	O
observed	O
and	O
treat	O
as	O
indicated	O
.	O
	
Depression	B
was	O
reported	O
as	O
serious	O
in	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
exposed	O
to	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/506	O
)	O
.	O
	
5.4	O
Hepatic	O
Toxicity	O
In	O
3865	O
patients	O
who	O
received	O
GILOTRIF	O
across	O
clinical	O
trials	O
,	O
10.1	O
%	O
had	O
liver	B
test	I
abnormalities	I
,	O
of	O
which	O
7	O
(	O
0.18	O
%	O
)	O
were	O
fatal	B
.	O
	
In	O
all	O
three	O
controlled	O
trials	O
,	O
patients	O
were	O
eligible	O
for	O
treatment	O
of	O
subsequent	O
attacks	O
in	O
an	O
open-label	O
extension	O
.	O
	
Adverse	O
reactions	O
leading	O
to	O
permanent	O
discontinuation	O
in	O
the	O
AFINITOR	O
arm	O
were	O
hypersensitivity/angioedema/bronchospasm	O
,	O
convulsion	B
,	O
and	O
hypophosphatemia	B
.	O
	
Avoid	O
use	O
of	O
FANAPT	O
in	O
combination	O
with	O
other	O
drugs	O
that	O
are	O
known	O
to	O
prolong	O
QTc	O
;	O
use	O
caution	O
and	O
consider	O
dose	O
modification	O
when	O
prescribing	O
FANAPT	O
with	O
other	O
drugs	O
that	O
inhibit	O
FANAPT	O
metabolism	O
.	O
	
What	O
is	O
DUAVEE	O
?	O
	
Patients	O
received	O
ERWINAZE	O
according	O
to	O
several	O
schedules	O
,	O
and	O
treatment	O
center	O
specifications	O
with	O
doses	O
that	O
ranged	O
from	O
20,000	O
to	O
25,000	O
International	O
Units/m	O
2	O
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
reactions	O
was	O
3.5	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
4.8	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
The	O
majority	O
of	O
adult	O
patients	O
were	O
enrolled	O
in	O
studies	O
in	O
Thailand	O
,	O
while	O
the	O
majority	O
of	O
pediatric	O
patients	O
were	O
enrolled	O
in	O
Africa	O
.	O
	
The	O
risk	O
of	O
developing	O
TD	B
and	O
the	O
likelihood	O
that	O
it	O
will	O
become	O
irreversible	O
are	O
believed	O
to	O
increase	O
as	O
the	O
duration	O
of	O
treatment	O
and	O
the	O
total	O
cumulative	O
dose	O
of	O
antipsychotic	O
drugs	O
administered	O
to	O
the	O
patient	O
increase	O
.	O
	
The	O
median	O
duration	O
of	O
study	O
treatment	O
was	O
10.9	O
months	O
for	O
patients	O
in	O
the	O
XALKORI	O
arm	O
and	O
4.1	O
months	O
for	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
to	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
one	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
Use	O
caution	O
when	O
driving	O
or	O
operating	O
machinery	O
.	O
	
Although	O
the	O
majority	O
of	O
these	O
events	O
were	O
observed	O
in	O
the	O
setting	O
of	O
CRS	B
,	O
some	O
were	O
observed	O
outside	O
of	O
this	O
setting	O
.	O
	
The	O
safety	O
of	O
HORIZANT	O
in	O
doses	O
ranging	O
from	O
600	O
to	O
2,400	O
mg	O
has	O
been	O
evaluated	O
in	O
515	O
patients	O
with	O
RLS	O
in	O
3	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
12	O
week	O
clinical	O
trials	O
.	O
	
Other	O
XIAFLEX-associated	O
serious	O
local	O
adverse	O
reactions	O
included	O
pulley	B
rupture	I
,	O
ligament	B
injury	I
,	O
complex	B
regional	I
pain	I
syndrome	I
(	O
CRPS	B
)	O
,	O
sensory	B
abnormality	I
of	I
the	I
hand	I
,	O
and	O
skin	B
laceration	I
)	O
.	O
	
Elderly	O
patients	O
may	O
be	O
at	O
greater	O
risk	O
of	O
developing	O
hyponatremia	B
with	O
SSRIs	O
and	O
SNRIs	O
.	O
	
Monitoring	O
of	O
orthostatic	O
vital	O
signs	O
should	O
be	O
considered	O
in	O
patients	O
who	O
are	O
vulnerable	O
to	O
hypotension	O
.	O
	
A	O
majority	O
of	O
reported	O
events	O
occurred	O
in	O
patients	O
who	O
had	O
experienced	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
or	O
dehydration	B
.	O
	
After	O
withdrawal	O
from	O
systemic	O
corticosteroids	O
,	O
a	O
number	O
of	O
months	O
are	O
required	O
for	O
recovery	O
of	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
function	O
.	O
	
Cases	O
have	O
occurred	O
after	O
the	O
first	O
dose	O
of	O
ADCETRIS	O
or	O
after	O
ADCETRIS	O
rechallenge	O
.	O
	
(	O
2.2	O
,	O
5.2	O
)	O
*	O
Interstitial	B
Lung	I
Disease	I
(	O
ILD	B
)	O
/Pneumonitis	O
:	O
Occurred	O
in	O
4	O
%	O
of	O
patients	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
associated	O
with	O
PROMACTA	O
are	O
described	O
in	O
other	O
sections	O
.	O
	
dIntracranial	O
bleed	B
included	O
subdural	B
bleeds	I
.	O
	
If	O
Grade	O
3	O
or	O
4	O
neutropenia	O
develops	O
,	O
consider	O
dose	O
delays	O
,	O
reductions	O
,	O
discontinuation	O
,	O
or	O
G-CSF	O
prophylaxis	O
with	O
subsequent	O
ADCETRIS	O
doses	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
5.4	O
Increased	O
Radiation	O
Exposure	O
in	O
Patients	O
with	O
Severe	O
Renal	O
Impairment	O
AdreView	O
is	O
cleared	O
by	O
glomerular	O
filtration	O
and	O
is	O
not	O
dialyzable	O
.	O
	
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
,	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
Blood	O
Disorders	O
:	O
Anemia	B
,	O
eosinophilia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
Eye	O
Disorders	O
:	O
Diplopia	B
,	O
vision	B
blurred	I
Gastrointestinal	O
Disorders	O
:	O
Abdominal	B
distention	I
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
Hypothermia	B
Investigations	O
:	O
Hepatic	B
enzyme	I
increased	I
Musculoskeletal	O
:	O
Muscle	B
spasms	I
Psychiatric	O
Disorders	O
:	O
Agitation	B
,	O
anxiety	B
,	O
apathy	B
,	O
confusional	B
state	I
,	O
depression	B
,	O
delirium	B
,	O
delusion	B
,	O
hallucination	B
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Urinary	B
retention	I
Respiratory	O
Disorders	O
:	O
Aspiration	B
,	O
respiratory	B
depression	I
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Rash	B
,	O
urticaria	B
,	O
angioedema	B
,	O
and	O
lip	B
edema	I
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Somnolence	B
or	O
Sedation	B
:	O
Monitor	O
for	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depression	O
.	O
	
For	O
COPD	O
,	O
increasing	O
the	O
daily	O
dose	O
of	O
BREO	O
ELLIPTA	O
100/25	O
is	O
not	O
appropriate	O
in	O
this	O
situation	O
.	O
	
A	O
total	O
of	O
2711	O
patients	O
treated	O
with	O
EYLEA	O
constituted	O
the	O
safety	O
population	O
in	O
seven	O
phase	O
3	O
studies	O
.	O
	
Bladder	O
cancer	O
risk	O
factors	O
and	O
hematuria	O
(	O
a	O
potential	O
indicator	O
of	O
pre-existing	O
tumors	O
)	O
were	O
balanced	O
between	O
treatment	O
arms	O
at	O
baseline	O
.	O
	
In	O
these	O
trials	O
,	O
patients	O
were	O
given	O
up	O
to	O
4	O
treatment	O
cycles	O
of	O
XIAFLEX	O
or	O
placebo	O
.	O
	
Prescriptions	O
for	O
FANAPT	O
should	O
be	O
written	O
for	O
the	O
smallest	O
quantity	O
of	O
tablets	O
consistent	O
with	O
good	O
patient	O
management	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
overdose	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
TB	B
for	O
all	O
patients	O
exposed	O
to	O
CIMZIA	O
across	O
all	O
indications	O
was	O
345	O
days	O
.	O
	
The	O
race	O
distribution	O
was	O
89	O
%	O
White	O
,	O
7	O
%	O
Black	O
,	O
3	O
%	O
Hispanic	O
,	O
1	O
%	O
other	O
,	O
and	O
<	O
1	O
%	O
Asian	O
.	O
	
Monitor	O
complete	O
blood	O
counts	O
monthly	O
.	O
	
Hematologic	B
toxicities	I
,	O
based	O
on	O
laboratory	O
values	O
and	O
CTC	O
grade	O
,	O
in	O
NHL	O
patients	O
treated	O
in	O
both	O
single	O
arm	O
studies	O
combined	O
are	O
described	O
in	O
Table	O
4	O
.	O
	
It	O
is	O
important	O
to	O
note	O
that	O
early	O
manifestations	O
of	O
hypersensitivity	B
,	O
such	O
as	O
fever	B
or	O
lymphadenopathy	B
,	O
may	O
be	O
present	O
even	O
though	O
rash	B
is	O
not	O
evident	O
.	O
	
Therefore	O
,	O
consider	O
dosage	O
modifications	O
of	O
both	O
APTIOM	O
and	O
carbamazepine	O
if	O
these	O
drugs	O
are	O
used	O
concomitantly	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Temporarily	O
suspend	O
,	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
XALKORI	O
.	O
	
Table	O
2	O
:	O
Proportion	O
of	O
Patients	O
With	O
at	O
Least	O
One	O
Volume	B
Depletion-Related	I
Adverse	I
Reaction	I
(	O
Pooled	O
Results	O
from	O
8	O
Clinical	O
Trials	O
)	O
Baseline	O
Characteristic	O
Comparator	O
Group	O
%	O
INVOKANA	O
100	O
mg	O
%	O
INVOKANA	O
300	O
mg	O
%	O
Overall	O
population	O
1.5	O
%	O
2.3	O
%	O
3.4	O
%	O
75	O
years	O
of	O
age	O
and	O
older	O
2.6	O
%	O
4.9	O
%	O
8.7	O
%	O
eGFR	B
less	I
than	I
60	I
mL/min/1.73	I
m	I
2	I
2.5	O
%	O
4.7	O
%	O
8.1	O
%	O
Use	O
of	O
loop	O
diuretic	O
4.7	O
%	O
3.2	O
%	O
8.8	O
%	O
Falls	O
In	O
a	O
pool	O
of	O
nine	O
clinical	O
trials	O
with	O
mean	O
duration	O
of	O
exposure	O
to	O
INVOKANA	O
of	O
85	O
weeks	O
,	O
the	O
proportion	O
of	O
patients	O
who	O
experienced	O
falls	B
was	O
1.3	O
%	O
,	O
1.5	O
%	O
,	O
and	O
2.1	O
%	O
with	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Risk	O
of	O
Suicidal	B
Thoughts	I
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Events	O
in	O
Drug	O
Patients/Incidence	O
in	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
Therefore	O
,	O
use	O
of	O
BENLYSTA	O
is	O
not	O
recommended	O
in	O
combination	O
with	O
biologic	O
therapies	O
or	O
intravenous	O
cyclophosphamide	O
.	O
	
Electrocardiographic	O
Findings	O
ECG	O
measurements	O
were	O
only	O
recorded	O
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
an	O
open-label	O
study	O
without	O
a	O
placebo	O
or	O
active	O
control	O
.	O
	
Adverse	O
events	O
leading	O
to	O
discontinuation	O
of	O
Kyprolis	O
occurred	O
in	O
12	O
%	O
of	O
patients	O
and	O
the	O
most	O
common	O
events	O
included	O
pneumonia	B
(	O
1	O
%	O
)	O
,	O
myocardial	B
infarction	I
(	O
0.8	O
%	O
)	O
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
(	O
0.8	O
%	O
)	O
.	O
	
*	O
currently	O
have	O
or	O
have	O
had	O
certain	O
cancers	O
.	O
	
More	O
serious	O
or	O
even	O
fatal	B
course	O
of	O
chickenpox	B
or	O
measles	B
can	O
occur	O
in	O
susceptible	O
patients	O
.	O
	
BENLYSTA	O
should	O
be	O
administered	O
by	O
healthcare	O
providers	O
prepared	O
to	O
manage	O
infusion	O
reactions	O
.	O
	
Breathing	O
Difficulty	O
Breathing	B
difficulties	I
were	O
reported	O
by	O
approximately	O
3	O
%	O
of	O
patients	O
following	O
DYSPORT	O
(	O
r	O
)	O
administration	O
and	O
in	O
1	O
%	O
of	O
placebo	O
patients	O
in	O
clinical	O
trials	O
during	O
the	O
double-blind	O
phase	O
.	O
	
Your	O
healthcare	O
provider	O
may	O
need	O
to	O
check	O
you	O
more	O
carefully	O
if	O
you	O
have	O
certain	O
conditions	O
,	O
such	O
as	O
asthma	O
(	O
wheezing	O
)	O
,	O
epilepsy	O
(	O
seizures	O
)	O
,	O
diabetes	O
,	O
migraine	O
,	O
endometriosis	O
,	O
lupus	O
,	O
or	O
problems	O
with	O
your	O
heart	O
,	O
liver	O
,	O
thyroid	O
,	O
kidneys	O
,	O
or	O
have	O
high	O
calcium	O
levels	O
in	O
your	O
blood	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Tables	O
2	O
and	O
3	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
200/25	O
included	O
viral	B
respiratory	I
tract	I
infection	I
,	O
pharyngitis	B
,	O
pyrexia	B
,	O
and	O
arthralgia	B
.	O
	
Six	O
of	O
the	O
9	O
patients	O
were	O
hospitalized	O
for	O
severe	O
endocrinopathies	B
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
Observed	O
in	O
Treatment-naive	O
and	O
Treatment-experienced	O
Trials	O
The	O
following	O
ADRs	O
occurred	O
in	O
less	O
than	O
2	O
%	O
of	O
treatment-naive	O
or	O
treatment-experienced	O
subjects	O
receiving	O
TIVICAY	O
in	O
a	O
combination	O
regimen	O
in	O
any	O
one	O
trial	O
.	O
	
Do	O
not	O
administer	O
in	O
combination	O
with	O
HEPSERA	O
.	O
	
Subjects	O
participating	O
in	O
this	O
trial	O
had	O
a	O
history	O
of	O
one	O
or	O
more	O
asthma	O
exacerbations	O
that	O
required	O
treatment	O
with	O
oral/systemic	O
corticosteroids	O
or	O
emergency	O
department	O
visit	O
or	O
in-patient	O
hospitalization	O
for	O
the	O
treatment	O
of	O
asthma	O
in	O
the	O
year	O
prior	O
to	O
trial	O
entry	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
,	O
rash	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
edema	B
,	O
abdominal	B
pain	I
,	O
nausea	B
,	O
fever	B
,	O
and	O
headache	B
.	O
	
Unless	O
an	O
alternate	O
etiology	O
has	O
been	O
identified	O
,	O
signs	O
or	O
symptoms	O
of	O
endocrinopathies	O
should	O
be	O
considered	O
immune-mediated	O
.	O
	
Of	O
the	O
353	O
patients	O
included	O
in	O
the	O
pooled	O
analyses	O
of	O
patients	O
with	O
CF	O
who	O
had	O
either	O
a	O
G551D	O
mutation	O
or	O
were	O
homozygous	O
for	O
the	O
F508del	O
mutation	O
in	O
the	O
CFTR	O
gene	O
,	O
50	O
%	O
of	O
patients	O
were	O
female	O
and	O
97	O
%	O
were	O
Caucasian	O
;	O
221	O
received	O
KALYDECO	O
,	O
and	O
132	O
received	O
placebo	O
from	O
16	O
to	O
48	O
weeks	O
.	O
	
In	O
these	O
studies	O
,	O
a	O
total	O
of	O
6285	O
patients	O
were	O
randomized	O
and	O
treated	O
,	O
3282	O
patients	O
with	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
,	O
and	O
2875	O
with	O
placebo	O
.	O
	
There	O
were	O
two	O
additional	O
reports	O
of	O
RPLS	B
in	O
other	O
clinical	O
trials	O
with	O
INLYTA	O
.	O
	
Good	O
oral	O
hygiene	O
practices	O
should	O
be	O
maintained	O
during	O
treatment	O
with	O
Prolia	O
.	O
	
Although	O
a	O
causal	O
link	O
between	O
the	O
emergence	O
of	O
such	O
symptoms	O
and	O
either	O
the	O
worsening	B
of	I
depression	I
and/or	O
the	O
emergence	O
of	O
suicidal	B
impulses	I
has	O
not	O
been	O
established	O
,	O
there	O
is	O
concern	O
that	O
such	O
symptoms	O
may	O
represent	O
precursors	O
to	O
emerging	O
suicidality	B
.	O
	
ONJ	B
has	O
been	O
reported	O
in	O
patients	O
receiving	O
denosumab	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
post-marketing	O
period	O
seizures	B
have	O
been	O
reported	O
.	O
	
EXCERPT	O
:	O
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
related	O
adverse	O
events	O
(	O
occurring	O
in	O
>	O
1	O
%	O
of	O
patients	O
)	O
were	O
paraesthesia	B
,	O
flushing	B
,	O
nausea	B
and/or	O
vomiting	B
,	O
hypotension	B
and	O
headache	B
.	O
	
It	O
is	O
possible	O
that	O
use	O
of	O
IL-1	O
inhibitors	O
such	O
as	O
ILARIS	O
increases	O
the	O
risk	O
of	O
reactivation	B
of	I
tuberculosis	I
or	O
of	O
opportunistic	B
infections	I
.	O
	
*	O
b	O
See	O
below	O
for	O
other	O
events	O
of	O
injection	B
site	I
reactions	I
reported	O
.	O
	
Due	O
to	O
the	O
long	O
half-life	O
of	O
DAMPA	O
(	O
t1/2of	O
approximately	O
9	O
hours	O
)	O
,	O
measurement	O
of	O
methotrexate	O
using	O
immunoassays	O
is	O
unreliable	O
for	O
samples	O
collected	O
within	O
48	O
hours	O
following	O
VORAXAZE	O
administration	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.1	O
)	O
]	O
.	O
	
Other	O
Adverse	O
Reactions	O
Table	O
1	O
summarizes	O
the	O
adverse	O
drug	O
reactions	O
that	O
occurred	O
at	O
a	O
rate	O
of	O
at	O
least	O
1	O
%	O
in	O
the	O
SIMPONI	O
ARIA	O
+	O
MTX	O
group	O
with	O
a	O
higher	O
incidence	O
than	O
in	O
the	O
placebo	O
+	O
MTX	O
group	O
during	O
the	O
controlled	O
period	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
.	O
	
Table	O
8	O
.	O
	
The	O
median	O
time	O
from	O
onset	O
to	O
resolution	O
or	O
improvement	O
of	O
any	O
grade	O
was	O
23	O
weeks	O
(	O
range	O
,	O
0.1-138	O
)	O
,	O
of	O
Grade	O
2	O
was	O
24	O
weeks	O
(	O
range	O
,	O
1-108	O
)	O
and	O
of	O
Grade	O
3	O
was	O
25	O
weeks	O
(	O
range	O
,	O
2-98	O
)	O
.	O
	
Because	O
this	O
adverse	O
reaction	O
was	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
possible	O
to	O
estimate	O
its	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
general	O
anesthesia	O
.	O
	
Exercise	O
caution	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
monitor	O
them	O
carefully	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
the	O
emergence	O
of	O
serotonin	O
syndrome	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
shock	B
have	O
uncommonly	O
occurred	O
following	O
EOVIST	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
If	O
mefloquine	O
is	O
administered	O
immediately	O
prior	O
to	O
Coartem	O
Tablets	O
there	O
may	O
be	O
a	O
decreased	O
exposure	O
to	O
lumefantrine	O
,	O
possibly	O
due	O
to	O
a	O
mefloquine-induced	O
decrease	O
in	O
bile	O
production	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
generalized	B
rash	I
,	O
Stevens	B
Johnson	I
Syndrome	I
,	O
hypersensitivity	B
skin	I
reactions	I
.	O
	
Events	O
resulting	O
in	O
discontinuation	O
were	O
similar	O
to	O
those	O
seen	O
in	O
previous	O
studies	O
with	O
PegIntron/REBETOL	O
.	O
	
*	O
In	O
those	O
patients	O
who	O
are	O
stable	O
on	O
alpha-blocker	O
therapy	O
,	O
PDE5	O
inhibitors	O
should	O
be	O
initiated	O
at	O
the	O
lowest	O
dose	O
(	O
STENDRA	O
50	O
mg	O
)	O
.	O
	
Therefore	O
,	O
physicians	O
should	O
inform	O
patients	O
that	O
substantial	O
consumption	O
of	O
alcohol	O
(	O
e.g.	O
,	O
greater	O
than	O
3	O
units	O
)	O
in	O
combination	O
with	O
STENDRA	O
may	O
increase	O
the	O
potential	O
for	O
orthostatic	O
signs	O
and	O
symptoms	O
,	O
including	O
increase	O
in	O
heart	O
rate	O
,	O
decrease	O
in	O
standing	O
blood	O
pressure	O
,	O
dizziness	O
,	O
and	O
headache	O
[	O
seeDrug	O
Interactions	O
(	O
7.1	O
)	O
andClinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
5.4	O
Extravasation	O
and	O
Injection	O
Site	O
Reactions	O
Ensure	O
catheter	O
and	O
venous	O
patency	O
before	O
the	O
injection	O
of	O
Gadavist	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Review	O
the	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
prior	O
to	O
initiation	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Monitoring	O
of	O
renal	O
function	O
,	O
including	O
measurement	O
of	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
,	O
urinary	O
protein	O
,	O
or	O
serum	O
creatinine	O
,	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-controlled	O
Trials	O
Reported	O
in	O
>	O
=5	O
%	O
of	O
Patients	O
Treated	O
with	O
TANZEUM	O
a	O
Adverse	O
Reaction	O
Placebo	O
(	O
N	O
=	O
468	O
)	O
%	O
TANZEUM	O
(	O
N	O
=	O
923	O
)	O
%	O
Upper	B
respiratory	I
tract	I
infection	I
13.0	O
14.2	O
Diarrhea	B
10.5	O
13.1	O
Nausea	B
9.6	O
11.1	O
Injection	B
site	I
reactionb	O
2.1	O
10.5	O
Cough	B
6.2	O
6.9	O
Back	B
pain	I
5.8	O
6.7	O
Arthralgia	B
6.4	O
6.6	O
Sinusitis	B
5.8	O
6.2	O
Influenza	B
3.2	O
5.2	O
*	O
a	O
Adverse	O
reactions	O
reported	O
includes	O
adverse	O
reactions	O
occurring	O
with	O
the	O
use	O
of	O
glycemic	O
rescue	O
medications	O
which	O
included	O
metformin	O
(	O
17	O
%	O
for	O
placebo	O
and	O
10	O
%	O
for	O
TANZEUM	O
)	O
and	O
insulin	O
(	O
24	O
%	O
for	O
placebo	O
and	O
14	O
%	O
for	O
TANZEUM	O
)	O
.	O
	
Eight	O
of	O
these	O
11	O
patients	O
had	O
received	O
a	O
single	O
dose	O
of	O
VORAXAZE	O
.	O
	
For	O
patients	O
with	O
SEGA	O
and	O
mild	O
or	O
moderate	O
hepatic	O
impairment	O
,	O
adjust	O
the	O
dose	O
of	O
AFINITOR	O
Tablets	O
or	O
AFINITOR	O
DISPERZ	O
based	O
on	O
therapeutic	O
drug	O
monitoring	O
.	O
	
Discontinue	O
GRANIX	O
in	O
patients	O
with	O
ARDS	O
.	O
	
Table	O
3	O
:	O
Bleeding	B
During	O
the	O
Treatment	O
Period	O
in	O
Patients	O
Undergoing	O
Elective	O
Hip	O
or	O
Knee	O
Replacement	O
Surgery	O
Bleeding	O
Endpoint*	O
ADVANCE-3Hip	O
Replacement	O
Surgery	O
ADVANCE-2Knee	O
Replacement	O
Surgery	O
ADVANCE-1Knee	O
Replacement	O
Surgery	O
*	O
All	O
bleeding	B
criteria	O
included	O
surgical	B
site	I
bleeding	I
.	O
	
Advise	O
female	O
patients	O
of	O
reproductive	O
potential	O
to	O
use	O
a	O
highly	O
effective	O
non-hormonal	O
method	O
of	O
contraception	O
since	O
TAFINLAR	O
can	O
render	O
hormonal	O
contraceptives	O
ineffective	O
,	O
during	O
treatment	O
and	O
for	O
at	O
least	O
2	O
weeks	O
after	O
treatment	O
with	O
TAFINLAR	O
or	O
for	O
4	O
months	O
after	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
majority	O
of	O
seizures	B
occurred	O
at	O
the	O
recommended	O
dose	O
and	O
in	O
patients	O
without	O
a	O
history	O
of	O
seizures	O
,	O
and	O
generally	O
within	O
days	O
to	O
weeks	O
of	O
starting	O
therapy	O
.	O
	
If	O
either	O
occurs	O
,	O
decrease	O
the	O
dose	O
of	O
Cleviprex	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
prematurely	O
discontinued	O
study	O
drug	O
due	O
to	O
adverse	O
reactions	O
was	O
2	O
%	O
for	O
KALYDECO-treated	O
patients	O
and	O
5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
All	O
patients	O
started	O
the	O
study	O
at	O
a	O
dose	O
of	O
100	O
mg/m	O
2	O
intravenously	O
over	O
30	O
minutes	O
on	O
Days	O
1	O
and	O
2	O
every	O
28	O
days	O
.	O
	
5.9	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
reversible	B
posterior	I
leukoencephalopathy	I
syndrome	I
(	O
RPLS	B
)	O
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
mean	O
exposure	O
across	O
studies	O
was	O
12	O
months	O
.	O
	
In	O
some	O
patients	O
infected	O
with	O
HBV	O
and	O
treated	O
with	O
EMTRIVA	O
,	O
the	O
exacerbations	B
of	I
hepatitis	I
B	I
were	O
associated	O
with	O
liver	B
decompensation	I
and	O
liver	B
failure	I
.	O
	
Immune-mediated	B
reactions	I
presenting	O
as	O
proteinuria	B
,	O
nephrotic	B
syndrome	I
,	O
and	O
necrotizing	B
skin	I
lesions	I
have	O
occurred	O
in	O
some	O
patients	O
following	O
alglucosidase	O
alfa	O
treatment	O
.	O
	
Overall	O
,	O
67	O
%	O
were	O
female	O
and	O
73	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
42	O
years	O
(	O
adolescents	O
aged	O
12	O
to	O
17	O
years	O
made	O
up	O
14	O
%	O
of	O
the	O
population	O
)	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
were	O
stomatitis	B
and	O
diarrhea	B
.	O
	
(	O
5.3	O
)	O
*	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
for	O
narrow-angle	O
glaucoma	O
,	O
and	O
only	O
where	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
(	O
5.4	O
)	O
*	O
Central	B
Nervous	I
System	I
Effects	I
:	O
Somnolence	B
has	O
been	O
reported	O
with	O
Toviaz	O
.	O
	
5.2	O
Bladder	O
Outlet	O
Obstruction	O
Toviaz	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
with	O
clinically	O
significant	O
bladder	O
outlet	O
obstruction	O
because	O
of	O
the	O
risk	O
of	O
urinary	O
retention	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
CK	B
elevations	I
>	O
=3	O
times	O
ULN	O
during	O
a	O
3-week	O
trial	O
in	O
pediatric	O
bipolar	O
I	O
disorder	O
at	O
any	O
time	O
were	O
1	O
%	O
,	O
0	O
%	O
,	O
and	O
1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
versus	O
3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
*	O
Take	O
1	O
DUAVEE	O
tablet	O
at	O
the	O
same	O
time	O
each	O
day	O
.	O
	
*	O
are	O
going	O
to	O
have	O
surgery	O
or	O
will	O
be	O
on	O
bed	O
rest	O
.	O
	
Other	O
errors	O
may	O
be	O
due	O
to	O
extensive	O
brain	O
atrophy	O
that	O
limits	O
the	O
ability	O
to	O
distinguish	O
gray	O
and	O
white	O
matter	O
on	O
the	O
Amyvid	O
scan	O
as	O
well	O
as	O
motion	O
artifacts	O
that	O
distort	O
the	O
image	O
.	O
	
No	O
serious	O
adverse	O
events	O
occurred	O
in	O
patients	O
who	O
received	O
XEOMIN	O
;	O
one	O
placebo-treated	O
patient	O
experienced	O
a	O
serious	O
adverse	O
event	O
(	O
dyspnea	B
)	O
.	O
	
Vascular	O
Events	O
Vascular	B
events	I
,	O
including	O
hemorrhagic	B
strokes	I
,	O
and	O
peripheral	B
arterial	I
occlusive	I
disease	I
were	O
reported	O
in	O
premarketing	O
clinical	O
trials	O
in	O
patients	O
who	O
received	O
GILENYA	O
doses	O
(	O
1.25-5	O
mg	O
)	O
higher	O
than	O
recommended	O
for	O
use	O
in	O
MS	O
.	O
	
In	O
clinical	O
trials	O
with	O
INLYTA	O
,	O
gastrointestinal	B
perforation	I
was	O
reported	O
in	O
5/715	O
patients	O
(	O
1	O
%	O
)	O
,	O
including	O
one	O
death	B
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
Among	O
SAPHRIS-Treated	O
(	O
Adjunctive	O
)	O
Bipolar	O
Patients	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
2	O
%	O
or	O
greater	O
,	O
rounded	O
to	O
the	O
nearest	O
percent	O
,	O
and	O
SAPHRIS	O
incidence	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
adjunctive	O
therapy	O
at	O
3	O
weeks	O
,	O
a	O
time	O
when	O
most	O
of	O
the	O
patients	O
were	O
still	O
participating	O
in	O
the	O
trial	O
,	O
are	O
shown	O
in	O
Table	O
11	O
.	O
	
Adverse	O
Reactions	O
Most	O
Commonly	O
Leading	O
to	O
Discontinuation	O
of	O
Treatment	O
in	O
Premarketing	O
Controlled	O
Trials	O
The	O
proportion	O
of	O
patients	O
with	O
Crohn	O
's	O
disease	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
clinical	O
studies	O
was	O
8	O
%	O
for	O
CIMZIA	O
and	O
7	O
%	O
for	O
placebo	O
.	O
	
5.7	O
Coexisting	O
Conditions	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
or	O
thyrotoxicosis	O
,	O
and	O
in	O
patients	O
who	O
are	O
unusually	O
responsive	O
to	O
sympathomimetic	O
amines	O
.	O
	
The	O
safety	O
and	O
efficacy	O
of	O
CIMZIA	O
in	O
patients	O
with	O
immunosuppression	O
has	O
not	O
been	O
formally	O
evaluated	O
.	O
	
Co-administration	O
of	O
SIRTURO	O
with	O
strong	O
CYP3A4	O
inhibitors	O
may	O
increase	O
the	O
systemic	O
exposure	O
to	O
bedaquiline	O
,	O
which	O
could	O
potentially	O
increase	O
the	O
risk	O
of	O
adverse	O
reactions	O
.	O
	
The	O
incidence	O
of	O
dizziness	B
was	O
greater	O
with	O
the	O
concomitant	O
use	O
of	O
APTIOM	O
and	O
carbamazepine	O
compared	O
to	O
the	O
use	O
of	O
APTIOM	O
without	O
carbamazepine	O
(	O
up	O
to	O
37	O
%	O
vs.	O
19	O
%	O
,	O
respectively	O
)	O
.	O
	
Advise	O
women	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
taking	O
IMBRUVICA	O
.	O
	
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
The	O
majority	O
of	O
these	O
immune-mediated	B
reactions	I
initially	O
manifested	O
during	O
treatment	O
;	O
however	O
,	O
a	O
minority	O
occurred	O
weeks	O
to	O
months	O
after	O
discontinuation	O
of	O
YERVOY	O
.	O
	
Some	O
women	O
may	O
encounter	O
amenorrhea	B
or	O
oligomenorrhea	B
after	O
stopping	O
COCs	O
,	O
especially	O
when	O
such	O
a	O
condition	O
was	O
pre-existent	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Consider	O
administration	O
of	O
platelet	O
concentrates	O
in	O
cases	O
where	O
thrombocytopenia	O
is	O
present	O
or	O
long-acting	O
antiplatelet	O
drugs	O
have	O
been	O
used	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatotoxicity	B
:	O
Beleodaq	O
may	O
cause	O
hepatic	B
toxicity	I
and	O
liver	B
function	I
test	I
abnormalities	I
.	O
	
(	O
5.5	O
)	O
*	O
Anaphylaxis	B
:	O
Monitor	O
patients	O
for	O
anaphylaxis	O
and	O
discontinue	O
Zydelig	O
.	O
	
5.2	O
Imaging	O
Errors	O
due	O
to	O
Concomitant	O
Medications	O
and	O
Risks	O
Associated	O
with	O
Withdrawal	O
of	O
Medications	O
Many	O
medications	O
have	O
the	O
potential	O
to	O
interfere	O
with	O
AdreView	O
imaging	O
and	O
review	O
of	O
the	O
patient	O
's	O
medications	O
is	O
required	O
prior	O
to	O
AdreView	O
dosing	O
due	O
to	O
the	O
risk	O
for	O
unreliable	O
imaging	O
results	O
.	O
	
5.5	O
Pneumonia	O
An	O
increase	O
in	O
the	O
incidence	O
of	O
pneumonia	B
has	O
been	O
observed	O
in	O
subjects	O
with	O
COPD	O
receiving	O
BREO	O
ELLIPTA	O
100/25	O
in	O
clinical	O
trials	O
.	O
	
Women	O
should	O
be	O
advised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
on	O
this	O
drug	O
.	O
	
COCs	O
have	O
been	O
shown	O
to	O
increase	O
both	O
the	O
relative	O
and	O
attributable	O
risks	O
of	O
cerebrovascular	B
events	I
(	O
hemorrhagic	B
strokes	I
)	O
,	O
although	O
,	O
in	O
general	O
,	O
the	O
risk	O
is	O
greatest	O
among	O
older	O
(	O
>	O
35	O
years	O
of	O
age	O
)	O
,	O
hypertensive	O
women	O
who	O
also	O
smoke	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
Grade	O
3-5	O
hepatotoxicity	O
and	O
administer	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
Increasing	O
use	O
of	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
is	O
a	O
marker	O
of	O
deteriorating	O
asthma	O
.	O
	
Adverse	O
reactions	O
are	O
categorized	O
by	O
system	O
organ	O
class	O
.	O
	
Ferriprox	O
can	O
also	O
cause	O
neutropenia	B
,	O
which	O
may	O
foreshadow	O
agranulocytosis	B
.	O
	
Table	O
3	O
Bleeding	B
Events	O
in	O
RE-COVER	O
and	O
RE-COVER	O
II	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
Risk	O
may	O
be	O
increased	O
with	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressants	O
.	O
	
Patients	O
should	O
not	O
use	O
more	O
than	O
1	O
inhalation	O
once	O
daily	O
of	O
BREO	O
ELLIPTA	O
.	O
	
Oral	O
contraceptives	O
must	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
cardiovascular	O
disease	O
risk	O
factors	O
.	O
	
*	O
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
patients	O
(	O
3.7	O
%	O
)	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
If	O
the	O
patient	O
is	O
known	O
or	O
strongly	O
suspected	O
to	O
have	O
hypersensitivity	O
to	O
iodine	O
,	O
an	O
iodine-containing	O
contrast	O
agent	O
or	O
other	O
products	O
containing	O
iodine	O
,	O
the	O
decision	O
to	O
administer	O
AdreView	O
should	O
be	O
based	O
upon	O
an	O
assessment	O
of	O
the	O
expected	O
benefits	O
compared	O
to	O
the	O
potential	O
hypersensitivity	O
risks	O
.	O
	
Discontinue	O
Zydelig	O
if	O
intestinal	O
perforation	O
is	O
suspected	O
.	O
	
5.14	O
Other	O
Conditions	O
In	O
women	O
with	O
hereditary	O
angioedema	O
,	O
exogenous	O
estrogens	O
may	O
induce	O
or	O
exacerbate	O
symptoms	O
of	O
angioedema	B
.	O
	
The	O
rate	O
of	O
progression	O
of	O
retinal	B
abnormalities	I
and	O
their	O
reversibility	O
are	O
unknown	O
.	O
	
Tuberculosis	O
and	O
Opportunistic	O
Infections	O
In	O
completed	O
and	O
ongoing	O
global	O
clinical	O
studies	O
in	O
all	O
indications	O
including	O
5,118	O
CIMZIA-treated	O
patients	O
,	O
the	O
overall	O
rate	O
of	O
tuberculosis	B
is	O
approximately	O
0.61	O
per	O
100	O
patient-years	O
across	O
all	O
indications	O
.	O
	
Documented	O
symptomatic	B
hypoglycemia	I
occurred	O
in	O
85	O
%	O
and	O
80	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
prandial	O
insulin	O
.	O
	
Epilepsy	O
and	O
many	O
other	O
illnesses	O
for	O
which	O
AEDs	O
are	O
prescribed	O
are	O
themselves	O
associated	O
with	O
morbidity	B
and	O
mortality	B
and	O
an	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
.	O
	
Frequent	O
symptoms	O
of	O
hypersensitivity	B
reactions	O
(	O
occurring	O
in	O
more	O
than	O
2	O
patients	O
)	O
included	O
anaphylactic	B
reactions	I
,	O
urticaria	B
,	O
peripheral	B
edema	I
,	O
cough	B
,	O
dyspnea	B
,	O
and	O
flushing	B
.	O
	
These	O
findings	O
confirm	O
the	O
myelosuppressive	B
effects	I
seen	O
in	O
patients	O
treated	O
with	O
TREANDA	O
.	O
	
Avoid	O
use	O
of	O
XALKORI	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
.	O
	
Other	O
binding	O
proteins	O
may	O
be	O
elevated	B
in	I
serum	I
,	I
for	I
example	I
,	I
corticosteroid	I
binding	I
globulin	I
)	O
,	O
leading	O
to	O
increased	B
total	I
circulating	I
corticosteroids	I
,	O
respectively	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
C	O
)	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
andClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
5.11	O
Immunosuppression	O
Since	O
TNF	O
mediates	O
inflammation	O
and	O
modulates	O
cellular	O
immune	O
responses	O
,	O
the	O
possibility	O
exists	O
for	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
to	O
affect	O
host	O
defenses	O
against	O
infections	O
and	O
malignancies	O
.	O
	
Following	O
the	O
second	O
dose	O
,	O
a	O
further	O
decrease	B
in	I
heart	I
rate	I
may	O
occur	O
when	O
compared	O
to	O
the	O
heart	O
rate	O
prior	O
to	O
the	O
second	O
dose	O
,	O
but	O
this	O
change	O
is	O
of	O
a	O
smaller	O
magnitude	O
than	O
that	O
observed	O
following	O
the	O
first	O
dose	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
clinical	O
studies	O
was	O
5	O
%	O
for	O
CIMZIA	O
and	O
2.5	O
%	O
for	O
placebo	O
.	O
	
Without	O
knowledge	O
of	O
the	O
background	O
incidence	O
and	O
recurrence	O
in	O
a	O
similar	O
population	O
not	O
treated	O
with	O
gabapentin	O
,	O
it	O
is	O
impossible	O
to	O
know	O
whether	O
the	O
incidence	O
reported	O
in	O
this	O
cohort	O
is	O
or	O
is	O
not	O
affected	O
by	O
treatment	O
.	O
	
Immune-mediated	B
dermatitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Laboratory	O
Abnormalities	O
Table	O
8	O
describes	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
reported	O
at	O
a	O
rate	O
of	O
>	O
10	O
%	O
for	O
patients	O
who	O
received	O
Kyprolis	O
monotherapy	O
.	O
	
The	O
risk	O
of	O
acute	O
kidney	O
injury	O
may	O
increase	O
with	O
increasing	O
dose	O
of	O
the	O
contrast	O
agent	O
;	O
administer	O
the	O
lowest	O
dose	O
necessary	O
for	O
adequate	O
imaging	O
.	O
	
During	O
the	O
trial	O
,	O
48	O
%	O
of	O
patients	O
on	O
the	O
XTANDI	O
arm	O
and	O
46	O
%	O
of	O
patients	O
on	O
the	O
placebo	O
arm	O
received	O
glucocorticoids	O
.	O
	
Out	O
of	O
2,133	O
patients	O
in	O
3	O
clinical	O
trials	O
,	O
a	O
total	O
of	O
14	O
deaths	B
occurred	O
during	O
the	O
placebo-controlled	O
,	O
double-blind	O
treatment	O
periods	O
:	O
3/675	O
(	O
0.4	O
%	O
)	O
,	O
5/673	O
(	O
0.7	O
%	O
)	O
,	O
0/111	O
(	O
0	O
%	O
)	O
,	O
and	O
6/674	O
(	O
0.9	O
%	O
)	O
deaths	B
in	O
the	O
groups	O
receiving	O
placebo	O
,	O
BENLYSTA	O
1	O
mg/kg	O
,	O
BENLYSTA	O
4	O
mg/kg	O
,	O
and	O
BENLYSTA	O
10	O
mg/kg	O
,	O
respectively	O
.	O
	
The	O
mean	O
age	O
was	O
39	O
years	O
;	O
adolescents	O
(	O
aged	O
12	O
to	O
17	O
years	O
)	O
made	O
up	O
16	O
%	O
of	O
the	O
population	O
.	O
	
The	O
adverse	O
events	O
observed	O
during	O
long-term	O
,	O
open-label	O
studies	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
12-week	O
,	O
placebo-controlled	O
studies	O
,	O
and	O
included	O
dry	B
mouth	I
,	O
constipation	B
,	O
dry	B
eyes	I
,	O
dyspepsia	B
,	O
and	O
abdominal	B
pain	I
.	O
	
In	O
short-term	O
trials	O
with	O
ENTEREG	O
(	O
r	O
)	O
,	O
no	O
increased	O
risk	O
of	O
myocardial	B
infarction	I
was	O
observed	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
the	O
JEVTANA	O
group	O
were	O
neutropenia	B
and	O
renal	B
failure	I
.	O
	
5.9	O
Autoimmunity	O
Treatment	O
with	O
CIMZIA	O
may	O
result	O
in	O
the	O
formation	B
of	I
autoantibodies	I
and	O
rarely	O
,	O
in	O
the	O
development	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ANAPHYLAXIS	B
WARNING	O
:	O
ANAPHYLAXIS	B
Anaphylaxis	B
has	O
been	O
reported	O
after	O
administration	O
of	O
KALBITOR	O
.	O
	
Closely	O
observe	O
patients	O
with	O
G6PD	O
deficiency	O
for	O
signs	O
of	O
hemolytic	O
anemia	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Division	O
of	O
Nuclear	O
Medicine	O
,	O
Department	O
of	O
Radiology	O
,	O
Mayo	O
Clinic	O
at	O
507-284-2511	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Imaging	O
errors	O
have	O
been	O
reported	O
;	O
blood	O
PSA	O
levels	O
<	O
2	O
ng/mL	O
have	O
been	O
associated	O
with	O
poor	O
imaging	O
performance	O
(	O
5.1	O
)	O
.	O
	
5.2	O
Monitoring	O
Methotrexate	O
Concentration/Interference	O
with	O
Assay	O
Methotrexate	O
concentrations	O
within	O
48	O
hours	O
following	O
administration	O
of	O
VORAXAZE	O
can	O
only	O
be	O
reliably	O
measured	O
by	O
a	O
chromatographic	O
method	O
.	O
	
Patients	O
should	O
be	O
informed	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
and	O
instructed	O
to	O
discontinue	O
AMPYRA	O
and	O
seek	O
immediate	O
medical	O
care	O
should	O
these	O
signs	O
and	O
symptoms	O
occur	O
(	O
17.3	O
)	O
.	O
	
Elderly	O
Population	O
:	O
The	O
following	O
grade	O
1-4	O
adverse	O
reactions	O
were	O
reported	O
at	O
rates	O
>	O
=	O
5	O
%	O
higher	O
in	O
patients	O
65	O
years	O
of	O
age	O
or	O
greater	O
compared	O
to	O
younger	O
patients	O
:	O
fatigue	B
(	O
40	O
%	O
vs.	O
30	O
%	O
)	O
,	O
neutropenia	B
(	O
97	O
%	O
vs.	O
89	O
%	O
)	O
,	O
asthenia	B
(	O
24	O
%	O
vs.	O
15	O
%	O
)	O
,	O
pyrexia	B
(	O
15	O
%	O
vs.	O
8	O
%	O
)	O
,	O
dizziness	B
(	O
10	O
%	O
vs.	O
5	O
%	O
)	O
,	O
urinary	B
tract	I
infection	I
(	O
10	O
%	O
vs.	O
3	O
%	O
)	O
and	O
dehydration	B
(	O
7	O
%	O
vs.	O
2	O
%	O
)	O
,	O
respectively	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
LABA	O
,	O
such	O
as	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
QT	O
Prolongation	O
:	O
In	O
Trial	O
2	O
,	O
QTcF	B
prolongation	I
to	O
>	O
500	O
msec	O
occurred	O
in	O
4	O
%	O
(	O
2/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
in	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
The	O
reported	O
endometrial	B
cancer	I
risk	O
among	O
unopposed	O
estrogen	O
users	O
is	O
about	O
2	O
to	O
12	O
times	O
greater	O
than	O
in	O
non-users	O
,	O
and	O
appears	O
dependent	O
on	O
duration	O
of	O
treatment	O
and	O
on	O
estrogen	O
dose	O
.	O
	
5.3	O
Increased	O
Risk	O
of	O
Stroke	O
in	O
Permanent	O
AF	O
In	O
a	O
placebo-controlled	O
study	O
in	O
patients	O
with	O
permanent	O
atrial	O
fibrillation	O
,	O
dronedarone	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
stroke	B
,	O
particularly	O
in	O
the	O
first	O
two	O
weeks	O
of	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.4	O
)	O
]	O
.	O
	
Consideration	O
should	O
be	O
given	O
to	O
the	O
following	O
:	O
*	O
Patients	O
should	O
be	O
stable	O
on	O
alpha-blocker	O
therapy	O
prior	O
to	O
initiating	O
treatment	O
with	O
a	O
PDE5	O
inhibitor	O
.	O
	
Seven	O
of	O
the	O
patients	O
treated	O
with	O
PROMACTA	O
in	O
the	O
controlled	O
trials	O
with	O
hepatobiliary	B
laboratory	I
abnormalities	I
were	O
re-exposed	O
to	O
PROMACTA	O
in	O
the	O
extension	O
trial	O
.	O
	
Periodic	O
skin	O
examinations	O
are	O
recommended	O
for	O
all	O
patients	O
,	O
particularly	O
those	O
with	O
risk	O
factors	O
for	O
skin	O
cancer	O
.	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronic	O
renal	O
impairment	O
,	O
acute	B
kidney	I
injury	I
sometimes	O
requiring	O
dialysis	O
has	O
been	O
observed	O
with	O
the	O
use	O
of	O
some	O
GBCAs	O
.	O
	
(	O
2.4	O
,	O
5.1	O
)	O
*	O
Cardiovascular	B
Events	I
:	O
A	O
higher	O
rate	O
of	O
cardiovascular	B
thromboembolic	I
events	I
was	O
observed	O
in	O
patients	O
treated	O
with	O
ULORIC	O
than	O
allopurinol	O
in	O
clinical	O
trials	O
.	O
	
Screening	O
patients	O
for	O
bipolar	O
disorder	O
A	O
major	O
depressive	O
episode	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
bipolar	O
disorder	O
.	O
	
(	O
14.4	O
)	O
.	O
	
5.7	O
Alcohol	O
Patients	O
should	O
be	O
made	O
aware	O
that	O
both	O
alcohol	O
and	O
PDE5	O
inhibitors	O
including	O
STENDRA	O
act	O
as	O
vasodilators	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
-	O
Anemia	B
,	O
Eosinophilia	B
,	O
Neutropenia	B
,	O
Thrombocytopenia	B
Cardiac	O
disorders	O
-	O
Bradycardia	B
,	O
Palpitations	B
Gastrointestinal	O
disorders	O
-	O
Abdominal	B
pain	I
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
-	O
Pyrexia	B
Hepatobiliary	O
disorders	O
-	O
Hepatitis	B
Immune	O
system	O
disorders	O
-	O
Hypersensitivity	B
,	O
Anaphylaxis	B
Infections	O
and	O
infestations	O
-	O
Clostridium	B
difficile	I
colitis	I
Metabolism	O
and	O
nutrition	O
disorders	O
-	O
Hyperglycemia	B
,	O
Hyperkalemia	B
Nervous	O
system	O
disorders	O
-	O
Dizziness	B
,	O
Convulsion	B
Renal	O
and	O
urinary	O
disorders	O
-	O
Renal	B
failure	I
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
-	O
Urticaria	B
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reaction	O
has	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
Teflaro	O
.	O
	
The	O
risk	O
of	O
acute	B
kidney	I
injury	I
might	O
be	O
lower	O
with	O
EOVIST	O
due	O
to	O
its	O
dual	O
excretory	O
pathways	O
.	O
	
*	O
?	O
	
(	O
5.1,5.2,12.3	O
)	O
*	O
Antimalarials	O
should	O
not	O
be	O
given	O
concomitantly	O
,	O
unless	O
there	O
is	O
no	O
other	O
treatment	O
option	O
,	O
due	O
to	O
limited	O
safety	O
data	O
.	O
	
The	O
effect	O
of	O
treatment	O
with	O
DUAVEE	O
on	O
the	O
risk	O
of	O
breast	O
cancer	O
is	O
unknown	O
.	O
	
5.7	O
Elevated	O
Blood	O
Pressure	O
In	O
a	O
small	O
number	O
of	O
case	O
reports	O
in	O
women	O
receiving	O
estrogens	O
,	O
substantial	O
increases	B
in	I
blood	I
pressure	I
have	O
been	O
attributed	O
to	O
idiosyncratic	O
reactions	O
to	O
estrogens	O
.	O
	
Even	O
in	O
the	O
absence	O
of	O
TNF-blocker	O
therapy	O
,	O
patients	O
with	O
RA	O
may	O
be	O
at	O
a	O
higher	O
risk	O
(	O
approximately	O
2-fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
leukemia	O
.	O
	
Most	O
hypersensitivity	O
reactions	O
to	O
Gadavist	O
have	O
occurred	O
within	O
half	O
an	O
hour	O
after	O
administration	O
.	O
	
In	O
patients	O
with	O
permanent	O
AF	O
,	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
,	O
stroke	B
,	O
and	O
hospitalization	O
for	O
heart	B
failure	I
.	O
	
Observe	O
for	O
hypersensitivity	O
signs	O
and	O
symptoms	O
following	O
Vizamyl	O
administration	O
.	O
	
Experience	O
in	O
Systemic	O
Anaplastic	O
Large	O
Cell	O
Lymphoma	O
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Relapsed	O
sALCL	O
(	O
Study	O
2	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
58	O
patients	O
with	O
sALCL	O
in	O
a	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
intravenously	O
every	O
3	O
weeks	O
.	O
	
5.2	O
ECG	O
Changes	O
and	O
Potential	O
for	O
Cardiac	O
Arrhythmias	O
Use	O
of	O
CERDELGA	O
in	O
patients	O
with	O
pre-existing	O
cardiac	O
conditions	O
has	O
not	O
been	O
studied	O
during	O
clinical	O
trials	O
.	O
	
Hepatic	O
Laboratory	O
Abnormalities	O
:	O
The	O
incidences	O
of	O
grade	O
3-4	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
and	O
increased	B
bilirubin	I
were	O
each	O
<	O
=	O
1	O
%	O
.	O
	
Urinary	B
tract	I
infections	I
occurred	O
more	O
frequently	O
in	O
female	O
patients	O
.	O
	
JARDIANCE	O
may	O
increase	O
the	O
risk	O
of	O
hypotension	B
in	O
patients	O
at	O
risk	O
for	O
volume	O
contraction	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
Caution	O
patients	O
about	O
risk	O
of	O
bleeding	O
associated	O
with	O
concomitant	O
use	O
of	O
PRISTIQ	O
and	O
NSAIDs	O
,	O
aspirin	O
,	O
or	O
other	O
drugs	O
that	O
affect	O
coagulation	O
(	O
5.4	O
)	O
.	O
	
Patients	O
who	O
develop	O
symptoms	O
of	O
capillary	O
leak	O
syndrome	O
should	O
be	O
closely	O
monitored	O
and	O
receive	O
standard	O
symptomatic	O
treatment	O
,	O
which	O
may	O
include	O
a	O
need	O
for	O
intensive	O
care	O
.	O
	
5.11	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
TAFINLAR	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
In	O
addition	O
,	O
Grade	O
1	O
insomnia	B
was	O
reported	O
by	O
1	O
%	O
and	O
less	O
than	O
1	O
%	O
of	O
subjects	O
receiving	O
TIVICAY	O
and	O
raltegravir	O
,	O
respectively	O
,	O
in	O
SPRING-2	O
;	O
whereas	O
in	O
SINGLE	O
the	O
rates	O
were	O
7	O
%	O
and	O
4	O
%	O
for	O
TIVICAY	O
and	O
ATRIPLA	O
,	O
respectively	O
.	O
	
Due	O
to	O
overlap	O
in	O
signs	O
and	O
symptoms	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
between	O
hypersensitivity	B
reactions	I
and	O
infusion	B
reactions	I
in	O
all	O
cases	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Placebo	O
patients	O
whose	O
tender	O
and	O
swollen	O
joint	O
counts	O
had	O
not	O
improved	O
by	O
at	O
least	O
20	O
%	O
were	O
re-randomized	O
1:1	O
in	O
a	O
blinded	O
fashion	O
to	O
either	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
or	O
30	O
mg	O
twice	O
daily	O
at	O
week	O
16	O
while	O
OTEZLA	O
patients	O
remained	O
on	O
their	O
initial	O
treatment	O
.	O
	
Overall	O
,	O
63	O
%	O
were	O
female	O
and	O
67	O
%	O
were	O
white	O
.	O
	
In	O
some	O
cases	O
angioedema	O
occurred	O
after	O
the	O
first	O
dose	O
.	O
	
Serum	O
creatinine	O
Small	O
reversible	O
increases	B
in	I
serum	I
creatinine	I
are	O
seen	O
in	O
patients	O
receiving	O
80	O
mg	O
of	O
Edarbi	O
.	O
	
Hypertension	B
led	O
to	O
study	O
discontinuation	O
in	O
<	O
1	O
%	O
of	O
patients	O
in	O
each	O
arm	O
.	O
	
Additionally	O
,	O
elevations	B
in	I
ALT	I
greater	O
than	O
five	O
times	O
the	O
ULN	O
occurred	O
in	O
184	O
(	O
11	O
%	O
)	O
and	O
93	O
(	O
5.7	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
13	O
%	O
of	O
placebo	O
patients	O
,	O
16	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
800	O
mg/day	O
APTIOM	O
,	O
and	O
28	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
1200	O
mg/day	O
APTIOM	O
.	O
	
(	O
5.12	O
)	O
*	O
Suicide	B
:	O
The	O
possibility	O
of	O
a	O
suicide	O
attempt	O
is	O
inherent	O
in	O
schizophrenia	O
and	O
bipolar	O
disorder	O
.	O
	
BEPREVE	O
should	O
not	O
be	O
instilled	O
while	O
wearing	O
contact	O
lenses	O
.	O
	
Severe	O
hypoglycemia	B
occurred	O
in	O
0	O
%	O
and	O
0.7	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
a	O
sulfonylurea	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RETINAL	B
ABNORMALITIES	I
AND	O
POTENTIAL	O
VISION	B
LOSS	I
WARNING	O
:	O
RETINAL	B
ABNORMALITIES	I
AND	O
POTENTIAL	O
VISION	B
LOSS	I
POTIGA	O
can	O
cause	O
retinal	B
abnormalities	I
,	O
which	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
the	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
Ankylosing	O
Spondylitis	O
Clinical	O
Study	O
CIMZIA	O
has	O
been	O
studied	O
in	O
325	O
patients	O
with	O
axial	O
spondyloarthritis	O
of	O
whom	O
the	O
majority	O
had	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
in	O
a	O
placebo-controlled	O
study	O
(	O
AS-1	O
)	O
.	O
	
The	O
adverse	O
reactions	O
reported	O
most	O
frequently	O
as	O
the	O
reason	O
for	O
discontinuation	O
of	O
treatment	O
included	O
encephalopathy	B
and	O
sepsis	B
.	O
	
In	O
Study	O
3	O
,	O
finger	O
extension	O
procedures	O
were	O
performed	O
approximately	O
24	O
to	O
72	O
hours	O
after	O
injection	O
.	O
	
In	O
animal	O
studies	O
,	O
administration	O
of	O
ceritinib	O
to	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
at	O
maternal	O
plasma	O
exposures	O
below	O
the	O
recommended	O
human	O
dose	O
of	O
750	O
mg	O
daily	O
caused	O
increases	B
in	I
skeletal	I
anomalies	I
in	O
rats	O
and	O
rabbits	O
.	O
	
In	O
the	O
breast	O
cancer	O
study	O
,	O
99	O
%	O
of	O
patients	O
were	O
female	O
,	O
the	O
median	O
age	O
was	O
50	O
years	O
,	O
and	O
86	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
Elevations	B
in	I
ALT	I
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
have	O
occurred	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Monitor	O
patients	O
with	O
advanced	O
stage	O
disease	O
and/or	O
high	O
tumor	O
burden	O
and	O
take	O
appropriate	O
precautions	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
,	O
or	O
permanently	O
discontinue	O
ZYKADIA	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Exclude	O
other	O
potential	O
causes	O
of	O
ILD/pneumonitis	O
,	O
and	O
permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
diagnosed	O
with	O
treatment-related	O
ILD/pneumonitis	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Corporal	O
Rupture	O
and	O
Other	O
Serious	O
Penile	O
Injury	O
*	O
Corporal	B
rupture	I
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
after	O
XIAFLEX	O
injections	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX	O
treated	O
patients	O
.	O
	
Benzyl	O
alcohol	O
has	O
been	O
associated	O
with	O
a	O
fatal	B
``	O
Gasping	B
Syndrome	I
''	O
in	B
premature	O
infants	O
and	O
infants	O
of	O
low	O
birth	O
weight	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
RE-MEDY	O
and	O
RE-SONATE	O
studies	O
provided	O
safety	O
information	O
on	O
the	O
use	O
of	O
PRADAXA	O
for	O
the	O
reduction	O
in	O
the	O
risk	O
of	O
recurrence	O
of	O
deep	O
vein	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O
	
(	O
5.1	O
)	O
*	O
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
report	O
immediately	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
an	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
.	O
	
In	O
this	O
pool	O
,	O
a	O
total	O
of	O
3342	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
TRULICITY	O
for	O
a	O
mean	O
duration	O
of	O
52	O
weeks	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8.0	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.0	O
%	O
.	O
	
Table	O
1	O
Adverse	O
reactions	O
observed	O
in	O
>	O
1	O
%	O
of	O
patients	O
with	O
acute	O
attacks	O
of	O
HAE	O
and	O
at	O
a	O
higher	O
rate	O
with	O
FIRAZYR	O
versus	O
placebo	O
in	O
the	O
placebo-controlled	O
trialsEvents	O
occurring	O
within	O
14	O
days	O
of	O
study	O
drug	O
administration	O
FIRAZYR	O
(	O
N	O
=77	O
)	O
Placebo	O
(	O
N	O
=	O
75	O
)	O
System	O
Organ	O
ClassPreferred	O
Term	O
Subjects	O
(	O
%	O
)	O
Subjects	O
(	O
%	O
)	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Injection	B
site	I
reaction	I
75	O
(	O
97	O
)	O
25	O
(	O
33	O
)	O
Pyrexia	B
3	O
(	O
4	O
)	O
0	O
Investigations	O
Transaminase	B
increased	I
3	O
(	O
4	O
)	O
0	O
Nervous	O
system	O
disorders	O
Dizziness	B
2	O
(	O
3	O
)	O
1	O
(	O
1	O
)	O
The	O
third	O
trial	O
was	O
active-controlled	O
and	O
was	O
comprised	O
of	O
35	O
patients	O
who	O
received	O
FIRAZYR	O
30	O
mg	O
and	O
38	O
patients	O
who	O
received	O
the	O
comparator	O
.	O
	
5.2	O
Risk	O
of	O
Bleeding	O
PRADAXA	O
increases	O
the	O
risk	O
of	O
bleeding	B
and	O
can	O
cause	O
significant	O
and	O
,	O
sometimes	O
,	O
fatal	B
bleeding	B
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
POTIGA	O
caused	O
this	O
decreased	B
visual	I
acuity	I
,	O
as	O
baseline	O
assessments	O
are	O
not	O
available	O
for	O
these	O
patients	O
.	O
	
EXCERPT	O
:	O
Immune-mediated	B
adverse	I
reactions	I
:	O
Permanently	O
discontinue	O
for	O
severe	O
reactions	O
.	O
	
Monitor	O
for	O
consequences	O
of	O
bone	O
oversuppression	O
(	O
5.9	O
)	O
5.1	O
Drug	O
Products	O
with	O
Same	O
Active	O
Ingredient	O
Prolia	O
contains	O
the	O
same	O
active	O
ingredient	O
(	O
denosumab	O
)	O
found	O
in	O
Xgeva	O
.	O
	
Nausea	B
and	O
vomiting	B
also	O
occurred	O
with	O
these	O
events	O
.	O
	
Patients	O
with	O
a	O
prior	O
dermatologic	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
median	O
duration	O
of	O
therapy	O
with	O
BOSULIF	O
was	O
approximately	O
17	O
months	O
(	O
range	O
,	O
0.03	O
to	O
95	O
)	O
for	O
patients	O
in	O
these	O
studies	O
.	O
	
In	O
developmental	O
toxicity	O
studies	O
in	O
mice	O
,	O
axitinib	O
was	O
teratogenic	B
,	O
embryotoxic	B
and	O
fetotoxic	B
at	O
maternal	O
exposures	O
that	O
were	O
lower	O
than	O
human	O
exposures	O
at	O
the	O
recommended	O
clinical	O
dose	O
.	O
	
There	O
was	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
during	O
the	O
titration	O
period	O
(	O
compared	O
to	O
the	O
maintenance	O
period	O
)	O
and	O
also	O
in	O
patients	O
60	O
years	O
of	O
age	O
and	O
older	O
(	O
compared	O
to	O
younger	O
adults	O
)	O
.	O
	
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
used	O
for	O
the	O
relief	O
of	O
acute	O
symptoms	O
,	O
i.e	O
.	O
	
Adverse	O
reactions	O
occurring	O
in	O
2-5	O
%	O
of	O
subjects	O
included	O
anterior	B
chamber	I
flare	I
,	O
corneal	B
edema	I
,	O
dry	B
eye	I
,	O
iridocyclitis	B
,	O
photophobia	B
,	O
and	O
reduced	B
visual	I
acuity	I
.	O
	
Because	O
these	O
reactions	O
were	O
reported	O
retrospectively	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Taper	O
patients	O
slowly	O
from	O
systemic	O
corticosteroids	O
if	O
transferring	O
to	O
BREO	O
ELLIPTA	O
.	O
	
6	O
24	O
Psychiatric	O
disorders	O
Anxiety	B
2	O
4	O
Depression	B
1	O
2	O
Insomnia	B
5	O
6	O
Monotherapy	O
in	O
Pediatric	O
Patients	O
with	O
Bipolar	O
Mania	O
:	O
The	O
following	O
findings	O
are	O
based	O
on	O
a	O
3-week	O
,	O
placebo-controlled	O
trial	O
for	O
bipolar	O
mania	O
in	O
which	O
SAPHRIS	O
was	O
administered	O
at	O
doses	O
of	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
or	O
10	O
mg	O
twice	O
daily	O
.	O
	
Laboratory	O
Findings	O
Patients	O
treated	O
with	O
DYSPORT	O
(	O
r	O
)	O
exhibited	O
a	O
small	O
increase	B
from	I
baseline	I
(	I
0.23	I
mol/L	I
)	I
in	I
mean	I
blood	I
glucose	I
relative	O
to	O
placebo-	O
treated	O
patients	O
.	O
	
Table	O
5	O
:	O
Common	O
Adverse	O
Events	O
(	O
>	O
=	O
10	O
%	O
in	O
the	O
KRd	O
Arm	O
)	O
Occurring	O
in	O
Cycles	O
1-12	O
(	O
Combination	O
Therapy	O
)	O
KRd	O
=	O
Kyprolis	O
,	O
lenalidomide	O
,	O
and	O
low-dose	O
dexamethasone	O
;	O
Rd	O
=	O
lenalidomide	O
and	O
low-dose	O
dexamethasone	O
a	O
Pneumonia	B
includes	O
preferred	O
terms	O
of	O
pneumonia	B
,	O
bronchopneumonia	B
b	O
Peripheral	B
neuropathies	I
NEC	I
includes	O
preferred	O
terms	O
under	O
HLT	O
peripheral	B
neuropathies	I
NEC	I
c	O
Dyspnea	B
includes	O
preferred	O
terms	O
of	O
dyspnea	B
,	O
dyspnea	B
exertional	I
d	O
Embolic	B
and	I
thrombotic	I
events	I
,	I
venous	I
include	O
preferred	O
terms	O
in	O
MedDRA	O
SMQ	O
narrow	O
scope	O
search	O
of	O
embolic	B
and	I
thrombotic	I
events	I
,	I
venous	I
.	O
	
Similar	O
to	O
the	O
controlled	O
studies	O
,	O
most	O
adverse	O
events	O
of	O
dry	B
mouth	I
and	O
constipation	B
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
.	O
	
Infections	B
leading	O
to	O
discontinuation	O
of	O
treatment	O
occurred	O
in	O
0.7	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
1.0	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
*	O
Renal	B
Failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
*	O
You	O
should	O
not	O
remove	O
DUAVEE	O
from	O
the	O
blister	O
until	O
right	O
before	O
you	O
are	O
ready	O
to	O
take	O
it	O
.	O
	
Monitoring	O
of	O
complete	O
blood	O
count	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
10	O
%	O
)	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
=	O
2	O
%	O
over	O
placebo	O
)	O
in	O
the	O
XTANDI-treated	O
patients	O
from	O
the	O
two	O
randomized	O
clinical	O
trials	O
were	O
asthenia/fatigue	O
,	O
back	B
pain	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
arthralgia	B
,	O
diarrhea	B
,	O
hot	B
flush	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
dyspnea	B
,	O
musculoskeletal	B
pain	I
,	O
weight	B
decreased	I
,	O
headache	B
,	O
hypertension	B
,	O
and	O
dizziness/vertigo	O
.	O
	
Consider	O
the	O
potential	O
risks	O
and	O
benefits	O
prior	O
to	O
the	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O
	
Patients	O
with	O
moderate	O
renal	O
impairment	O
at	O
baseline	O
had	O
larger	O
mean	O
changes	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
For	O
patients	O
with	O
mild	O
(	O
Child-Pugh	O
class	O
A	O
)	O
or	O
moderate	O
(	O
Child-Pugh	O
class	O
B	O
)	O
hepatic	O
impairment	O
,	O
a	O
dose	O
reduction	O
is	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
In	O
a	O
clinical	O
trial	O
of	O
liver	O
transplant	O
patients	O
,	O
use	O
of	O
NULOJIX	O
regimens	O
with	O
more	O
frequent	O
administration	O
of	O
belatacept	O
than	O
any	O
of	O
those	O
studied	O
in	O
kidney	O
transplant	O
,	O
along	O
with	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
and	O
corticosteroids	O
,	O
was	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
graft	B
loss	I
and	O
death	B
compared	O
to	O
the	O
tacrolimus	O
control	O
arms	O
.	O
	
Delay	O
in	O
diagnosis	O
and	O
treatment	O
may	O
lead	O
to	O
permanent	O
neurological	O
sequelae	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
controlled	O
but	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
VORAXAZE	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
experience	O
in	O
open-label	O
clinical	O
trials	O
is	O
consistent	O
with	O
the	O
safety	O
profile	O
observed	O
in	O
the	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Patients	O
who	O
seroconvert	O
may	O
be	O
at	O
a	O
higher	O
risk	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
Hepatic	O
Transaminases	O
Elevations	B
of	I
transaminases	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
ILARIS	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
the	O
patient	O
and	O
health	O
care	O
worker	O
(	O
5.3	O
)	O
.	O
	
New	O
primary	B
melanoma	I
occurred	O
in	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
in	O
none	O
of	O
the	O
55	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Monitor	O
serum	O
glucose	O
levels	O
as	O
clinically	O
appropriate	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
in	O
patients	O
with	O
pre-existing	O
diabetes	O
or	O
hyperglycemia	O
.	O
	
The	O
most	O
common	O
reason	O
for	O
dose	O
reduction	O
was	O
anemia	B
,	O
which	O
occurred	O
more	O
frequently	O
in	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
than	O
in	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
However	O
,	O
the	O
duration	O
of	O
exposure	O
associated	O
with	O
increased	O
risk	O
is	O
not	O
consistent	O
across	O
all	O
epidemiologic	O
studies	O
,	O
and	O
some	O
report	O
no	O
association	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
No	O
adverse	O
reactions	O
occurred	O
in	O
greater	O
than	O
5	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bristol-Myers	O
Squibb	O
at	O
1-800-721-5072	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Consideration	O
should	O
be	O
given	O
to	O
changing	O
the	O
therapeutic	O
regimen	O
,	O
including	O
possibly	O
discontinuing	O
the	O
medication	O
,	O
in	O
patients	O
whose	O
depression	O
is	O
persistently	O
worse	O
,	O
or	O
who	O
are	O
experiencing	O
emergent	O
suicidality	O
or	O
symptoms	O
that	O
might	O
be	O
precursors	O
to	O
worsening	O
depression	O
or	O
suicidality	O
,	O
especially	O
if	O
these	O
symptoms	O
are	O
severe	O
,	O
abrupt	O
in	O
onset	O
,	O
or	O
were	O
not	O
part	O
of	O
the	O
patient	O
's	O
presenting	O
symptoms	O
.	O
	
The	O
most	O
common	O
reported	O
adverse	O
reaction	O
occurring	O
in	O
approximately	O
25	O
%	O
of	O
subjects	O
was	O
a	O
mild	O
taste	B
following	I
instillation	I
.	O
	
Four	O
patients	O
(	O
1	O
%	O
)	O
treated	O
with	O
PROMACTA	O
and	O
three	O
patients	O
in	O
the	O
placebo	O
group	O
(	O
2	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
hepatobiliary	B
laboratory	I
abnormalities	I
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Palmar-plantar	B
erythrodysesthesia	I
syndrome	I
,	O
hyperkeratosis	B
,	O
hyperhidrosis	B
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
In	O
the	O
short-term	O
placebo-controlled	O
trials	O
for	O
both	O
schizophrenia	O
and	O
acute	O
bipolar	O
disorder	O
,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
suggestive	O
of	O
body	B
temperature	I
increases	I
was	O
low	O
(	O
<	O
=1	O
%	O
)	O
and	O
comparable	O
to	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
Breast	O
Cancer	O
The	O
most	O
important	O
randomized	O
clinical	O
study	O
providing	O
information	O
about	O
breast	O
cancer	O
in	O
estrogen-alone	O
users	O
is	O
the	O
WHI	O
substudy	O
of	O
daily	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
.	O
	
Other	O
clinically	O
important	O
adverse	O
reactions	O
(	O
N	O
=	O
202	O
)	O
observed	O
in	O
<	O
10	O
%	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
were	O
:	O
Eye	O
Disorders	O
:	O
Vision	B
blurred	I
,	O
transient	B
blindness	I
.	O
	
*	O
Before	O
Gadavist	O
administration	O
,	O
assess	O
all	O
patients	O
for	O
any	O
history	O
of	O
a	O
reaction	O
to	O
contrast	O
media	O
,	O
bronchial	O
asthma	O
and/or	O
allergic	O
disorders	O
.	O
	
(	O
4	O
,	O
5.2	O
)	O
EXCERPT	O
:	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
MULTAQ	O
is	O
contraindicated	O
in	O
patients	O
with	O
symptomatic	O
heart	O
failure	O
with	O
recent	O
decompensation	O
requiring	O
hospitalization	O
or	O
NYHA	O
Class	O
IV	O
heart	O
failure	O
.	O
	
Other	O
adverse	O
reactions	O
occurring	O
in	O
2-5	O
%	O
of	O
subjects	O
were	O
eye	B
irritation	I
,	O
headache	B
,	O
and	O
nasopharyngitis	B
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
>	O
2	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
in	O
the	O
pooled	O
phase	O
3	O
clinical	O
trials	O
were	O
diarrhea	B
,	O
nausea	B
,	O
and	O
rash	B
.	O
	
Some	O
patients	O
have	O
been	O
able	O
to	O
be	O
rechallenged	O
and	O
have	O
continued	O
to	O
receive	O
alglucosidase	O
alfa	O
under	O
close	O
clinical	O
supervision	O
.	O
	
The	O
majority	O
of	O
reports	O
have	O
occurred	O
in	O
patients	O
concomitantly	O
receiving	O
other	O
medications	O
that	O
suppress	O
the	O
immune	O
system	O
,	O
which	O
may	O
also	O
contribute	O
to	O
HBV	B
reactivation	I
.	O
	
Drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
,	O
including	O
antimalarials	O
such	O
as	O
quinine	O
and	O
quinidine	O
,	O
should	O
be	O
used	O
cautiously	O
following	O
Coartem	O
Tablets	O
,	O
due	O
to	O
the	O
long	O
elimination	O
half-life	O
of	O
lumefantrine	O
(	O
3	O
to	O
6	O
days	O
)	O
and	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
;	O
ECG	O
monitoring	O
is	O
advised	O
if	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
is	O
medically	O
required	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.7	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
5.7	O
Hematological	O
Reactions	O
Rare	O
reports	O
of	O
pancytopenia	B
,	O
including	O
aplastic	B
anemia	I
,	O
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
.	O
	
In	O
the	O
pool	O
of	O
five	O
placebo-controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
(	O
e.g.	O
,	O
blood	B
pressure	I
(	I
ambulatory	I
)	I
decreased	I
,	O
blood	B
pressure	I
systolic	I
decreased	I
,	O
dehydration	B
,	O
hypotension	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
and	O
syncope	B
)	O
were	O
reported	O
by	O
0.3	O
%	O
,	O
0.5	O
%	O
,	O
and	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
respectively	O
.	O
	
Discard	O
unused	O
portion	O
12	O
hours	O
after	O
stopper	O
puncture	O
.	O
	
Drugs	O
that	O
inhibit	O
CYP2D6	O
and	O
CYP3A	O
metabolism	O
pathways	O
may	O
significantly	O
increase	O
the	O
exposure	O
to	O
eliglustat	O
and	O
result	O
in	O
prolongation	B
of	I
the	I
PR	I
,	I
QTc	I
,	I
and/or	I
QRS	I
cardiac	I
intervals	I
that	O
could	O
result	O
in	O
cardiac	B
arrhythmias	I
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Gastrointestinal	O
:	O
Gastritis	B
,	O
intestinal	B
obstruction	I
.	O
	
Reactions	O
can	O
occur	O
on	O
initial	O
exposure	O
.	O
	
Dose	O
delays	O
were	O
reported	O
in	O
28	O
%	O
of	O
JEVTANA-treated	O
patients	O
and	O
15	O
%	O
of	O
mitoxantrone-treated	O
patients	O
.	O
	
Study	O
1	O
:	O
Metastatic	O
Castration-Resistant	O
Prostate	O
Cancer	O
Following	O
Chemotherapy	O
Study	O
1	O
enrolled	O
1199	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
previously	O
received	O
docetaxel	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Common	O
adverse	O
reactions	O
(	O
reported	O
in	O
>	O
=4	O
%	O
of	O
patients	O
treated	O
with	O
NESINA	O
25	O
mg	O
and	O
more	O
frequently	O
than	O
in	O
patients	O
who	O
received	O
placebo	O
)	O
are	O
:	O
nasopharyngitis	B
,	O
headache	B
and	O
upper	B
respiratory	I
tract	I
infection	I
.	O
	
Withhold	O
or	O
discontinue	O
GILOTRIF	O
for	O
severe	O
or	O
worsening	O
liver	O
tests	O
.	O
	
Serious	O
adverse	O
events	O
,	O
judged	O
to	O
be	O
at	O
least	O
possibly	O
related	O
to	O
study	O
medication	O
by	O
the	O
investigator	O
and	O
reported	O
more	O
than	O
once	O
during	O
the	O
open-label	O
treatment	O
period	O
of	O
up	O
to	O
3	O
years	O
,	O
included	O
urinary	B
retention	I
(	O
3	O
cases	O
)	O
,	O
diverticulitis	B
(	O
3	O
cases	O
)	O
,	O
constipation	B
(	O
2	O
cases	O
)	O
,	O
irritable	B
bowel	I
syndrome	I
(	O
2	O
cases	O
)	O
,	O
and	O
electrocardiogram	O
QT	B
corrected	I
interval	I
prolongation	I
(	O
2	O
cases	O
)	O
.	O
	
Of	O
the	O
21	O
patients	O
with	O
moderate	O
to	O
life-threatening	O
endocrinopathy	B
,	O
17	O
patients	O
required	O
long-term	O
hormone	O
replacement	O
therapy	O
including	O
,	O
most	O
commonly	O
,	O
adrenal	O
hormones	O
(	O
n=10	O
)	O
and	O
thyroid	O
hormones	O
(	O
n=13	O
)	O
.	O
	
Through	O
96	O
weeks	O
,	O
the	O
rates	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
3	O
%	O
in	O
subjects	O
receiving	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
+	O
EPZICOM	O
and	O
12	O
%	O
in	O
subjects	O
receiving	O
ATRIPLA	O
once	O
daily	O
.	O
	
Laboratory	O
Abnormalities	O
Transaminase	O
Elevations	O
:	O
In	O
Trials	O
1	O
,	O
2	O
,	O
and	O
3	O
the	O
incidence	O
of	O
maximum	O
AST	B
)	I
>	I
8	I
,	I
>	I
5	I
,	I
or	I
>	I
3	I
*	I
ULN	I
was	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
in	O
KALYDECO-treated	O
patients	O
and	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
8	O
%	O
in	O
placebo-treated	O
patients	O
,	O
respectively	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
61	O
years	O
(	O
range	O
28-93	O
years	O
)	O
,	O
and	O
75	O
%	O
were	O
Caucasian	O
.	O
	
*	O
During	O
and	O
following	O
DOTAREM	O
administration	O
,	O
observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
who	O
had	O
a	O
venous	O
thromboembolic	O
event	O
within	O
the	O
previous	O
6	O
months	O
.	O
	
It	O
is	O
not	O
known	O
if	O
DUAVEE	O
is	O
safe	O
and	O
effective	O
in	O
people	O
with	O
kidney	O
problems	O
.	O
	
Upper	O
Limb	O
Spasticity	O
Table	O
6	O
lists	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
in	O
any	O
DYSPORT	O
(	O
r	O
)	O
dose	O
group	O
and	O
more	O
frequent	O
than	O
placebo	O
in	O
double	O
blind	O
studies	O
evaluating	O
the	O
treatment	O
of	O
upper	O
limb	O
spasticity	O
in	O
adults	O
with	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
(	O
5.6	O
)	O
*	O
Risk	O
of	O
impaired	B
adrenal	I
function	I
when	O
transferring	O
from	O
systemic	O
corticosteroids	O
.	O
	
The	O
majority	O
of	O
patients	O
who	O
reported	O
serious	O
depression	B
or	O
suicidal	B
behavior	I
had	O
a	O
history	O
of	O
depression	O
or	O
other	O
serious	O
psychiatric	O
disorders	O
and	O
most	O
were	O
receiving	O
psychoactive	O
medications	O
.	O
	
Extravasation	O
into	O
tissues	O
during	O
DOTAREM	O
administration	B
may	I
result	I
in	I
tissue	I
irritation	I
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
in	O
either	O
Study	O
1	O
or	O
2	O
,	O
regardless	O
of	O
causality	O
,	O
using	O
the	O
NCI	O
Common	O
Toxicity	O
Criteria	O
(	O
CTC	O
)	O
Version	O
3.0	O
,	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
When	O
prescribing	O
ARCAPTA	O
NEOHALER	O
,	O
the	O
healthcare	O
provider	O
should	O
also	O
prescribe	O
an	O
inhaled	O
,	O
short-acting	O
beta2-	O
agonist	O
and	O
instruct	O
the	O
patient	O
on	O
how	O
it	O
should	O
be	O
used	O
.	O
	
Cognitive	O
Dysfunction	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
cognitive	B
dysfunction-related	O
events	O
(	O
memory	B
impairment	I
,	O
disturbance	B
in	I
attention	I
,	O
amnesia	B
,	O
confusional	B
state	I
,	O
aphasia	B
,	O
speech	B
disorder	I
,	O
slowness	B
of	I
thought	I
,	O
disorientation	B
,	O
and	O
psychomotor	B
retardation	I
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
IOP	B
)	I
increase-	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
result	O
in	O
glaucoma	B
with	O
damage	B
to	I
the	I
optic	I
nerve	I
,	O
defects	B
in	I
visual	I
acuity	I
.	O
	
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
Table	O
2	O
shows	O
the	O
number	O
of	O
adjudicated	O
major	O
bleeding	B
events	O
during	O
the	O
treatment	O
period	O
in	O
the	O
RE-LY	O
study	O
,	O
with	O
the	O
bleeding	B
rate	O
per	O
100	O
subject-years	O
(	O
%	O
)	O
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
0.8	O
%	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
placebo	O
group	O
and	O
0.8	O
%	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
receiving	O
INLYTA	O
.	O
	
Clinically	O
important	O
chemistry	O
laboratory	O
values	O
that	O
were	O
new	O
or	O
worsened	O
from	O
baseline	O
and	O
occurred	O
in	O
>	O
1	O
%	O
of	O
patients	O
at	O
Grade	O
3	O
or	O
4	O
,	O
in	O
NHL	O
patients	O
treated	O
in	O
both	O
single	O
arm	O
studies	O
combined	O
were	O
hyperglycemia	B
(	O
3	O
%	O
)	O
,	O
elevated	B
creatinine	I
(	O
2	O
%	O
)	O
,	O
hyponatremia	B
(	O
2	O
%	O
)	O
,	O
and	O
hypocalcemia	B
(	O
2	O
%	O
)	O
.	O
	
Remove	O
contact	O
lenses	O
prior	O
to	O
instillation	O
of	O
BEPREVE	O
.	O
	
5.5	O
Second	O
Primary	O
Malignancies	O
Other	O
malignancies	B
(	O
range	O
,	O
5	O
to	O
14	O
%	O
)	O
including	O
non-skin	B
carcinomas	I
(	O
range	O
,	O
1	O
to	O
3	O
%	O
)	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
Serious	O
Adverse	O
Reactions	O
:	O
myocardial	B
infarction	I
(	O
2	O
cases	O
)	O
,	O
ruptured	B
ovarian	I
cyst	I
(	O
2	O
cases	O
)	O
,	O
deep	B
vein	I
thrombosis	I
,	O
focal	B
nodular	I
hyperplasia	I
of	I
the	I
liver	I
,	O
uterine	B
leiomyoma	I
,	O
acute	B
cholecystitis	I
,	O
and	O
chronic	B
acalculous	I
cholecystitis	I
.	O
	
Patients	O
treated	O
with	O
concomitant	O
immunosuppressants	O
(	O
MTX	O
)	O
had	O
a	O
lower	O
rate	O
of	O
antibody	O
development	O
than	O
patients	O
not	O
taking	O
immunosuppressants	O
at	O
baseline	O
.	O
	
The	O
infections	B
consisted	O
primarily	O
of	O
upper	B
respiratory	I
infections	I
(	O
20	O
%	O
for	O
CIMZIA	O
,	O
13	O
%	O
for	O
placebo	O
)	O
.	O
	
The	O
mean	O
age	O
of	O
patients	O
was	O
56	O
years	O
,	O
2	O
%	O
were	O
75	O
years	O
or	O
older	O
and	O
51	O
%	O
were	O
male	O
.	O
	
5.2	O
Hepatotoxicity	O
Drug-induced	O
hepatotoxicity	B
occurred	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
XIAFLEX-Treated	O
Patients	O
with	O
Dupuytren	O
's	O
Contracture	O
and	O
at	O
a	O
Greater	O
Incidence	O
than	O
Placebo	O
in	O
the	O
Placebo-Controlled	O
Trials	O
Through	O
Day	O
90	O
After	O
Up	O
to	O
3	O
Injections	O
a	O
Most	O
of	O
these	O
events	O
were	O
swelling	B
of	I
the	I
injected	I
hand	I
.	O
	
5.2	O
Immune-mediated	O
Hepatitis	O
In	O
Study	O
1	O
,	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
hepatotoxicity	B
(	O
ALT	B
elevations	I
of	O
more	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
total	B
bilirubin	I
elevations	I
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
;	O
Grade	O
3-5	O
)	O
occurred	O
in	O
8	O
(	O
2	O
%	O
)	O
YERVOY-treated	O
patients	O
,	O
with	O
fatal	B
hepatic	B
failure	I
in	O
0.2	O
%	O
and	O
hospitalization	O
in	O
0.4	O
%	O
of	O
YERVOY-treated	O
patients	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
certolizumab	O
pegol	O
in	O
an	O
ELISA	O
,	O
and	O
are	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
of	O
XIAFLEX	O
in	O
Peyronie	O
's	O
disease	O
,	O
1044	O
patients	O
received	O
a	O
total	O
of	O
7466	O
XIAFLEX	O
injections	O
.	O
	
Adrenocortical	B
insufficiency	I
was	O
reported	O
in	O
patients	O
receiving	O
ZYTIGA	O
in	O
combination	O
with	O
prednisone	O
,	O
following	O
interruption	O
of	O
daily	O
steroids	O
and/or	O
with	O
concurrent	O
infection	O
or	O
stress	O
.	O
	
Monitor	O
ALT	O
and	O
AST	O
in	O
all	O
patients	O
every	O
2	O
weeks	O
for	O
the	O
first	O
3	O
months	O
of	O
treatment	O
,	O
every	O
4	O
weeks	O
for	O
the	O
next	O
3	O
months	O
,	O
then	O
every	O
1	O
to	O
3	O
months	O
thereafter	O
.	O
	
EXCERPT	O
:	O
*	O
Most	O
common	O
adverse	O
reaction	O
to	O
GRANIX	O
is	O
bone	B
pain	I
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
TEVA	O
at	O
1-866-832-8537	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
(	O
5.1	O
)	O
*	O
Patients	O
who	O
fail	O
to	O
show	O
substantial	O
clinical	O
benefit	O
after	O
adequate	O
titration	O
should	O
be	O
discontinued	O
from	O
POTIGA	O
.	O
	
5.13	O
Drug	O
Interactions	O
Women	O
who	O
take	O
medications	O
that	O
are	O
strong	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inducers	O
(	O
for	O
example	O
,	O
carbamazepine	O
,	O
phenytoin	O
,	O
rifampicin	O
,	O
and	O
St.	O
John	O
's	O
wort	O
)	O
should	O
not	O
choose	O
Natazia	O
as	O
their	O
oral	O
contraceptive	O
while	O
using	O
these	O
inducers	O
and	O
for	O
at	O
least	O
28	O
days	O
after	O
discontinuation	O
of	O
these	O
inducers	O
due	O
to	O
the	O
possibility	O
of	O
decreased	O
contraceptive	O
efficacy	O
.	O
	
Approximately	O
one	O
third	O
of	O
the	O
patients	O
who	O
had	O
eye	O
examinations	O
performed	O
after	O
approximately	O
4	O
years	O
of	O
treatment	O
were	O
found	O
to	O
have	O
retinal	B
pigmentary	I
abnormalities	I
.	O
	
For	O
the	O
100	O
mg	O
dose	O
of	O
PRISTIQ	O
the	O
discontinuation	O
rate	O
due	O
to	O
an	O
adverse	O
reaction	O
was	O
8.7	O
%	O
.	O
	
*	O
A	O
24-week	O
open-label	O
trial	O
(	O
Trial	O
6	O
)	O
in	O
34	O
patients	O
2	O
to	O
less	O
than	O
6	O
years	O
of	O
age	O
.	O
	
May	O
worsen	O
,	O
especially	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
However	O
,	O
across	O
clinical	O
trials	O
no	O
renal	B
abscesses	I
were	O
confirmed	O
by	O
microbiology	O
tests	O
.	O
	
BOSULIF	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
an	O
inhaled	O
short-acting	O
beta2-agonist	O
.	O
	
Visual	O
Changes	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
events	O
related	O
to	O
visual	B
changes	I
including	O
diplopia	B
,	O
blurred	B
vision	I
,	O
and	O
impaired	B
vision	I
.	O
	
Other	O
adverse	O
reactions	O
occurred	O
at	O
a	O
rate	O
of	O
1	O
%	O
or	O
less	O
and	O
the	O
reported	O
events	O
consisted	O
of	O
headache	B
,	O
nausea	B
,	O
vertigo	B
,	O
dry	B
mouth	I
or	O
dizziness	B
.	O
	
You	O
and	O
your	O
healthcare	O
provider	O
should	O
talk	O
regularly	O
about	O
whether	O
you	O
still	O
need	O
treatment	O
with	O
DUAVEE	O
.	O
	
Please	O
see	O
www.proliasafety.com	O
or	O
call	O
1-800-772-6436	O
for	O
more	O
information	O
about	O
this	O
program	O
.	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
and	O
sedation	B
.	O
	
(	O
5.7	O
)	O
*	O
Hypercorticism	B
and	O
adrenal	B
suppression	I
may	O
occur	O
with	O
very	O
high	O
dosages	O
or	O
at	O
the	O
regular	O
dosage	O
in	O
susceptible	O
individuals	O
.	O
	
In	O
the	O
clinical	O
trials	O
of	O
STRIBILD	O
over	O
144	O
weeks	O
,	O
13	O
(	O
1.9	O
%	O
)	O
subjects	O
in	O
the	O
STRIBILD	O
group	O
(	O
N=701	O
)	O
,	O
8	O
(	O
2.3	O
%	O
)	O
subjects	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
(	O
N=355	O
)	O
and	O
no	O
subjects	O
in	O
the	O
ATRIPLA	O
group	O
(	O
N	O
=	O
352	O
)	O
discontinued	O
study	O
drug	O
due	O
to	O
a	O
renal	B
adverse	I
reaction	I
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
observed	O
with	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
in	O
the	O
5	O
studies	O
were	O
diarrhea	B
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
vomiting	B
,	O
and	O
asthenia	B
.	O
	
Therefore	O
,	O
when	O
treating	O
patients	O
with	O
asthma	O
,	O
physicians	O
should	O
only	O
prescribe	O
BREO	O
ELLIPTA	O
for	O
patients	O
not	O
adequately	O
controlled	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
inhaled	O
corticosteroid	O
,	O
or	O
whose	O
disease	O
severity	O
clearly	O
warrants	O
initiation	O
of	O
treatment	O
with	O
both	O
an	O
inhaled	O
corticosteroid	O
and	O
a	O
LABA	O
.	O
	
Remove	O
1	O
tablet	O
at	O
a	O
time	O
from	O
the	O
blister	O
package	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Administer	O
topical	O
or	O
systemic	O
corticosteroids	O
if	O
there	O
is	O
no	O
improvement	O
of	O
symptoms	O
within	O
1	O
week	O
.	O
	
*	O
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
Permanently	O
discontinue	O
GRANIX	O
in	O
patients	O
with	O
serious	O
allergic	O
reactions	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
91	O
%	O
of	O
the	O
study	O
population	O
and	O
moderately	O
impaired	O
(	O
eGFR	O
30	O
to	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
9	O
%	O
.	O
	
Withhold	O
trametinib	O
for	O
any	O
fever	O
higher	O
than	O
104oF	O
.	O
	
*	O
Angle	B
Closure	I
Glaucoma	I
:	O
Angle	B
closure	I
glaucoma	I
has	O
occurred	O
in	O
patients	O
with	O
untreated	O
anatomically	O
narrow	O
angles	O
treated	O
with	O
antidepressants	O
.	O
	
Subjects	O
treated	O
with	O
apixaban	O
with	O
diabetes	O
bled	B
more	O
(	O
3.0	O
%	O
per	O
year	O
)	O
than	O
did	O
subjects	O
without	O
diabetes	O
(	O
1.9	O
%	O
per	O
year	O
)	O
.	O
	
In	O
Trial	O
1	O
,	O
5	O
of	O
12	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
required	O
more	O
intensive	O
hypoglycemic	O
therapy	O
while	O
taking	O
TAFINLAR	O
.	O
	
The	O
pooled	O
analyses	O
of	O
placebo-controlled	O
studies	O
in	O
adults	O
with	O
MDD	O
or	O
other	O
psychiatric	O
disorders	O
included	O
a	O
total	O
of	O
295	O
short-term	O
studies	O
(	O
median	O
duration	O
of	O
2	O
months	O
)	O
of	O
11	O
antidepressant	O
drugs	O
in	O
over	O
77,000	O
patients	O
.	O
	
Discontinue	O
and	O
do	O
not	O
restart	O
AMPYRA	O
if	O
this	O
occurs	O
(	O
5.4	O
)	O
5.1	O
Seizures	O
AMPYRA	O
can	O
cause	O
seizures	B
.	O
	
Prophylaxis	O
of	O
Deep	O
Vein	O
Thrombosis	O
Following	O
Hip	O
or	O
Knee	O
Replacement	O
Surgery	O
The	O
safety	O
of	O
ELIQUIS	O
has	O
been	O
evaluated	O
in	O
1	O
Phase	O
II	O
and	O
3	O
Phase	O
III	O
studies	O
including	O
5924	O
patients	O
exposed	O
to	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
undergoing	O
major	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limbs	O
(	O
elective	O
hip	O
replacement	O
or	O
elective	O
knee	O
replacement	O
)	O
treated	O
for	O
up	O
to	O
38	O
days	O
.	O
	
Overall	O
,	O
20.2	O
%	O
of	O
patients	O
seroconverted	O
to	O
anti-ecallantide	O
antibodies	O
.	O
	
Do	O
not	O
exceed	O
the	O
recommended	O
dose	O
;	O
the	O
risk	O
of	O
acute	O
kidney	O
injury	O
may	O
increase	O
with	O
higher	O
than	O
recommended	O
doses	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
Patients	O
Receiving	O
Teflaro	O
in	O
the	O
Pooled	O
Phase	O
3	O
Clinical	O
Trials	O
a	O
Comparators	O
included	O
vancomycin	O
1	O
gram	O
IV	O
every	O
12h	O
plus	O
aztreonam	O
1	O
gram	O
IV	O
every	O
12h	O
in	O
the	O
Phase	O
3	O
ABSSSI	O
trials	O
,	O
and	O
ceftriaxone	O
1	O
gram	O
IV	O
every	O
24h	O
in	O
the	O
Phase	O
3	O
CABP	O
trials	O
.	O
	
5.2	O
Use	O
of	O
QT	O
Prolonging	O
Drugs	O
and	O
Other	O
Antimalarials	O
Halofantrine	O
and	O
Coartem	O
Tablets	O
should	O
not	O
be	O
administered	O
within	O
1	O
month	O
of	O
each	O
other	O
due	O
to	O
the	O
long	O
elimination	O
half-life	O
of	O
lumefantrine	O
(	O
3	O
to	O
6	O
days	O
)	O
and	O
potential	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
anaphylaxis	B
,	O
anaphylactic	B
reaction	I
.	O
	
The	O
majority	O
of	O
reported	O
TNF	O
blocker	O
cases	O
occurred	O
in	O
adolescent	O
and	O
young	O
adult	O
males	O
with	O
Crohn	O
's	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
	
In	O
short-term	O
,	O
fixed-dose	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
somnolence	B
was	O
reported	O
in	O
15	O
%	O
(	O
41/274	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
and	O
in	O
13	O
%	O
(	O
26/208	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
7	O
%	O
(	O
26/378	O
)	O
of	O
placebo	O
patients	O
.	O
	
at	O
1-800-323-0000	O
,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Phosphodiesterase	O
type	O
5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
and	O
alpha-adrenergic	O
blocking	O
agents	O
are	O
both	O
vasodilators	O
with	O
blood	O
pressure-lowering	O
effects	O
.	O
	
Record	O
the	O
specific	O
GBCA	O
and	O
the	O
dose	O
administrated	O
to	O
a	O
patient	O
.	O
	
(	O
5.1,5.2,7.7,12.3	O
)	O
*	O
Substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
CYP3A4	O
,	O
including	O
antiretroviral	O
medications	O
,	O
should	O
be	O
used	O
cautiously	O
with	O
Coartem	O
Tablets	O
,	O
due	O
to	O
a	O
potential	O
loss	O
of	O
efficacy	O
of	O
the	O
concomitant	O
drug	O
or	O
additive	O
QT	O
prolongation	O
.	O
	
5.3	O
Risk	O
of	O
Acute	O
Cardiorespiratory	O
Failure	O
Patients	O
with	O
acute	O
underlying	O
respiratory	O
illness	O
or	O
compromised	O
cardiac	O
and/or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
exacerbation	B
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
during	O
infusions	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
AMPYRA	O
can	O
cause	O
seizures	B
;	O
the	O
risk	O
of	O
seizures	B
increases	O
with	O
increasing	O
AMPYRA	O
doses	O
;	O
discontinue	O
AMPYRA	O
and	O
do	O
not	O
restart	O
if	O
a	O
seizure	O
occurs	O
(	O
5.1	O
)	O
*	O
AMPYRA	O
should	O
not	O
be	O
taken	O
with	O
other	O
forms	O
of	O
4-aminopyridine	O
(	O
4-AP	O
,	O
fampridine	O
)	O
,	O
since	O
the	O
active	O
ingredient	O
is	O
the	O
same	O
(	O
5.3	O
)	O
*	O
AMPYRA	O
can	O
cause	O
anaphylaxis	B
.	O
	
These	O
patients	O
may	O
also	O
develop	O
marked	O
elevations	B
of	I
serum	I
parathyroid	I
hormone	I
(	O
PTH	O
)	O
.	O
	
In	O
these	O
patients	O
,	O
extensive	O
dental	O
surgery	O
to	O
treat	O
ONJ	O
may	O
exacerbate	O
the	O
condition	O
.	O
	
Increased	B
thyroid-binding	I
globulin	I
)	O
leading	O
to	O
increased	B
circulating	I
total	I
thyroid	I
hormone	I
by	O
radioimmunoassay	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
excluding	O
hypoglycemia	B
associated	O
with	O
the	O
use	O
of	O
TANZEUM	O
in	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
.	O
	
There	O
was	O
no	O
adverse	O
reaction	O
that	O
was	O
more	O
than	O
2	O
%	O
more	O
common	O
on	O
Cleviprex	O
than	O
on	O
the	O
average	O
of	O
all	O
comparators	O
.	O
	
Intracranial	B
bleed	I
includes	O
subarachnoid	B
bleeding	I
.	O
	
Some	O
drugs	O
that	O
are	O
inhibitors	O
of	O
CYP2D6	O
and	O
CYP3A	O
are	O
contraindicated	O
with	O
CERDELGA	O
depending	O
on	O
the	O
patient	O
's	O
CYP2D6	O
metabolizer	O
status	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
chronic	O
or	O
recurrent	O
urinary	O
tract	O
infections	O
were	O
more	O
likely	O
to	O
experience	O
a	O
urinary	B
tract	I
infection	I
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
patients	O
during	O
an	O
active	O
infection	O
requiring	O
medical	O
intervention	O
.	O
	
The	O
same	O
dose	O
of	O
HORIZANT	O
results	O
in	O
different	O
plasma	O
concentrations	O
of	O
gabapentin	O
relative	O
to	O
other	O
gabapentin	O
products	O
.	O
	
(	O
5.1	O
)	O
*	O
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
.	O
	
*	O
Use	O
in	O
Patients	O
with	O
Hepatic	O
Impairment	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
(	O
5.5	O
)	O
*	O
Decreases	B
in	I
bone	I
mineral	I
density	I
)	O
:	O
Consider	O
monitoring	O
BMD	O
in	O
patients	O
with	O
a	O
history	O
of	O
pathologic	O
fracture	O
or	O
other	O
risk	O
factors	O
of	O
osteoporosis	O
or	O
bone	O
loss	O
.	O
	
Among	O
the	O
32	O
patients	O
with	O
evaluable	O
pharmacokinetic	O
(	O
PK	O
)	O
samples	O
,	O
5	O
patients	O
tested	O
positive	O
for	O
uptake	O
inhibition	O
.	O
	
In	O
SINGLE	O
,	O
833	O
subjects	O
were	O
randomized	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
either	O
TIVICAY	O
50	O
mg	O
with	O
fixed-dose	O
abacavir	O
sulfate	O
and	O
lamivudine	O
(	O
EPZICOM	O
)	O
once	O
daily	O
or	O
fixed-dose	O
efavirenz/emtricitabine/tenofovir	O
(	O
ATRIPLA	O
(	O
r	O
)	O
)	O
once	O
daily	O
.	O
	
5.11	O
Elevation	O
of	O
Liver	O
Enzymes	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
ALT	B
)	I
elevations	I
of	O
all	O
grades	O
occurred	O
in	O
22	O
%	O
of	O
patients	O
on	O
both	O
arms	O
,	O
with	O
Grade	O
3/4	O
events	O
in	O
<	O
1	O
%	O
of	O
patients	O
on	O
the	O
INLYTA	O
arm	O
and	O
2	O
%	O
of	O
patients	O
on	O
the	O
sorafenib	O
arm	O
.	O
	
Grade	O
3/4	O
cardiac	B
failure	I
was	O
observed	O
in	O
2/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
1/355	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Resulting	O
oligohydramnios	B
can	O
be	O
associated	O
with	O
fetal	B
lung	I
hypoplasia	I
.	O
	
Serious	O
psychiatric	B
events	I
were	O
reported	O
in	O
0.8	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
(	O
0.6	O
%	O
and	O
1.2	O
%	O
with	O
1	O
and	O
10	O
mg/kg	O
,	O
respectively	O
)	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
If	O
such	O
changes	O
occur	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
slowly	O
.	O
	
(	O
5.1	O
)	O
*	O
Do	O
not	O
initiate	O
in	O
acutely	O
deteriorating	O
COPD	O
or	O
asthma	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=7	O
%	O
and	O
higher	O
than	O
placebo	O
)	O
:	O
upper	B
respiratory	I
tract	I
infection	I
,	O
rash	B
,	O
and	O
urinary	B
tract	I
infection	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
UCB	O
,	O
Inc.	O
at	O
1-866-822-0068	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Monitor	O
with	O
electrocardiograms	O
and	O
electrolytes	O
in	O
patients	O
who	O
have	O
a	O
history	O
of	O
or	O
predisposition	O
for	O
QTc	O
prolongation	O
,	O
or	O
who	O
are	O
taking	O
medications	O
that	O
prolong	O
QT	O
.	O
	
Somnolence	B
and	O
fatigue	B
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Discontinue	O
XALKORI	O
in	O
patients	O
with	O
severe	O
visual	O
loss	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
1976	O
patients	O
to	O
JARDIANCE	O
with	O
a	O
mean	O
exposure	O
duration	O
of	O
approximately	O
23	O
weeks	O
.	O
	
Bosutinib	O
caused	O
embryofetal	B
toxicities	I
in	O
rabbits	O
at	O
maternal	O
exposures	O
that	O
were	O
greater	O
than	O
the	O
clinical	O
exposure	O
at	O
the	O
recommended	O
bosutinib	O
dose	O
of	O
500	O
mg/day	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hepatotoxicity	B
:	O
Fatal	B
hepatotoxicity	B
occurred	O
in	O
0.1	O
%	O
of	O
patients	O
.	O
	
Treatment	O
to	O
Increase	O
Bone	O
Mass	O
in	O
Men	O
with	O
Osteoporosis	O
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
men	O
with	O
osteoporosis	O
was	O
assessed	O
in	O
a	O
1-year	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
60	O
years	O
and	O
5	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
Patients	O
with	O
MPS	O
IVA	O
should	O
be	O
monitored	O
for	O
signs	O
and	O
symptoms	O
of	O
SCC	O
(	O
including	O
back	O
pain	O
,	O
paralysis	O
of	O
limbs	O
below	O
the	O
level	O
of	O
compression	O
,	O
urinary	O
and	O
fecal	O
incontinence	O
)	O
and	O
given	O
appropriate	O
clinical	O
care	O
.	O
	
Consider	O
interruption	O
of	O
TECFIDERA	O
in	O
patients	O
with	O
lymphocyte	O
counts	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
persisting	O
for	O
more	O
than	O
six	O
months	O
.	O
	
Serious	O
and	O
sometimes	O
fatal	B
dermatologic	B
reactions	I
,	O
including	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
and	O
SJS	B
,	O
have	O
been	O
reported	O
in	O
patients	O
using	O
oxcarbazepine	O
or	O
carbamazepine	O
which	O
are	O
chemically	O
related	O
to	O
APTIOM	O
.	O
	
Patients	O
treated	O
with	O
TREANDA	O
may	O
also	O
have	O
changes	B
in	I
their	I
creatinine	I
levels	I
.	O
	
Anaphylaxis	B
and	O
Hypersensitivity	B
Reactions	I
:	O
Life-threatening	O
anaphylaxis	B
and	O
hypersensitivity	B
reactions	O
have	O
been	O
observed	O
in	O
some	O
patients	O
during	O
treatment	O
with	O
Vimizim	O
.	O
	
Apprise	O
women	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
new	O
cases	O
of	O
infections	B
in	O
controlled	O
clinical	O
studies	O
in	O
rheumatoid	O
arthritis	O
was	O
0.91	O
per	O
patient-year	O
for	O
all	O
CIMZIA-treated	O
patients	O
and	O
0.72	O
per	O
patient-year	O
for	O
placebo-treated	O
patients	O
.	O
	
(	O
5.9	O
)	O
*	O
Embryofetal	B
toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Some	O
studies	O
suggest	O
that	O
COCs	O
are	O
associated	O
with	O
an	O
increase	O
in	O
the	O
risk	O
of	O
cervical	B
cancer	I
.	O
	
Monitor	O
liver	O
function	O
tests	O
and	O
omit	O
or	O
modify	O
dosage	O
for	O
hepatic	O
toxicities	O
.	O
	
(	O
5.3	O
)	O
*	O
Serious	O
Dermatological	B
Reactions	I
(	O
including	O
Stevens-Johnson	B
syndrome	I
and	O
toxic	B
epidermal	I
necrolysis	I
)	O
:	O
Discontinue	O
ONFI	O
at	O
first	O
sign	O
of	O
rash	O
unless	O
the	O
rash	O
is	O
clearly	O
not	O
drug-related	O
.	O
	
There	O
have	O
been	O
rare	O
reports	O
of	O
deaths	O
,	O
primarily	O
in	O
preterm	O
infants	O
,	O
associated	O
with	O
exposure	O
to	O
excessive	O
amounts	O
of	O
benzyl	O
alcohol	O
[	O
see	O
Description	O
(	O
11	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Severe	O
,	O
potentially	O
life	O
threatening	O
and	O
fatal	B
skin	B
reactions	I
have	O
been	O
reported	O
.	O
	
(	O
5.3	O
)	O
*	O
Fatal	B
and	O
serious	O
intestinal	B
perforation	I
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
.	O
	
Control	O
hypertension	O
and	O
correct	O
hypokalemia	O
before	O
treatment	O
.	O
	
Prior	O
to	O
administration	O
,	O
question	O
the	O
patient	O
for	O
a	O
history	O
of	O
prior	O
reactions	O
to	O
iodine	O
,	O
an	O
iodine-containing	O
contrast	O
agent	O
or	O
other	O
products	O
containing	O
iodine	O
.	O
	
If	O
pathology	O
and	O
pregnancy	O
are	O
excluded	O
,	O
bleeding	O
irregularities	O
may	O
resolve	O
over	O
time	O
or	O
with	O
a	O
change	O
to	O
a	O
different	O
COC	O
.	O
	
Cabozantinib	O
was	O
embryolethal	B
in	O
rats	O
at	O
exposures	O
below	O
the	O
recommended	O
human	O
dose	O
,	O
with	O
increased	O
incidences	O
of	O
skeletal	B
variations	I
in	O
rats	O
and	O
visceral	B
variations	I
in	O
rabbits	O
.	O
	
Laboratory	O
Abnormalities	O
in	O
Treatment-Experienced	O
Patients	O
Selected	O
Grade	O
2	O
to	O
Grade	O
4	O
laboratory	O
abnormalities	O
that	O
represent	O
a	O
worsening	O
from	O
baseline	O
observed	O
in	O
adult	O
subjects	O
treated	O
with	O
INTELENCE	O
(	O
r	O
)	O
are	O
presented	O
in	O
Table	O
2	O
.	O
	
Uncontrolled	O
hyperammonemia	O
can	O
rapidly	O
result	O
in	O
brain	O
injury/damage	O
or	O
death	O
,	O
and	O
prompt	O
use	O
of	O
all	O
therapies	O
necessary	O
to	O
reduce	O
plasma	O
ammonia	O
levels	O
is	O
essential	O
.	O
	
BREO	O
ELLIPTA	O
has	O
not	O
been	O
studied	O
in	O
subjects	O
with	O
acutely	O
deteriorating	O
COPD	O
or	O
asthma	O
.	O
	
In	O
patients	O
with	O
baseline	O
moderate	O
hepatic	O
impairment	O
receiving	O
a	O
reduced	O
ZYTIGA	O
dose	O
of	O
250	O
mg	O
,	O
measure	O
ALT	O
,	O
AST	O
,	O
and	O
bilirubin	O
prior	O
to	O
the	O
start	O
of	O
treatment	O
,	O
every	O
week	O
for	O
the	O
first	O
month	O
,	O
every	O
two	O
weeks	O
for	O
the	O
following	O
two	O
months	O
of	O
treatment	O
and	O
monthly	O
thereafter	O
.	O
	
If	O
pneumonitis	O
is	O
suspected	O
,	O
interrupt	O
Zydelig	O
until	O
the	O
etiology	O
of	O
the	O
pulmonary	O
symptoms	O
has	O
been	O
determined	O
.	O
	
In	O
general	O
,	O
somnolence	B
and	O
sedation	B
begin	O
within	O
the	O
first	O
month	O
of	O
treatment	O
and	O
may	O
diminish	O
with	O
continued	O
treatment	O
.	O
	
5.5	O
Severe	O
Cutaneous	O
Reactions	O
One	O
case	O
of	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
occurred	O
in	O
a	O
study	O
of	O
Zydelig	O
in	O
combination	O
with	O
rituximab	O
and	O
bendamustine	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
WBC	O
or	O
a	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
should	O
discontinue	O
FANAPT	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
69	O
%	O
White	O
,	O
7	O
%	O
Black	O
or	O
African	O
American	O
,	O
13	O
%	O
Asian	O
;	O
30	O
%	O
were	O
of	O
Hispanic	O
or	O
Latino	O
ethnicity	O
.	O
	
In	O
pooled	O
analysis	O
from	O
clinical	O
studies	O
including	O
longer	O
term	O
trials	O
,	O
in	O
3210	O
adults	O
treated	O
with	O
iloperidone	O
,	O
gynecomastia	B
was	O
reported	O
in	O
2	O
male	O
subjects	O
(	O
0.1	O
%	O
)	O
compared	O
to	O
0	O
%	O
in	O
placebo-treated	O
patients	O
,	O
and	O
galactorrhea	B
was	O
reported	O
in	O
8	O
female	O
subjects	O
(	O
0.2	O
%	O
)	O
compared	O
to	O
3	O
female	O
subjects	O
(	O
0.5	O
%	O
)	O
in	O
placebo-treated	O
patients	O
.	O
	
Adverse	O
drug	O
reactions	O
for	O
SIRTURO	O
were	O
identified	O
from	O
the	O
pooled	O
safety	O
data	O
from	O
335	O
SIRTURO-exposed	O
patients	O
who	O
received	O
8	O
weeks	O
(	O
Study	O
2	O
)	O
and	O
24	O
weeks	O
(	O
Studies	O
1	O
and	O
3	O
)	O
at	O
the	O
proposed	O
dose	O
.	O
	
Of	O
the	O
34	O
patients	O
with	O
Grade	O
3-5	O
enterocolitis	B
,	O
74	O
%	O
experienced	O
complete	O
resolution	O
,	O
3	O
%	O
experienced	O
improvement	O
to	O
Grade	O
2	O
severity	O
,	O
and	O
24	O
%	O
did	O
not	O
improve	O
.	O
	
In	O
the	O
double-blind	O
,	O
placebo-controlled	O
portions	O
of	O
the	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
a	O
greater	O
proportion	O
of	O
XIAFLEX-treated	O
patients	O
(	O
4	O
%	O
)	O
compared	O
to	O
placebo-treated	O
patients	O
(	O
1	O
%	O
)	O
had	O
localized	B
pruritus	I
after	O
up	O
to	O
4	O
treatment	O
cycles	O
(	O
involving	O
up	O
to	O
8	O
XIAFLEX	O
injection	O
procedures	O
)	O
.	O
	
Perform	O
an	O
oral	O
examination	O
prior	O
to	O
initiation	O
of	O
COMETRIQ	O
and	O
periodically	O
during	O
COMETRIQ	O
therapy	O
.	O
	
Risk	O
factors	O
for	O
bleeding	O
include	O
the	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	O
of	O
bleeding	O
(	O
e.g.	O
,	O
anti-platelet	O
agents	O
,	O
heparin	O
,	O
fibrinolytic	O
therapy	O
,	O
and	O
chronic	O
use	O
of	O
NSAIDs	O
)	O
.	O
	
However	O
,	O
if	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
stop	O
the	O
infusion	O
of	O
Vimizim	O
and	O
initiate	O
appropriate	O
treatment	O
.	O
	
Avoid	O
using	O
XALKORI	O
in	O
combination	O
with	O
other	O
agents	O
known	O
to	O
cause	O
bradycardia	O
(	O
e.g.	O
,	O
beta-blockers	O
,	O
non-dihydropyridine	O
calcium	O
channel	O
blockers	O
,	O
clonidine	O
and	O
digoxin	O
)	O
to	O
the	O
extent	O
possible	O
.	O
	
In	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
,	O
2	O
%	O
of	O
patients	O
experienced	O
lymphocyte	B
counts	I
<	I
0.5	I
x	I
10	I
9	I
/L	I
for	O
at	O
least	O
six	O
months	O
.	O
	
Consider	O
the	O
benefit-risk	O
of	O
withholding	O
IMBRUVICA	O
for	O
at	O
least	O
3	O
to	O
7	O
days	O
pre	O
and	O
post-surgery	O
depending	O
upon	O
the	O
type	O
of	O
surgery	O
and	O
the	O
risk	O
of	O
bleeding	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.3	O
Hepatic	O
Toxicity	O
One	O
case	O
consistent	O
with	O
drug	B
induced	I
liver	I
injury	I
(	O
defined	O
as	O
concurrent	O
elevations	B
in	I
ALT	I
greater	O
than	O
or	O
equal	O
to	O
3*ULN	O
with	O
total	B
bilirubin	I
greater	I
than	I
2*ULN	I
and	O
alkaline	B
phosphatase	I
less	I
than	I
2*ULN	I
)	O
occurred	O
in	O
a	O
trial	O
of	O
BOSULIF	O
in	O
combination	O
with	O
letrozole	O
.	O
	
ARCAPTA	O
NEOHALER	O
has	O
not	O
been	O
investigated	O
in	O
patients	O
whose	O
diabetes	O
mellitus	O
is	O
not	O
well	O
controlled	O
.	O
	
SAPHRIS	O
(	O
r	O
)	O
(	O
asenapine	O
)	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
]	O
.	O
	
Use	O
INLYTA	O
with	O
caution	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
,	O
or	O
who	O
have	O
a	O
history	O
of	O
,	O
these	O
events	O
.	O
	
In	O
patients	O
receiving	O
anti-TNF	O
therapy	O
,	O
limited	O
data	O
are	O
available	O
on	O
the	O
response	O
to	O
live	O
vaccination	O
,	O
or	O
on	O
the	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
.	O
	
have	O
occurred	O
following	O
administration	O
of	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Some	O
patients	O
required	O
hospitalization	O
and	O
renal	O
replacement	O
therapy	O
.	O
	
These	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
have	O
been	O
associated	O
with	O
TREANDA	O
in	O
clinical	O
trials	O
and	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
.	O
	
The	O
study	O
population	O
characteristics	O
were	O
:	O
median	O
age	O
53	O
years	O
,	O
age	O
less	O
than	O
65	O
(	O
84	O
%	O
)	O
,	O
female	O
(	O
53	O
%	O
)	O
,	O
Caucasian	O
(	O
63	O
%	O
)	O
,	O
Asian	O
(	O
34	O
%	O
)	O
,	O
NSCLC	O
adenocarcinoma	O
histology	O
(	O
90	O
%	O
)	O
,	O
never	O
or	O
former	O
smoker	O
(	O
97	O
%	O
)	O
,	O
ECOG	O
PS	O
0	O
or	O
1	O
(	O
89	O
%	O
)	O
,	O
brain	O
metastasis	O
(	O
49	O
%	O
)	O
,	O
and	O
number	O
of	O
prior	O
therapies	O
2	O
or	O
more	O
(	O
67	O
%	O
)	O
.	O
	
Two	O
patients	O
treated	O
with	O
KALYDECO	O
were	O
reported	O
to	O
have	O
serious	O
adverse	O
reactions	O
of	O
elevated	B
liver	I
transaminases	I
compared	O
to	O
none	O
on	O
placebo	O
.	O
	
All	O
reported	O
reactions	O
are	O
included	O
except	O
those	O
already	O
listed	O
in	O
Table	O
7	O
,	O
or	O
other	O
parts	O
of	O
the	O
Adverse	O
Reactions	O
(	O
6	O
)	O
section	O
,	O
those	O
considered	O
in	O
the	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
,	O
those	O
reaction	O
terms	O
which	O
were	O
so	O
general	O
as	O
to	O
be	O
uninformative	O
,	O
reactions	O
reported	O
in	O
fewer	O
than	O
3	O
patients	O
and	O
which	O
were	O
neither	O
serious	O
nor	O
life-threatening	O
,	O
reactions	O
that	O
are	O
otherwise	O
common	O
as	O
background	O
reactions	O
,	O
and	O
reactions	O
considered	O
unlikely	O
to	O
be	O
drug	O
related	O
.	O
	
During	O
the	O
controlled	O
trials	O
in	O
patients	O
with	O
RLS	O
,	O
somnolence/sedation	O
was	O
reported	O
in	O
20	O
%	O
of	O
patients	O
treated	O
with	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
6	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Dose	O
adjustments	O
(	O
interruptions	O
or	O
reductions	O
)	O
were	O
more	O
frequent	O
among	O
patients	O
in	O
the	O
AFINITOR	O
plus	O
exemestane	O
arm	O
than	O
in	O
the	O
placebo	O
plus	O
exemestane	O
arm	O
(	O
63	O
%	O
versus	O
14	O
%	O
)	O
.	O
	
If	O
appropriate	O
,	O
initiation	O
of	O
anti-hepatitis	O
B	O
therapy	O
may	O
be	O
warranted	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Therefore	O
,	O
co-administration	O
is	O
not	O
recommended	O
.	O
	
During	O
the	O
controlled	O
period	O
of	O
the	O
trials	O
in	O
psoriasis	O
,	O
weight	B
decrease	I
between	O
5	O
%	O
-10	O
%	O
of	O
body	O
weight	O
occurred	O
in	O
12	O
%	O
(	O
96/784	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
compared	O
to	O
5	O
%	O
(	O
19/382	O
)	O
treated	O
with	O
placebo	O
.	O
	
Lymphocyte	O
counts	O
generally	O
return	O
to	O
the	O
normal	O
range	O
within	O
1-2	O
months	O
of	O
stopping	O
therapy	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Advise	O
patients	O
to	O
seek	O
prompt	O
medical	O
attention	O
if	O
they	O
develop	O
signs	O
or	O
symptoms	O
of	O
severe	O
infection	O
,	O
including	O
cellulitis	O
.	O
	
*	O
Seizure	B
:	O
Can	O
occur	O
.	O
	
Injection	B
site	I
reactions	I
.	O
	
Patients	O
were	O
allowed	O
,	O
but	O
not	O
required	O
,	O
to	O
take	O
glucocorticoids	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
BENLYSTA	O
plus	O
standard	O
of	O
care	O
compared	O
with	O
placebo	O
plus	O
standard	O
of	O
care	O
in	O
2,133	O
patients	O
in	O
3	O
controlled	O
trials	O
.	O
	
The	O
majority	O
of	O
elevations	O
occurred	O
within	O
6	O
to	O
9	O
months	O
.	O
	
(	O
5.2	O
)	O
*	O
Dihydropyridine	O
calcium	O
channel	O
blockers	O
can	O
produce	O
negative	B
inotropic	I
effects	I
and	O
exacerbate	B
heart	I
failure	I
.	O
	
Number	O
(	O
%	O
)	O
of	O
Patients	O
PlaceboN=995	O
JARDIANCE	O
10	O
mgN=999	O
JARDIANCE	O
25	O
mgN=977	O
Urinary	B
tract	I
infection	I
a	O
7.6	O
%	O
9.3	O
%	O
7.6	O
%	O
Female	B
genital	I
mycotic	I
infections	I
b	O
1.5	O
%	O
5.4	O
%	O
6.4	O
%	O
Upper	B
respiratory	I
tract	I
infection	I
3.8	O
%	O
3.1	O
%	O
4.0	O
%	O
Increased	B
urination	I
c	O
1.0	O
%	O
3.4	O
%	O
3.2	O
%	O
Dyslipidemia	B
3.4	O
%	O
3.9	O
%	O
2.9	O
%	O
Arthralgia	B
2.2	O
%	O
2.4	O
%	O
2.3	O
%	O
Male	B
genital	I
mycotic	I
infections	I
d	O
0.4	O
%	O
3.1	O
%	O
1.6	O
%	O
Nausea	B
1.4	O
%	O
2.3	O
%	O
1.1	O
%	O
Thirst	B
(	O
including	O
polydipsia	B
)	O
was	O
reported	O
in	O
0	O
%	O
,	O
1.7	O
%	O
,	O
and	O
1.5	O
%	O
for	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
The	O
most	O
common	O
fatal	B
adverse	O
reactions	O
in	O
JEVTANA-treated	O
patients	O
were	O
infections	B
(	O
n=5	O
)	O
and	O
renal	B
failure	I
(	O
n=4	O
)	O
.	O
	
There	O
were	O
differences	O
in	O
absolute	O
risk	O
of	O
suicidality	B
across	O
the	O
different	O
indications	O
,	O
with	O
the	O
highest	O
incidence	O
in	O
MDD	O
.	O
	
The	O
duration	O
of	O
ELIQUIS	O
exposure	O
was	O
>	O
=12	O
months	O
for	O
9375	O
patients	O
and	O
>	O
=24	O
months	O
for	O
3369	O
patients	O
in	O
the	O
two	O
studies	O
.	O
	
Through	O
Week	O
24	O
,	O
the	O
incidence	O
of	O
serious	O
infections	B
per	O
100	O
patient-years	O
of	O
follow-up	O
was	O
2.2	O
(	O
95	O
%	O
CI	O
0.61	O
,	O
5.71	O
)	O
for	O
the	O
SIMPONI	O
ARIA	O
group	O
,	O
and	O
0	O
(	O
0.00	O
,	O
3.79	O
)	O
for	O
the	O
placebo	O
group	O
.	O
	
Patients	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
prior	O
to	O
therapy	O
;	O
use	O
two	O
or	O
more	O
forms	O
of	O
contraception	O
,	O
and	O
have	O
monthly	O
pregnancy	O
tests	O
.	O
	
In	O
limited	O
comparative	O
studies	O
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
Coartem	O
Tablets	O
appeared	O
similar	O
to	O
that	O
of	O
another	O
antimalarial	O
regimen	O
.	O
	
Appropriate	O
measures	O
such	O
as	O
fluid	O
and	O
electrolyte	O
management	O
,	O
protein	O
supplementation	O
,	O
antibacterial	O
treatment	O
of	O
C.	O
difficile	O
,	O
and	O
surgical	O
evaluation	O
should	O
be	O
instituted	O
as	O
clinically	O
indicated	O
.	O
	
Vomiting	B
was	O
the	O
primary	O
adverse	O
reaction	O
leading	O
to	O
discontinuation	O
of	O
dosing	O
;	O
this	O
occurred	O
at	O
an	O
incidence	O
of	O
0.5	O
%	O
in	O
both	O
the	O
fidaxomicin	O
and	O
vancomycin	O
patients	O
in	O
Phase	O
3	O
studies	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
bleeding	O
.	O
	
The	O
risk	O
differences	O
(	O
drug	O
vs.	O
placebo	O
)	O
,	O
however	O
,	O
were	O
relatively	O
stable	O
within	O
age	O
strata	O
and	O
across	O
indications	O
.	O
	
Estrogens	O
may	O
be	O
poorly	O
metabolized	O
in	O
women	O
with	O
impaired	O
liver	O
function	O
.	O
	
Prophylaxis	O
with	O
antipyretics	O
may	O
be	O
required	O
when	O
resuming	O
TAFINLAR	O
or	O
trametinib	O
.	O
	
Table	O
1	O
:	O
Bleeding	B
Events	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
in	O
ARISTOTLE*	O
ELIQUISN=9088n	O
(	O
per	O
100	O
pt-year	O
)	O
WarfarinN=9052n	O
(	O
per	O
100	O
pt-year	O
)	O
Hazard	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
P-value	O
*	O
Bleeding	B
events	O
within	O
each	O
subcategory	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
Monitor	O
for	O
symptoms	O
of	O
motor	O
or	O
sensory	O
neuropathy	O
such	O
as	O
unilateral	O
or	O
bilateral	O
weakness	O
,	O
sensory	O
alterations	O
,	O
or	O
paresthesia	O
.	O
	
Hepatic	O
function	O
should	O
be	O
monitored	O
closely	O
with	O
both	O
clinical	O
and	O
laboratory	O
follow-up	O
for	O
at	O
least	O
several	O
months	O
in	O
patients	O
who	O
are	O
coinfected	O
with	O
HIV-1	O
and	O
HBV	O
and	O
discontinue	O
STRIBILD	O
.	O
	
Weight	B
decrease	I
of	O
>	O
=10	O
%	O
of	O
body	O
weight	O
occurred	O
in	O
2	O
%	O
(	O
16/784	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
compared	O
to	O
1	O
%	O
(	O
3/382	O
)	O
subjects	O
treated	O
with	O
placebo	O
.	O
	
KALYDECO	O
was	O
permanently	O
discontinued	O
in	O
one	O
patient	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
clearance	O
values	O
for	O
4	O
of	O
these	O
5	O
patients	O
were	O
approximately	O
1.2-	O
to	O
1.8-fold	O
greater	O
in	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
(	O
Week	O
52	O
)	O
as	O
compared	O
to	O
in	O
the	O
absence	O
of	O
inhibitory	O
antibodies	O
(	O
Week	O
0	O
)	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Once	O
asthma	O
control	O
is	O
achieved	O
and	O
maintained	O
,	O
assess	O
the	O
patient	O
at	O
regular	O
intervals	O
and	O
step	O
down	O
therapy	O
(	O
e.g.	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
)	O
if	O
possible	O
without	O
loss	O
of	O
asthma	O
control	O
and	O
maintain	O
the	O
patient	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
inhaled	O
corticosteroid	O
.	O
	
The	O
most	O
common	O
infusion	B
reactions	I
(	O
>	O
=3	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
)	O
were	O
headache	B
,	O
nausea	B
,	O
and	O
skin	B
reactions	I
.	O
	
Dry	B
mouth	I
led	O
to	O
discontinuation	O
in	O
0.4	O
%	O
,	O
0.4	O
%	O
,	O
and	O
0.8	O
%	O
of	O
patients	O
receiving	O
placebo	O
,	O
Toviaz	O
4	O
mg	O
,	O
and	O
Toviaz	O
8	O
mg	O
,	O
respectively	O
.	O
	
Hyperthyroidism	B
was	O
reported	O
in	O
4/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
4/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Who	O
should	O
not	O
take	O
DUAVEE	O
?	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
It	O
is	O
unknown	O
if	O
treatment	O
with	O
BENLYSTA	O
is	O
associated	O
with	O
increased	O
risk	O
for	O
these	O
events	O
.	O
	
(	O
5.1	O
)	O
*	O
Drugs	O
that	O
act	O
directly	O
on	O
the	O
renin-angiotensin	O
system	O
can	O
cause	O
death	B
to	I
the	I
developing	I
fetus	I
.	O
	
Six	O
XEOMIN	O
treated	O
subjects	O
experienced	O
six	O
serious	O
adverse	O
events	O
.	O
	
Some	O
medicines	O
may	O
affect	O
how	O
DUAVEE	O
works	O
.	O
	
Some	O
of	O
these	O
events	O
have	O
been	O
fatal	B
or	O
life-threatening	O
.	O
	
(	O
5.13,8.1	O
)	O
5.1	O
Hypertension	O
and	O
Hypertensive	O
Crisis	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
hypertension	B
was	O
reported	O
in	O
145/359	O
patients	O
(	O
40	O
%	O
)	O
receiving	O
INLYTA	O
and	O
103/355	O
patients	O
(	O
29	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Appropriate	O
medical	O
support	O
and	O
monitoring	O
measures	O
should	O
be	O
available	O
during	O
infusion	O
(	O
5.3	O
)	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
6.1	O
%	O
and	O
7.0	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
SIRTURO	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
ventricular	O
arrhythmias	O
or	O
recent	O
myocardial	O
infarction	O
.	O
	
Using	O
an	O
electrochemiluminescent	O
bridging	O
immunoassay	O
,	O
less	O
than	O
1	O
%	O
(	O
55	O
out	O
of	O
8113	O
)	O
of	O
patients	O
treated	O
with	O
Prolia	O
for	O
up	O
to	O
5	O
years	O
tested	O
positive	O
for	O
binding	O
antibodies	O
(	O
including	O
pre-existing	O
,	O
transient	O
,	O
and	O
developing	O
antibodies	O
)	O
.	O
	
Prior	O
to	O
neuraxial	O
intervention	O
the	O
physician	O
should	O
consider	O
the	O
potential	O
benefit	O
versus	O
the	O
risk	O
in	O
anticoagulated	O
patients	O
or	O
in	O
patients	O
to	O
be	O
anticoagulated	O
for	O
thromboprophylaxis	O
.	O
	
Limited	O
information	O
is	O
presented	O
on	O
the	O
110	O
mg	O
dosing	O
arm	O
because	O
this	O
dose	O
is	O
not	O
approved	O
.	O
	
5.5	O
Renal	O
Toxicity	O
An	O
on-treatment	O
decline	B
in	I
estimated	I
glomerular	I
filtration	I
rate	I
(	O
eGFR	O
)	O
has	O
occurred	O
in	O
patients	O
treated	O
with	O
BOSULIF	O
.	O
	
Patient	O
exposure	O
PRISTIQ	O
was	O
evaluated	O
for	O
safety	O
in	O
8,394	O
patients	O
diagnosed	O
with	O
major	O
depressive	O
disorder	O
who	O
participated	O
in	O
multiple-dose	O
pre-marketing	O
studies	O
,	O
representing	O
2,784	O
patient-years	O
of	O
exposure	O
.	O
	
After	O
initiation	O
of	O
NESINA	O
,	O
patients	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
.	O
	
Required	O
components	O
of	O
the	O
XIAFLEX	O
REMS	O
Program	O
include	O
the	O
following	O
:	O
*	O
Prescribers	O
must	O
be	O
certified	O
with	O
the	O
program	O
by	O
enrolling	O
and	O
completing	O
training	O
in	O
the	O
administration	O
of	O
XIAFLEX	O
treatment	O
for	O
Peyronie	O
's	O
disease	O
.	O
	
Approximately	O
one	O
third	O
(	O
3	O
%	O
,	O
39	O
of	O
1,509	O
)	O
of	O
these	O
patients	O
had	O
antibodies	O
with	O
neutralizing	O
activity	O
in	O
vitro	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
:	O
*	O
Hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Pancreatitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Glucose	B
intolerance	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Thrombosis	B
and	O
hemorrhage	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
1	O
%	O
or	O
greater	O
)	O
with	O
ERWINAZE	O
treatment	O
are	O
systemic	B
hypersensitivity	I
,	O
hyperglycemia	B
,	O
transaminases	B
abnormal	I
,	O
fever	B
,	O
pancreatitis	B
,	O
local	B
reactions	I
,	O
vomiting	B
,	O
nausea	B
,	O
thrombosis	B
,	O
hyperbilirubinemia	B
,	O
abdominal	B
pain	I
,	O
and	O
diarrhea	B
.	O
	
When	O
prescribing	O
BREO	O
ELLIPTA	O
,	O
the	O
healthcare	O
provider	O
should	O
also	O
prescribe	O
an	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
and	O
instruct	O
the	O
patient	O
on	O
how	O
it	O
should	O
be	O
used	O
.	O
	
Other	O
severe	O
or	O
life-threatening	O
(	O
Grade	O
>	O
=3	O
)	O
cutaneous	B
reactions	I
,	O
including	O
dermatitis	B
exfoliative	I
,	O
rash	B
,	O
rash	B
erythematous	I
,	O
rash	B
generalized	I
,	O
rash	B
macular	I
,	O
rash	B
maculo-papular	I
,	O
rash	B
papular	I
,	O
rash	B
pruritic	I
,	O
exfoliative	B
rash	I
,	O
and	O
skin	B
disorder	I
,	O
have	O
been	O
reported	O
in	O
Zydelig-treated	O
patients	O
.	O
	
The	O
safety	O
of	O
ZYTIGA	O
re-treatment	O
of	O
patients	O
who	O
develop	O
AST	O
or	O
ALT	O
greater	O
than	O
or	O
equal	O
to	O
20*	O
ULN	O
and/or	O
bilirubin	O
greater	O
than	O
or	O
equal	O
to	O
10*	O
ULN	O
is	O
unknown	O
.	O
	
For	O
agranulocytosis	O
(	O
ANC	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
)	O
:	O
Consider	O
hospitalization	O
and	O
other	O
management	O
as	O
clinically	O
appropriate	O
.	O
	
Image	O
interpretation	O
should	O
be	O
performed	O
independently	O
of	O
the	O
patient	O
's	O
clinical	O
information	O
.	O
	
In	O
the	O
placebo-controlled	O
study	O
,	O
a	O
similar	O
rate	O
of	O
non-fatal	O
and	O
fatal	B
clinical	O
myocardial	B
infarction	I
was	O
reported	O
in	O
patients	O
who	O
received	O
PRADAXA	O
[	O
1	O
(	O
0.32	O
per	O
100	O
patient-years	O
)	O
]	O
and	O
in	O
those	O
who	O
received	O
placebo	O
[	O
1	O
(	O
0.34	O
per	O
100	O
patient-years	O
)	O
]	O
.	O
	
5.6	O
Bradycardia	O
Bradycardia	B
can	O
occur	O
in	O
patients	O
receiving	O
ZYKADIA	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
is	O
highly	O
dependent	O
on	O
several	O
factors	O
,	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
The	O
more	O
severe	O
withdrawal	O
symptoms	O
have	O
usually	O
been	O
limited	O
to	O
patients	O
who	O
received	O
excessive	O
doses	O
over	O
an	O
extended	O
period	O
of	O
time	O
,	O
followed	O
by	O
an	O
abrupt	O
discontinuation	O
.	O
	
The	O
initiation	O
of	O
BREO	O
ELLIPTA	O
in	O
this	O
setting	O
is	O
not	O
appropriate	O
.	O
	
5.5	O
Physical	O
and	O
Psychological	O
Dependence	O
Patients	O
with	O
a	O
history	O
of	O
substance	O
abuse	O
should	O
be	O
under	O
careful	O
surveillance	O
when	O
receiving	O
ONFI	O
or	O
other	O
psychotropic	O
agents	O
because	O
of	O
the	O
predisposition	O
of	O
such	O
patients	O
to	O
habituation	O
and	O
dependence	O
[	O
see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
HALAVEN	O
were	O
neutropenia	B
,	O
anemia	B
,	O
asthenia/fatigue	O
,	O
alopecia	B
,	O
peripheral	B
neuropathy	I
,	O
nausea	B
,	O
and	O
constipation	B
.	O
	
Peripheral	B
neuropathy	I
was	O
the	O
most	O
common	O
toxicity	O
leading	O
to	O
discontinuation	O
of	O
HALAVEN	O
(	O
5	O
%	O
of	O
patients	O
;	O
24/503	O
)	O
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
who	O
develop	O
QTc	O
interval	O
prolongation	O
in	O
combination	O
with	O
Torsade	O
de	O
pointes	O
or	O
polymorphic	O
ventricular	O
tachycardia	O
or	O
signs/symptoms	O
of	O
serious	O
arrhythmia	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
The	O
mean	O
age	O
at	O
study	O
entry	O
was	O
38	O
years	O
(	O
range	O
18	O
to	O
83	O
years	O
)	O
,	O
64	O
%	O
were	O
female	O
,	O
and	O
95	O
%	O
were	O
white	O
.	O
	
In	O
the	O
controlled	O
rheumatoid	O
arthritis	O
studies	O
,	O
there	O
were	O
more	O
new	O
cases	O
of	O
serious	O
infection	B
adverse	O
reactions	O
in	O
the	O
CIMZIA	O
treatment	O
groups	O
,	O
compared	O
to	O
the	O
placebo	O
groups	O
(	O
0.06	O
per	O
patient-year	O
for	O
all	O
CIMZIA	O
doses	O
vs.	O
0.02	O
per	O
patient-year	O
for	O
placebo	O
)	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
the	O
NULOJIX	O
regimen	O
is	O
identical	O
to	O
the	O
recommended	O
regimen	O
,	O
but	O
is	O
slightly	O
different	O
in	O
Study	O
3	O
.	O
	
Withhold	O
COMETRIQ	O
in	O
patients	O
with	O
dehiscence	O
or	O
wound	O
healing	O
complications	O
requiring	O
medical	O
intervention	O
.	O
	
The	O
total	O
number	O
of	O
NULOJIX	O
patients	O
from	O
these	O
three	O
studies	O
(	O
949	O
)	O
was	O
compared	O
to	O
the	O
pooled	O
cyclosporine	O
control	O
groups	O
from	O
all	O
three	O
studies	O
(	O
476	O
patients	O
)	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
trials	O
,	O
somnolence	B
(	O
including	O
sedation	B
)	O
was	O
reported	O
in	O
11.9	O
%	O
(	O
104/874	O
)	O
of	O
adult	O
patients	O
treated	O
with	O
FANAPT	O
at	O
doses	O
of	O
10	O
mg/day	O
or	O
greater	O
versus	O
5.3	O
%	O
(	O
31/587	O
)	O
treated	O
with	O
placebo	O
.	O
	
The	O
following	O
adverse	O
events	O
were	O
reported	O
in	O
Crohn	O
's	O
disease	O
patients	O
who	O
were	O
antibody-positive	O
(	O
N	O
=	O
100	O
)	O
at	O
an	O
incidence	O
at	O
least	O
3	O
%	O
higher	O
compared	O
to	O
antibody-negative	O
patients	O
(	O
N	O
=	O
1,242	O
)	O
:	O
abdominal	B
pain	I
,	O
arthralgia	B
,	O
edema	B
peripheral	I
,	O
erythema	B
nodosum	I
,	O
injection	B
site	I
erythema	I
,	O
injection	B
site	I
pain	I
,	O
pain	B
in	I
extremity	I
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
.	O
	
ONJ	B
can	O
manifest	O
as	O
jaw	B
pain	I
,	O
osteomyelitis	B
,	O
osteitis	B
,	O
bone	B
erosion	I
,	O
periodontal	B
infection	I
,	O
toothache	B
,	O
gingival	B
ulceration	I
,	O
persistent	B
jaw	I
pain	I
or	O
slow	B
healing	I
of	I
the	I
mouth	I
or	I
jaw	I
after	I
dental	I
surgery	I
.	O
	
Non-hematologic	O
adverse	O
reactions	O
(	O
any	O
grade	O
)	O
in	O
the	O
TREANDA	O
group	O
that	O
occurred	O
with	O
a	O
frequency	O
greater	O
than	O
15	O
%	O
were	O
pyrexia	B
(	O
24	O
%	O
)	O
,	O
nausea	B
(	O
20	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
16	O
%	O
)	O
.	O
	
Monitor	O
with	O
liver	O
function	O
tests	O
including	O
ALT	O
and	O
total	O
bilirubin	O
every	O
2	O
weeks	O
during	O
the	O
first	O
2	O
months	O
of	O
treatment	O
,	O
then	O
once	O
a	O
month	O
and	O
as	O
clinically	O
indicated	O
,	O
with	O
more	O
frequent	O
repeat	O
testing	O
for	O
increased	O
liver	O
transaminases	O
,	O
alkaline	O
phosphatase	O
,	O
or	O
total	O
bilirubin	O
in	O
patients	O
who	O
develop	O
transaminase	O
elevations	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
.	O
	
If	O
paradoxical	O
bronchospasm	O
occurs	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
be	O
discontinued	O
immediately	O
and	O
alternative	O
therapy	O
instituted	O
.	O
	
5.7	O
Suicidal	O
Behavior	O
and	O
Ideation	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
including	O
POTIGA	O
,	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
Therapeutic	O
Monitoring	O
:	O
Plasma	O
ammonia	O
levels	O
should	O
be	O
maintained	O
within	O
normal	O
range	O
for	O
age	O
via	O
individual	O
dose	O
adjustment	O
.	O
	
6.3	O
Immunogenicity	O
Denosumab	O
is	O
a	O
human	O
monoclonal	O
antibody	O
.	O
	
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Peripheral	O
T-Cell	O
Lymphoma	O
The	O
safety	O
of	O
Beleodaq	O
was	O
evaluated	O
in	O
129	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
in	O
the	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
patients	O
were	O
administered	O
Beleodaq	O
at	O
a	O
dosage	O
of	O
1,000	O
mg/m2	O
administered	O
over	O
30	O
minutes	O
by	O
IV	O
infusion	O
once	O
daily	O
on	O
Days	O
1-5	O
of	O
a	O
21-day	O
cycle	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Because	O
most	O
trials	O
included	O
in	O
the	O
analysis	O
did	O
not	O
extend	O
beyond	O
24	O
weeks	O
,	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
beyond	O
24	O
weeks	O
could	O
not	O
be	O
assessed	O
.	O
	
5.4	O
Thrombosis	O
and	O
Hemorrhage	O
Serious	O
thrombotic	B
events	I
,	O
including	O
sagittal	B
sinus	I
thrombosis	I
and	O
pulmonary	B
embolism	I
have	O
been	O
reported	O
with	O
both	O
E.	O
coli	O
and	O
Erwinia	O
-derived	O
L-asparaginase	O
therapy	O
.	O
	
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
Grade	O
3/4	O
arterial	B
thromboembolic	I
events	I
were	O
reported	O
in	O
4/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
4/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Study	O
2	O
:	O
Chemotherapy-naive	O
Metastatic	O
Castration-Resistant	O
Prostate	O
Cancer	O
Study	O
2	O
enrolled	O
1717	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
not	O
received	O
prior	O
cytotoxic	O
chemotherapy	O
,	O
of	O
whom	O
1715	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O
	
Keep	O
a	O
list	O
of	O
your	O
medicines	O
and	O
show	O
it	O
to	O
your	O
healthcare	O
provider	O
and	O
pharmacist	O
when	O
you	O
get	O
a	O
new	O
medicine	O
.	O
	
*	O
Risk	O
of	O
Acute	B
Cardiorespiratory	I
Failure	I
:	O
Patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
acute	B
cardiorespiratory	I
failure	I
.	O
	
It	O
is	O
important	O
to	O
note	O
that	O
early	O
manifestations	O
of	O
hypersensitivity	B
,	O
such	O
as	O
fever	B
or	O
lymphadenopathy	B
,	O
may	O
be	O
present	O
even	O
though	O
rash	B
is	O
not	O
evident	O
.	O
	
Fatal	B
hemorrhage	B
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
(	O
gastric	B
hemorrhage	I
)	O
and	O
3/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Routine	O
monitoring	O
of	O
estimated	O
creatinine	O
clearance	O
,	O
urine	O
glucose	O
,	O
and	O
urine	O
protein	O
should	O
be	O
performed	O
during	O
STRIBILD	O
therapy	O
in	O
all	O
patients	O
.	O
	
(	O
5.2	O
)	O
*	O
Monitor	O
for	O
worsening	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
Monitoring	O
for	O
proteinuria	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
is	O
recommended	O
.	O
	
Dizziness	B
was	O
reported	O
in	O
13	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
to	O
ZYKADIA	O
was	O
6	O
months	O
.	O
	
Fatigue/asthenia	O
was	O
reported	O
in	O
6	O
%	O
of	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
1	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
*	O
Myelosuppression	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Anaphylaxis	B
and	O
Infusion	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Tumor	B
Lysis	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Skin	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Other	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Extravasation	B
injury	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
*	O
*	O
Most	O
common	O
non-hematologic	O
adverse	O
reactions	O
for	O
CLL	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
pyrexia	B
,	O
nausea	B
,	O
and	O
vomiting	B
.	O
	
EXCERPT	O
:	O
Most	O
common	O
all	O
grades	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
neutropenia	B
,	O
anemia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
asthenia	B
,	O
abdominal	B
pain	I
,	O
hematuria	B
,	O
back	B
pain	I
,	O
anorexia	B
,	O
peripheral	B
neuropathy	I
,	O
pyrexia	B
,	O
dyspnea	B
,	O
dysgeusia	B
,	O
cough	B
,	O
arthralgia	B
,	O
and	O
alopecia	B
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Pruritus	B
.	O
	
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
worsening	B
renal	I
impairment	I
:	O
Can	O
include	O
acute	B
renal	I
failure	I
and	O
Fanconi	B
syndrome	I
.	O
	
Table	O
2	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
The	O
data	O
described	O
below	O
are	O
based	O
on	O
two	O
pooled	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
through	O
Day	O
90	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
Because	O
there	O
was	O
no	O
apparent	O
dose-related	O
increase	O
in	O
the	O
majority	O
of	O
adverse	O
events	O
observed	O
with	O
BENLYSTA	O
,	O
the	O
safety	O
data	O
summarized	O
below	O
are	O
presented	O
for	O
the	O
3	O
doses	O
pooled	O
,	O
unless	O
otherwise	O
indicated	O
;	O
the	O
adverse	O
reaction	O
table	O
displays	O
the	O
results	O
for	O
the	O
recommended	O
dose	O
of	O
10	O
mg/kg	O
compared	O
with	O
placebo	O
.	O
	
Serious	O
skin	B
infections	I
,	O
as	O
well	O
as	O
infections	B
of	I
the	I
abdomen	I
,	O
were	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
Prolia	O
.	O
	
Two	O
randomized	O
clinical	O
trials	O
enrolled	O
patients	O
with	O
metastatic	O
prostate	O
cancer	O
that	O
has	O
progressed	O
on	O
androgen	O
deprivation	O
therapy	O
(	O
GnRH	O
therapy	O
or	O
bilateral	O
orchiectomy	O
)	O
,	O
a	O
disease	O
setting	O
that	O
is	O
also	O
defined	O
as	O
metastatic	O
CRPC	O
.	O
	
Although	O
no	O
high	O
risk	O
group	O
has	O
been	O
identified	O
,	O
exercise	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
CIMZIA	O
who	O
have	O
ongoing	O
,	O
or	O
a	O
history	O
of	O
,	O
significant	O
hematologic	O
abnormalities	O
.	O
	
In	O
the	O
randomized	O
,	O
placebo-controlled	O
portion	O
of	O
SJIA	O
Study	O
2	O
decreased	B
white	I
blood	I
cell	I
counts	I
)	O
less	O
than	O
or	O
equal	O
to	O
0.8	O
times	O
lower	O
limit	O
of	O
normal	O
(	O
LLN	O
)	O
were	O
reported	O
in	O
5	O
patients	O
(	O
10.4	O
%	O
)	O
in	O
the	O
ILARIS	O
group	O
compared	O
to	O
2	O
(	O
4.0	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Percentages	O
calculated	O
with	O
the	O
number	O
of	O
female	O
subjects	O
in	O
each	O
group	O
as	O
denominator	O
:	O
placebo	O
(	O
N=481	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=443	O
)	O
,	O
JARDIANCE	O
25	O
mg	O
(	O
N=420	O
)	O
.	O
	
(	O
5.1	O
,	O
2.3	O
)	O
*	O
Tumor	B
Promotion	I
in	I
BRAF	I
Wild-Type	I
Melanoma	I
:	O
Increased	B
cell	I
proliferation	I
can	O
occur	O
with	O
BRAF	O
inhibitors	O
.	O
	
Experience	O
in	O
Classical	O
Hodgkin	O
Lymphoma	O
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Relapsed	O
Classical	O
HL	O
(	O
Study	O
1	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
102	O
patients	O
with	O
classical	O
HL	O
in	O
a	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
intravenously	O
every	O
3	O
weeks	O
.	O
	
If	O
a	O
hypersensitivity	O
reaction	O
occurs	O
,	O
discontinue	O
Teflaro	O
.	O
	
Patients	O
who	O
have	O
serum	O
ALT	O
greater	O
than	O
three	O
times	O
the	O
reference	O
range	O
with	O
serum	O
total	O
bilirubin	O
greater	O
than	O
two	O
times	O
the	O
reference	O
range	O
without	O
alternative	O
etiologies	O
are	O
at	O
risk	O
for	O
severe	O
drug-induced	O
liver	O
injury	O
and	O
should	O
not	O
be	O
restarted	O
on	O
ULORIC	O
.	O
	
Since	O
no	O
data	O
are	O
available	O
on	O
either	O
the	O
efficacy	O
or	O
on	O
the	O
risks	O
of	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
in	O
patients	O
receiving	O
ILARIS	O
,	O
live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
.	O
	
Chronic	O
Hepatitis	O
C-associated	O
Thrombocytopenia	O
:	O
In	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
955	O
patients	O
with	O
chronic	O
hepatitis	O
C-associated	O
thrombocytopenia	O
received	O
PROMACTA	O
.	O
	
The	O
safety	O
of	O
JEVTANA	O
in	O
combination	O
with	O
prednisone	O
was	O
evaluated	O
in	O
371	O
patients	O
with	O
hormone-refractory	O
metastatic	O
prostate	O
cancer	O
treated	O
in	O
a	O
single	O
randomized	O
trial	O
,	O
compared	O
to	O
mitoxantrone	O
plus	O
prednisone	O
.	O
	
The	O
causal	O
relationship	O
of	O
these	O
events	O
to	O
CIMZIA	O
remains	O
unclear	O
.	O
	
c	O
Predefined	O
adverse	O
event	O
grouping	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
polyuria	B
,	O
pollakiuria	B
,	O
and	O
nocturia	B
d	O
Male	O
genital	O
mycotic	O
infections	O
include	O
the	O
following	O
adverse	O
reactions	O
:	O
balanoposthitis	B
,	O
balanitis	B
,	O
genital	B
infections	I
fungal	I
,	O
genitourinary	B
tract	I
infection	I
,	O
balanitis	B
candida	I
,	O
scrotal	B
abscess	I
,	O
penile	B
infection	I
.	O
	
Use	O
of	O
DUAVEE	O
in	O
patients	O
with	O
hepatic	O
impairment	O
is	O
contraindicated	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
5.17	O
Drug-Laboratory	O
Test	O
Interactions	O
Accelerated	B
prothrombin	I
time	I
;	O
increased	B
platelet	I
count	I
;	O
increased	B
factors	I
II	I
;	O
decreased	B
levels	I
of	I
antifactor	I
Xa	I
,	O
decreased	B
antithrombin	I
III	I
activity	I
;	O
increased	B
levels	I
of	I
fibrinogen	I
;	O
increased	B
plasminogen	I
antigen	I
.	O
	
Bilirubin	O
Asymptomatic	O
and	O
mild	O
elevations	B
of	I
serum	I
bilirubin	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
ILARIS	O
without	O
concomitant	O
elevations	B
of	I
transaminases	I
.	O
	
If	O
a	O
diagnosis	O
of	O
invasive	O
systemic	O
fungal	O
infection	O
is	O
made	O
,	O
discontinue	O
AFINITOR	O
and	O
treat	O
with	O
appropriate	O
antifungal	O
therapy	O
.	O
	
Therefore	O
,	O
exercise	O
caution	O
when	O
considering	O
resumption	O
of	O
CIMZIA	O
therapy	O
in	O
this	O
situation	O
and	O
monitor	O
patients	O
closely	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
the	O
incidence	O
of	O
pyrexia	B
was	O
57	O
%	O
(	O
116/202	O
)	O
.	O
	
AMPYRA	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
adverse	O
events	O
observed	O
within	O
one	O
hour	O
of	O
the	O
end	O
of	O
the	O
infusion	O
were	O
similar	O
in	O
patients	O
who	O
received	O
Cleviprex	O
and	O
in	O
those	O
who	O
received	O
comparator	O
agents	O
.	O
	
During	O
Prolia	O
treatment	O
,	O
patients	O
should	O
be	O
advised	O
to	O
report	O
new	O
or	O
unusual	O
thigh	O
,	O
hip	O
,	O
or	O
groin	O
pain	O
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
one	O
subject	O
treated	O
with	O
OTEZLA	O
attempted	B
suicide	I
while	O
one	O
who	O
received	O
placebo	O
committed	O
suicide	B
.	O
	
Dose-Related	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
greater	O
than	O
2	O
%	O
incidence	O
in	O
the	O
patients	O
treated	O
with	O
FANAPT	O
,	O
and	O
for	O
which	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
FANAPT	O
20	O
to	O
24	O
mg/day	O
were	O
twice	O
than	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
FANAPT	O
10	O
to	O
16	O
mg/day	O
were	O
:	O
abdominal	B
discomfort	I
,	O
dizziness	B
,	O
hypotension	B
,	O
musculoskeletal	B
stiffness	I
,	O
tachycardia	B
,	O
and	O
weight	B
increased	I
.	O
	
In	O
this	O
study	O
,	O
the	O
majority	O
of	O
myocardial	B
infarctions	I
occurred	O
between	O
1	O
and	O
4	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
The	O
safety	O
evaluation	O
of	O
ZYKADIA	O
is	O
based	O
on	O
255	O
ALK-positive	O
patients	O
in	O
Study	O
1	O
(	O
246	O
patients	O
with	O
NSCLC	O
and	O
9	O
patients	O
with	O
other	O
cancers	O
who	O
received	O
ZYKADIA	O
at	O
a	O
dose	O
of	O
750	O
mg	O
daily	O
)	O
.	O
	
In	O
patients	O
who	O
had	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
<	O
5	O
muU/mL	O
before	O
treatment	O
,	O
elevations	B
of	I
TSH	I
to	O
>	O
=10	O
muU/mL	O
occurred	O
in	O
79/245	O
patients	O
(	O
32	O
%	O
)	O
receiving	O
INLYTA	O
and	O
25/232	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Some	O
patients	O
in	O
the	O
clinical	O
studies	O
or	O
in	O
the	O
postmarketing	O
setting	O
have	O
undergone	O
testing	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
.	O
	
If	O
hypotension	O
does	O
occur	O
,	O
the	O
patient	O
should	O
be	O
placed	O
in	O
the	O
supine	O
position	O
and	O
,	O
if	O
necessary	O
,	O
given	O
an	O
intravenous	O
infusion	O
of	O
normal	O
saline	O
.	O
	
10	O
22	O
Psychiatric	O
disorders	O
Insomnia	B
8	O
10	O
Vascular	O
disorders	O
Hypertension	B
<	O
1	O
3	O
Dystonia	O
:	O
Symptoms	O
of	O
dystonia	B
,	O
prolonged	B
abnormal	I
contractions	I
of	I
muscle	I
groups	I
,	O
may	O
occur	O
in	O
susceptible	O
individuals	O
during	O
the	O
first	O
few	O
days	O
of	O
treatment	O
.	O
	
In	O
most	O
cases	O
,	O
initial	O
symptoms	O
occurred	O
within	O
minutes	O
of	O
DOTAREM	O
administration	O
and	O
resolved	O
with	O
prompt	O
emergency	O
treatment	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.10	O
Hypersensitivity	O
Reactions	O
In	O
post-marketing	O
experience	O
,	O
serious	O
systemic	O
hypersensitivity	B
reactions	I
(	O
including	O
anaphylactic	B
reaction	I
)	O
have	O
been	O
reported	O
following	O
administration	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
(	O
e.g.	O
,	O
high-dose	O
or	O
multiple	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
]	O
.	O
	
How	O
should	O
I	O
take	O
DUAVEE	O
?	O
	
The	O
median	O
number	O
of	O
cycles	O
initiated	O
was	O
4	O
(	O
range	O
1-35	O
)	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
Prolia	O
:	O
*	O
Drug-related	O
hypersensitivity	B
reactions	I
:	O
anaphylaxis	B
,	O
rash	B
,	O
urticaria	B
,	O
facial	B
swelling	I
,	O
and	O
erythema	B
*	O
Hypocalcemia	B
:	O
severe	O
hypocalcemia	B
*	O
Musculoskeletal	B
pain	I
,	O
including	O
severe	O
cases	O
*	O
Parathyroid	O
Hormone	O
(	O
PTH	O
)	O
:	O
Marked	O
elevation	B
in	I
serum	I
PTH	I
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
)	O
or	O
receiving	O
dialysis	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
while	O
being	O
treated	O
with	O
BOSULIF	O
.	O
	
Prompt	O
use	O
of	O
all	O
therapies	O
necessary	O
to	O
reduce	O
plasma	O
ammonia	O
levels	O
is	O
essential	O
.	O
	
*	O
Choking	B
has	O
been	O
reported	O
by	O
patients	O
,	O
some	O
of	O
whom	O
may	O
have	O
also	O
experienced	O
oropharyngeal	B
muscular	I
dysfunction	I
or	O
hypoesthesia	B
.	O
	
A	O
total	O
of	O
120	O
men	O
were	O
exposed	O
to	O
placebo	O
and	O
120	O
men	O
were	O
exposed	O
to	O
Prolia	O
administered	O
subcutaneously	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
dose	O
.	O
	
Perform	O
complete	O
blood	O
counts	O
weekly	O
for	O
the	O
first	O
month	O
of	O
therapy	O
and	O
then	O
monthly	O
thereafter	O
,	O
or	O
as	O
clinically	O
indicated	O
.	O
	
The	O
numbers	O
of	O
patients	O
and	O
their	O
exposures	O
are	O
described	O
in	O
Table	O
1	O
.	O
	
Adverse	O
reactions	O
were	O
reported	O
according	O
to	O
NCI	O
CTC	O
v.2.0	O
.	O
	
*	O
Healthcare	O
sites	O
must	O
be	O
certified	O
with	O
the	O
program	O
and	O
ensure	O
that	O
XIAFLEX	O
is	O
only	O
dispensed	O
for	O
use	O
by	O
certified	O
prescribers	O
.	O
	
Table	O
4	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
was	O
7.4	O
weeks	O
(	O
range	O
:	O
1.6-13.4	O
)	O
and	O
6.3	O
weeks	O
(	O
range	O
:	O
0.3-18.9	O
)	O
after	O
the	O
initiation	O
of	O
YERVOY	O
for	O
patients	O
with	O
Grade	O
3-5	O
enterocolitis	B
and	O
with	O
Grade	O
2	O
enterocolitis	B
,	O
respectively	O
.	O
	
One	O
of	O
the	O
476	O
patients	O
treated	O
with	O
cyclosporine	O
developed	O
PTLD	B
,	O
without	O
CNS	O
involvement	O
.	O
	
In	O
this	O
trial	O
,	O
elevated	B
plasma	I
prolactin	I
levels	I
were	O
observed	O
in	O
26	O
%	O
of	O
adults	O
treated	O
with	O
FANAPT	O
compared	O
to	O
12	O
%	O
in	O
the	O
placebo-group	O
.	O
	
Withhold	O
ZYKADIA	O
in	O
patients	O
who	O
develop	O
a	O
QTc	O
interval	O
greater	O
than	O
500	O
msec	O
on	O
at	O
least	O
2	O
separate	O
ECGs	O
until	O
the	O
QTc	O
interval	O
is	O
less	O
than	O
481	O
msec	O
or	O
recovery	O
to	O
baseline	O
if	O
the	O
QTc	O
interval	O
is	O
greater	O
than	O
or	O
equal	O
to	O
481	O
msec	O
,	O
then	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
.	O
	
However	O
,	O
the	O
incidence	O
of	O
pruritus	B
increased	O
with	O
more	O
injections	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
ECG	O
analysis	O
did	O
not	O
identify	O
QTc	B
prolongation	I
.	O
	
Observe	O
infants	O
for	O
signs	O
or	O
symptoms	O
of	O
benzyl	O
alcohol	O
toxicity	O
following	O
AdreView	O
administration	O
.	O
	
Monitor	O
serum	O
ALT	O
values	O
monthly	O
during	O
therapy	O
with	O
Ferriprox	O
,	O
and	O
consider	O
interruption	O
of	O
therapy	O
if	O
there	O
is	O
a	O
persistent	O
increase	O
in	O
the	O
serum	O
transaminase	O
levels	O
.	O
	
COPD	O
may	O
deteriorate	O
acutely	O
over	O
a	O
period	O
of	O
hours	O
or	O
chronically	O
over	O
several	O
days	O
or	O
longer	O
.	O
	
Ongoing	O
monitoring	O
of	O
plasma	O
ammonia	O
levels	O
,	O
neurological	O
status	O
,	O
laboratory	O
tests	O
and	O
clinical	O
responses	O
in	O
patients	O
receiving	O
Carbaglu	O
is	O
crucial	O
to	O
assess	O
patient	O
response	O
to	O
treatment	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
for	O
YERVOY	O
,	O
mycophenolate	O
treatment	O
has	O
been	O
administered	O
in	O
patients	O
who	O
have	O
persistent	O
severe	O
hepatitis	O
despite	O
high-dose	O
corticosteroids	O
.	O
	
Monitor	O
patients	O
for	O
the	O
development	O
of	O
severe	O
cutaneous	O
reactions	O
and	O
discontinue	O
Zydelig	O
.	O
	
Correct	O
hypokalemia	O
or	O
hypomagnesemia	O
prior	O
to	O
initiating	O
HALAVEN	O
and	O
monitor	O
these	O
electrolytes	O
periodically	O
during	O
therapy	O
.	O
	
Diarrhea	B
can	O
occur	O
at	O
any	O
time	O
.	O
	
In	O
each	O
cycle	O
,	O
two	O
injections	O
of	O
XIAFLEX	O
or	O
two	O
injections	O
of	O
placebo	O
were	O
administered	O
1	O
to	O
3	O
days	O
apart	O
.	O
	
Testing	O
should	O
include	O
visual	O
acuity	O
and	O
dilated	O
fundus	O
photography	O
.	O
	
In	O
the	O
studies	O
with	O
CIMZIA	O
in	O
RA	O
,	O
there	O
were	O
36	O
cases	O
of	O
TB	B
among	O
2,367	O
exposed	O
patients	O
,	O
including	O
some	O
fatal	B
cases	O
.	O
	
The	O
long-term	O
clinical	O
effects	O
of	O
the	O
increase	B
in	I
HR	I
have	O
not	O
been	O
established	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
,	O
rapid	O
corticosteroid	O
tapering	O
resulted	O
in	O
recurrence	O
or	O
worsening	O
symptoms	O
of	O
enterocolitis	O
in	O
some	O
patients	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
*	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
The	O
preservative	O
in	O
DUREZOL	O
may	O
be	O
absorbed	O
by	O
soft	O
contact	O
lenses	O
.	O
	
Sleep	O
apnea	O
is	O
common	O
in	O
MPS	O
IVA	O
patients	O
.	O
	
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
bone	O
loss	O
in	O
women	O
with	O
nonmetastatic	O
breast	O
cancer	O
receiving	O
aromatase	O
inhibitor	O
(	O
AI	O
)	O
therapy	O
was	O
assessed	O
in	O
a	O
2-year	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multinational	O
study	O
of	O
252	O
postmenopausal	O
women	O
aged	O
35	O
to	O
84	O
years	O
.	O
	
Pain	B
in	I
extremity	I
(	O
7.7	O
%	O
placebo	O
vs.	O
9.9	O
%	O
Prolia	O
)	O
and	O
musculoskeletal	B
pain	I
(	O
3.8	O
%	O
placebo	O
vs.	O
6.0	O
%	O
Prolia	O
)	O
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
The	O
laboratory	O
findings	O
in	O
these	O
4	O
subjects	O
improved	O
but	O
did	O
not	O
completely	O
resolve	O
in	O
all	O
subjects	O
upon	O
discontinuation	O
of	O
STRIBILD	O
.	O
	
Hypertension	B
In	O
the	O
two	O
randomized	O
trials	O
,	O
hypertension	B
was	O
reported	O
in	O
11	O
%	O
of	O
patients	O
receiving	O
XTANDI	O
and	O
4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Therefore	O
,	O
the	O
combination	O
of	O
anakinra	O
with	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Ask	O
your	O
healthcare	O
provider	O
if	O
you	O
do	O
not	O
know	O
if	O
you	O
take	O
any	O
of	O
these	O
medicines	O
.	O
	
*	O
have	O
any	O
other	O
medical	O
conditions	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-experienced	O
Subjects	O
:	O
In	O
a	O
multicenter	O
,	O
open-label	O
,	O
single-arm	O
trial	O
(	O
ING112574	O
,	O
VIKING-3	O
)	O
,	O
183	O
HIV-1-infected	O
,	O
antiretroviral	O
treatment-experienced	O
adults	O
with	O
virological	O
failure	O
and	O
current	O
or	O
historical	O
evidence	O
of	O
raltegravir	O
and/or	O
elvitegravir	O
resistance	O
received	O
TIVICAY	O
50	O
mg	O
twice	O
daily	O
with	O
the	O
current	O
failing	O
background	O
regimen	O
for	O
7	O
days	O
and	O
with	O
optimized	O
background	O
therapy	O
from	O
Day	O
8	O
.	O
	
Transaminase	O
elevations	O
were	O
more	O
common	O
in	O
patients	O
who	O
had	O
abnormal	O
transaminases	O
at	O
baseline	O
.	O
	
(	O
5.3	O
)	O
*	O
Avoid	O
coadministration	O
with	O
other	O
anti-retroviral	O
products	O
:	O
Do	O
not	O
use	O
with	O
products	O
containing	O
any	O
of	O
the	O
components	O
of	O
STRIBILD	O
(	O
cobicistat	O
,	O
elvitegravir	O
,	O
emtricitabine	O
,	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
,	O
including	O
ATRIPLA	O
,	O
COMPLERA	O
,	O
EMTRIVA	O
,	O
TRUVADA	O
,	O
TYBOST	O
,	O
VIREAD	O
,	O
or	O
VITEKTA	O
;	O
with	O
drugs	O
containing	O
lamivudine	O
;	O
or	O
with	O
drugs	O
or	O
regimens	O
containing	O
ritonavir	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
GILOTRIF-treated	O
patients	O
in	O
Study	O
1	O
included	O
pulmonary	B
toxicity/ILD-like	O
adverse	B
reactions	I
(	O
1.3	O
%	O
)	O
,	O
sepsis	B
(	O
0.43	O
%	O
)	O
,	O
and	O
pneumonia	B
(	O
0.43	O
%	O
)	O
.	O
	
Dizziness	B
was	O
reported	O
in	O
17	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
15	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Some	O
patients	O
(	O
13	O
%	O
)	O
received	O
premedication	O
,	O
which	O
may	O
have	O
mitigated	O
or	O
masked	O
a	O
hypersensitivity	O
response	O
;	O
however	O
,	O
there	O
is	O
insufficient	O
evidence	O
to	O
determine	O
whether	O
premedication	O
diminishes	O
the	O
frequency	O
or	O
severity	O
of	O
hypersensitivity	O
reactions	O
.	O
	
5.3	O
Angioedema	O
with	O
Concomitant	O
Use	O
of	O
Angiotensin-Converting	O
Enzyme	O
(	O
ACE	O
)	O
Inhibitors	O
Patients	O
taking	O
concomitant	O
ACE	O
inhibitor	O
therapy	O
may	O
be	O
at	O
increased	O
risk	O
for	O
angioedema	B
(	O
e.g.	O
,	O
swelling	B
of	I
the	I
airways	I
,	O
with	O
or	O
without	O
respiratory	B
impairment	I
)	O
.	O
	
Physicians	O
should	O
exercise	O
caution	O
when	O
administering	O
ILARIS	O
to	O
patients	O
with	O
infections	O
,	O
a	O
history	O
of	O
recurring	O
infections	O
or	O
underlying	O
conditions	O
which	O
may	O
predispose	O
them	O
to	O
infections	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
91	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
9	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
86.8	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Bleeding	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
in	O
ARISTOTLE	O
and	O
AVERROES	O
Tables	O
1	O
and	O
2	O
show	O
the	O
number	O
of	O
patients	O
experiencing	O
major	O
bleeding	B
during	O
the	O
treatment	O
period	O
and	O
the	O
bleeding	B
rate	O
(	O
percentage	O
of	O
subjects	O
with	O
at	O
least	O
one	O
bleeding	B
event	O
per	O
100	O
patient-years	O
)	O
in	O
ARISTOTLE	O
and	O
AVERROES	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
severe	O
skin	B
toxicity	I
and	O
secondary	B
infections	I
of	I
the	I
skin	I
requiring	O
hospitalization	O
occurred	O
in	O
2.5	O
%	O
(	O
5/202	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
An	O
increased	O
incidence	O
of	O
serious	O
infections	B
has	O
been	O
associated	O
with	O
administration	O
of	O
another	O
IL-1	O
blocker	O
in	O
combination	O
with	O
TNF	O
inhibitors	O
.	O
	
Blood	O
pressure	O
should	O
be	O
monitored	O
during	O
treatment	O
with	O
GILENYA	O
.	O
	
5.3	O
Concurrent	O
Treatment	O
with	O
Other	O
Forms	O
of	O
4-Aminopyridine	O
AMPYRA	O
should	O
not	O
be	O
taken	O
with	O
other	O
forms	O
of	O
4-aminopyridine	O
(	O
4-AP	O
,	O
fampridine	O
)	O
since	O
the	O
active	O
ingredient	O
is	O
the	O
same	O
.	O
	
KALIBITORN=100	O
PlaceboN=81	O
Adverse	O
Reactions	O
n	O
(	O
%	O
)	O
a	O
n	O
(	O
%	O
)	O
a	O
Headache	B
8	O
(	O
8	O
%	O
)	O
6	O
(	O
7	O
%	O
)	O
Nausea	B
5	O
(	O
5	O
%	O
)	O
1	O
(	O
1	O
%	O
)	O
Diarrhea	B
4	O
(	O
4	O
%	O
)	O
3	O
(	O
4	O
%	O
)	O
Pyrexia	B
4	O
(	O
4	O
%	O
)	O
0	O
Injection	B
site	I
reactions	I
3	O
(	O
3	O
%	O
)	O
1	O
(	O
1	O
%	O
)	O
Nasopharyngitis	B
3	O
(	O
3	O
%	O
)	O
0	O
Some	O
patients	O
in	O
EDEMA3	O
and	O
EDEMA4	O
received	O
a	O
second	O
,	O
open-label	O
30	O
mg	O
subcutaneous	O
dose	O
of	O
KALBITOR	O
within	O
24	O
hours	O
following	O
the	O
initial	O
dose	O
.	O
	
During	O
controlled	O
and	O
open-labeled	O
portions	O
of	O
CIMZIA	O
studies	O
of	O
Crohn	O
's	O
disease	O
and	O
other	O
diseases	O
,	O
malignancies	B
(	O
excluding	O
non-melanoma	B
skin	I
cancer	I
)	O
were	O
observed	O
at	O
a	O
rate	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
0.5	O
(	O
0.4	O
,	O
0.7	O
)	O
per	O
100	O
patient-years	O
among	O
4,650	O
CIMZIA-treated	O
patients	O
versus	O
a	O
rate	O
of	O
0.6	O
(	O
0.1	O
,	O
1.7	O
)	O
per	O
100	O
patient-years	O
among	O
1,319	O
placebo-treated	O
patients	O
.	O
	
Cardiovert	O
patients	O
who	O
are	O
in	O
atrial	O
fibrillation	O
(	O
if	O
clinically	O
indicated	O
)	O
or	O
discontinue	O
MULTAQ	O
.	O
	
For	O
patients	O
taking	O
concomitant	O
strong	O
CYP3A4	O
inhibitors	O
(	O
including	O
ketoconazole	O
,	O
ritonavir	O
,	O
atazanavir	O
,	O
clarithromycin	O
,	O
indinavir	O
,	O
itraconazole	O
,	O
nefazodone	O
,	O
nelfinavir	O
,	O
saquinavir	O
,	O
and	O
telithromycin	O
)	O
,	O
do	O
not	O
use	O
STENDRA	O
[	O
seeDrug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Patients	O
who	O
experience	O
anaphylactic	O
or	O
hypersensitivity	O
reactions	O
may	O
also	O
be	O
tested	O
for	O
IgE	O
antibodies	O
to	O
alglucosidase	O
alfa	O
and	O
other	O
mediators	O
of	O
anaphylaxis	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
of	O
PROMACTA	O
to	O
446	O
patients	O
with	O
chronic	O
ITP	O
aged	O
18	O
to	O
85	O
years	O
,	O
of	O
whom	O
65	O
%	O
were	O
female	O
,	O
across	O
the	O
ITP	O
clinical	O
development	O
program	O
including	O
three	O
placebo-controlled	O
trials	O
.	O
	
(	O
5.10	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Consider	O
discontinuation	O
of	O
DUAVEE	O
if	O
pancreatitis	O
occurs	O
.	O
	
If	O
a	O
gout	O
flare	O
occurs	O
during	O
treatment	O
,	O
ULORIC	O
need	O
not	O
be	O
discontinued	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Gout	B
Flare	I
:	O
An	O
increase	O
in	O
gout	B
flares	I
is	O
frequently	O
observed	O
during	O
initiation	O
of	O
anti-hyperuricemic	O
agents	O
,	O
including	O
ULORIC	O
.	O
	
6.1	O
Adverse	O
Reactions	O
from	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
However	O
,	O
prior	O
to	O
initiating	O
treatment	O
with	O
an	O
antidepressant	O
,	O
patients	O
with	O
depressive	O
symptoms	O
should	O
be	O
adequately	O
screened	O
to	O
determine	O
if	O
they	O
are	O
at	O
risk	O
for	O
bipolar	O
disorder	O
;	O
such	O
screening	O
should	O
include	O
a	O
detailed	O
psychiatric	O
history	O
,	O
including	O
a	O
family	O
history	O
of	O
suicide	O
,	O
bipolar	O
disorder	O
,	O
and	O
depression	O
.	O
	
Motion	O
artifacts	O
may	O
distort	O
the	O
image	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
5.5	O
Risk	O
of	O
Antibody	O
Development	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
,	O
infections	B
were	O
observed	O
in	O
27	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
compared	O
with	O
24	O
%	O
of	O
control-treated	O
patients	O
,	O
and	O
serious	O
infections	B
were	O
observed	O
in	O
0.9	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0.0	O
%	O
of	O
control-treated	O
patients	O
.	O
	
Adverse	O
events	O
such	O
as	O
dry	B
mouth	I
,	O
nausea	B
,	O
vomiting	B
and	O
diarrhea	B
were	O
also	O
reported	O
at	O
an	O
increased	O
frequency	O
in	O
subjects	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Patients	O
treated	O
with	O
dronedarone	O
should	O
undergo	O
monitoring	O
of	O
cardiac	O
rhythm	O
no	O
less	O
often	O
than	O
every	O
3	O
months	O
.	O
	
5.2	O
Malignancies	O
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
studies	O
of	O
some	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
Do	O
not	O
administer	O
leucovorin	O
within	O
2	O
hours	O
before	O
or	O
after	O
a	O
dose	O
of	O
VORAXAZE	O
because	O
leucovorin	O
is	O
a	O
substrate	O
for	O
VORAXAZE	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Hypertension	B
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
8	O
%	O
of	O
patients	O
on	O
GILENYA	O
0.5	O
mg	O
and	O
in	O
4	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
The	O
incidence	O
of	O
grade	O
>	O
=	O
2	O
hematuria	B
was	O
6	O
%	O
in	O
JEVTANA-treated	O
patients	O
and	O
2	O
%	O
in	O
mitoxantrone-treated	O
patients	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-877-423-6597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
most	O
common	O
reason	O
for	O
treatment	O
discontinuation	O
in	O
both	O
studies	O
was	O
for	O
bleeding-related	B
adverse	I
reactions	I
;	O
in	O
ARISTOTLE	O
this	O
occurred	O
in	O
1.7	O
%	O
and	O
2.5	O
%	O
of	O
patients	O
treated	O
with	O
ELIQUIS	O
and	O
warfarin	O
,	O
respectively	O
,	O
and	O
in	O
AVERROES	O
,	O
in	O
1.5	O
%	O
and	O
1.3	O
%	O
on	O
ELIQUIS	O
and	O
aspirin	O
,	O
respectively	O
.	O
	
Peyronie	O
's	O
Disease	O
(	O
6.2	O
)	O
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
reported	O
with	O
>	O
=	O
25	O
%	O
of	O
patients	O
treated	O
with	O
XIAFLEX	O
and	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
were	O
penile	B
hematoma	I
,	O
penile	B
swelling	I
and	O
penile	B
pain	I
.	O
	
LDL-C	B
increased	I
by	O
2.3	O
%	O
,	O
4.6	O
%	O
,	O
and	O
6.5	O
%	O
in	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
These	O
trials	O
evaluated	O
the	O
use	O
of	O
TANZEUM	O
as	O
monotherapy	O
,	O
and	O
as	O
add-on	O
therapy	O
to	O
oral	O
antidiabetic	O
agents	O
,	O
and	O
as	O
add-on	O
therapy	O
to	O
basal	O
insulin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Women	O
dependent	O
on	O
thyroid	O
hormone	O
replacement	O
therapy	O
who	O
are	O
also	O
receiving	O
estrogens	O
may	O
require	O
increased	O
doses	O
of	O
their	O
thyroid	O
replacement	O
therapy	O
.	O
	
The	O
majority	O
(	O
4	O
of	O
5	O
patients	O
)	O
of	O
fatal	B
infection-related	B
adverse	I
reactions	I
occurred	O
after	O
a	O
single	O
dose	O
of	O
JEVTANA	O
.	O
	
Patients	O
who	O
are	O
carriers	O
of	O
HBV	O
and	O
require	O
treatment	O
with	O
CIMZIA	O
should	O
be	O
closely	O
monitored	O
for	O
clinical	O
and	O
laboratory	O
signs	O
of	O
active	O
HBV	O
infection	O
throughout	O
therapy	O
and	O
for	O
several	O
months	O
following	O
termination	O
of	O
therapy	O
.	O
	
All	O
patients	O
being	O
treated	O
with	O
antidepressants	O
for	O
any	O
indication	O
should	O
be	O
monitored	O
appropriately	O
and	O
observed	O
closely	O
for	O
clinical	O
worsening	O
,	O
suicidality	O
,	O
and	O
unusual	O
changes	O
in	O
behavior	O
,	O
especially	O
during	O
the	O
initial	O
few	O
months	O
of	O
a	O
course	O
of	O
drug	O
therapy	O
,	O
or	O
at	O
times	O
of	O
dose	O
changes	O
,	O
either	O
increases	O
or	O
decreases	O
.	O
	
5.13	O
Hereditary	O
Angioedema	O
Exogenous	O
estrogens	O
may	O
exacerbate	B
symptoms	I
of	I
angioedema	I
in	O
women	O
with	O
hereditary	O
angioedema	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
92	O
%	O
of	O
the	O
population	O
and	O
moderately	O
impaired	O
(	O
eGFR	O
30	O
to	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
8	O
%	O
of	O
the	O
population	O
.	O
	
ILARIS	O
has	O
been	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
serious	O
infections	B
.	O
	
In	O
those	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
who	O
reported	O
dizziness	B
,	O
symptoms	O
persisted	O
during	O
treatment	O
in	O
about	O
6	O
%	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
for	O
patients	O
taking	O
OTEZLA	O
were	O
nausea	B
(	O
1.8	O
%	O
)	O
,	O
diarrhea	B
(	O
1.8	O
%	O
)	O
,	O
and	O
headache	B
(	O
1.2	O
%	O
)	O
.	O
	
The	O
decision	O
to	O
resume	O
INLYTA	O
therapy	O
after	O
surgery	O
should	O
be	O
based	O
on	O
clinical	O
judgment	O
of	O
adequate	O
wound	O
healing	O
.	O
	
Administer	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
Deaths	B
during	O
double-blind	O
treatment	O
where	O
an	O
adverse	O
event	O
was	O
the	O
primary	O
cause	O
occurred	O
in	O
seven	O
patients	O
on	O
AFINITOR	O
and	O
one	O
patient	O
on	O
placebo	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GE	O
Healthcare	O
at	O
1-800-654-0118	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
c	O
Dyspnea	B
includes	O
the	O
preferred	O
terms	O
of	O
dyspnea	B
,	O
dyspnea	B
exertional	I
.	O
	
Especially	O
tell	O
your	O
healthcare	O
provider	O
if	O
you	O
take	O
other	O
hormonal	O
medicines	O
,	O
including	O
progestins	O
or	O
other	O
medicines	O
like	O
DUAVEE	O
.	O
	
Fall-related	B
injuries	I
were	O
more	O
severe	O
in	O
patients	O
treated	O
with	O
XTANDI	O
and	O
included	O
non-pathologic	B
fractures	I
,	O
joint	B
injuries	I
,	O
and	O
hematomas	B
.	O
	
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
There	O
were	O
13	O
(	O
0.8	O
%	O
)	O
patients	O
with	O
Grade	O
3	O
and	O
4	O
(	O
0.2	O
%	O
)	O
patients	O
with	O
Grade	O
4	O
visual	B
impairment	I
.	O
	
Therefore	O
,	O
use	O
of	O
ELIQUIS	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
INVOKANA	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
treated	O
with	O
either	O
INVOKANA	O
100	O
mg	O
or	O
INVOKANA	O
300	O
mg.	O
Table	O
1	O
:	O
Adverse	O
Reactions	O
From	O
Pool	O
of	O
Four	O
26-Week	O
Placebo-Controlled	O
Studies	O
Reported	O
in	O
>	O
=	O
2	O
%	O
of	O
INVOKANA-Treated	O
PatientsThe	O
four	O
placebo-controlled	O
trials	O
included	O
one	O
monotherapy	O
trial	O
and	O
three	O
add-on	O
combination	O
trials	O
with	O
metformin	O
,	O
metformin	O
and	O
sulfonylurea	O
,	O
or	O
metformin	O
and	O
pioglitazone	O
.	O
	
Therefore	O
,	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
disorders	O
,	O
especially	O
coronary	O
insufficiency	O
,	O
cardiac	O
arrhythmias	O
,	O
and	O
hypertension	O
.	O
	
Test	O
for	O
viral	O
hepatitis	O
and	O
discontinue	O
other	O
hepatotoxic	O
medications	O
if	O
evidence	O
of	O
new	O
or	O
worsening	O
liver	O
dysfunction	O
occurs	O
.	O
	
The	O
management	O
of	O
NMS	O
should	O
include	O
:	O
1	O
)	O
immediate	O
discontinuation	O
of	O
antipsychotic	O
drugs	O
and	O
other	O
drugs	O
not	O
essential	O
to	O
concurrent	O
therapy	O
;	O
2	O
)	O
intensive	O
symptomatic	O
treatment	O
and	O
medical	O
monitoring	O
;	O
and	O
3	O
)	O
treatment	O
of	O
any	O
concomitant	O
serious	O
medical	O
problems	O
for	O
which	O
specific	O
treatments	O
are	O
available	O
.	O
	
Consider	O
periodic	O
monitoring	O
with	O
electrocardiograms	O
(	O
ECGs	O
)	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
.	O
	
These	O
cases	O
generally	O
occurred	O
within	O
3	O
months	O
after	O
the	O
initiation	O
of	O
XALKORI	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
patient	O
's	O
clinical	O
status	O
prior	O
to	O
administration	O
of	O
Vimizim	O
and	O
consider	O
delaying	O
the	O
Vimizim	O
infusion	O
.	O
	
APTIOM	O
should	O
be	O
discontinued	O
and	O
not	O
be	O
resumed	O
if	O
an	O
alternative	O
etiology	O
for	O
the	O
signs	O
or	O
symptoms	O
can	O
not	O
be	O
established	O
.	O
	
Monitor	O
patients	O
for	O
symptoms	O
of	O
perforations	O
and	O
fistulas	O
.	O
	
In	O
the	O
XIAFLEX	O
controlled	O
trials	O
in	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
65.5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
penile	B
hematoma	I
,	O
and	O
14.5	O
%	O
developed	O
penile	B
ecchymosis	I
(	O
see	O
Table	O
4	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
CTCAE	O
Grade	O
3-4	O
hyperglycemia	B
,	O
based	O
on	O
laboratory	O
values	O
,	O
occurred	O
in	O
13	O
%	O
of	O
255	O
patients	O
.	O
	
5.6	O
Anaphylaxis	O
Serious	O
allergic	B
reactions	I
,	O
including	O
anaphylaxis	B
,	O
have	O
been	O
reported	O
in	O
patients	O
on	O
Zydelig	O
.	O
	
One	O
percent	O
(	O
1	O
%	O
)	O
of	O
patients	O
discontinued	O
ZYKADIA	O
in	O
Study	O
1	O
due	O
to	O
ILD/pneumonitis	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=25	O
%	O
)	O
were	O
neutropenia	B
,	O
anemia	B
,	O
asthenia/fatigue	O
,	O
alopecia	B
,	O
peripheral	B
neuropathy	I
,	O
nausea	B
,	O
and	O
constipation	B
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Eisai	O
Inc.	O
at	O
(	O
1-877-873-4724	O
)	O
or	O
contact	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
clinical	O
trials	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
therapy	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
5.4	O
High	O
Blood	O
Pressure	O
For	O
women	O
with	O
well-controlled	O
hypertension	O
,	O
monitor	O
blood	O
pressure	O
and	O
stop	O
Natazia	O
if	O
blood	O
pressure	O
rises	O
significantly	O
.	O
	
5.10	O
Drug	O
Interactions	O
Avoid	O
administration	O
of	O
COMETRIQ	O
with	O
agents	O
that	O
are	O
strong	O
CYP3A4	O
inducers	O
or	O
inhibitors	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
,	O
7.2	O
)	O
]	O
.	O
	
Immune-mediated	B
hepatitis	I
:	O
Evaluate	O
liver	O
function	O
tests	O
before	O
each	O
dose	O
of	O
YERVOY	O
.	O
	
Patients	O
received	O
6	O
doses	O
of	O
ERWINAZE	O
25,000	O
International	O
Units/m	O
2	O
intramuscularly	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
and	O
Friday	O
schedule	O
as	O
a	O
replacement	O
for	O
each	O
scheduled	O
dose	O
of	O
pegaspargase	O
remaining	O
on	O
their	O
original	O
treatment	O
protocol	O
.	O
	
Dizziness	B
362014	O
31	O
<	O
1	O
Psychiatric	O
disorders	O
Insomnia	B
15	O
0	O
Respiratory	O
,	O
thoracic	O
,	O
and	O
mediastinal	O
disorders	O
Cough	B
DyspneaDyspnea	O
includes	O
the	O
following	O
terms	O
:	O
acute	B
respiratory	I
failure	I
,	O
bronchial	B
hyperactivity	I
,	O
bronchospasm	B
,	O
dyspnea	B
,	O
dyspnea	B
exertional	I
,	O
respiratory	B
distress	I
,	O
respiratory	B
failure	I
,	O
and	O
wheezing	B
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
FARXIGA	O
;	O
treat	O
per	O
standard	O
of	O
care	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
.	O
	
*	O
Atrial	B
Fibrillation	I
:	O
Monitor	O
patients	O
for	O
atrial	O
fibrillation	O
(	O
5.4	O
)	O
.	O
	
Withhold	O
XALKORI	O
in	O
patients	O
who	O
develop	O
QTc	O
greater	O
than	O
500	O
ms	O
on	O
at	O
least	O
2	O
separate	O
ECGs	O
until	O
recovery	O
to	O
a	O
QTc	O
less	O
than	O
or	O
equal	O
to	O
480	O
ms	O
,	O
then	O
resume	O
XALKORI	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Hyponatremia	B
was	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Baseline	O
evaluations	O
of	O
liver	O
laboratory	O
tests	O
are	O
recommended	O
.	O
	
Neuropathy	O
Neuropathy	B
in	O
nature	O
,	O
occurred	O
in	O
419	O
(	O
25	O
%	O
)	O
of	O
1669	O
patients	O
.	O
	
(	O
5.5	O
)	O
*	O
Hypersensitivity	B
Reactions	I
:	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
and	O
angioedema	B
,	O
have	O
been	O
observed	O
.	O
	
Serum	O
creatinine	O
levels	O
and	O
estimated	O
GFR	O
may	O
not	O
reliably	O
assess	O
renal	O
function	O
in	O
the	O
setting	O
of	O
acute	O
kidney	O
injury	O
.	O
	
No	O
patients	O
experienced	O
hypertensive	B
crisis	I
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
fatigue/asthenia	O
,	O
which	O
occurred	O
in	O
1	O
%	O
of	O
patients	O
on	O
each	O
treatment	O
arm	O
.	O
	
In	O
addition	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
A	O
transient	O
hypotensive	O
response	O
is	O
not	O
a	O
contraindication	O
to	O
further	O
treatment	O
,	O
which	O
usually	O
can	O
be	O
continued	O
without	O
difficulty	O
once	O
the	O
blood	O
pressure	O
has	O
stabilized	O
.	O
	
You	O
should	O
not	O
do	O
both	O
.	O
	
Hypertension	B
was	O
managed	O
with	O
standard	O
antihypertensive	O
therapy	O
.	O
	
Table	O
3	O
compares	O
the	O
incidence	O
of	O
the	O
most	O
frequent	O
adverse	O
reactions	O
from	O
a	O
single	O
treatment	O
cycle	O
of	O
500	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
compared	O
to	O
placebo	O
[	O
seeClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
(	O
5.5	O
)	O
*	O
Not	O
recommended	O
in	O
patients	O
with	O
complete	O
gastrointestinal	O
obstruction	O
or	O
in	O
patients	O
who	O
have	O
surgery	O
for	O
correction	O
of	O
complete	O
bowel	O
obstruction	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
AND	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
AND	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
Life-threatening	O
anaphylactic	B
reactions	I
and	O
severe	O
hypersensitivity	B
reactions	I
,	O
presenting	O
as	O
respiratory	B
distress	I
,	O
hypoxia	B
,	O
apnea	B
,	O
dyspnea	B
,	O
bradycardia	B
,	O
tachycardia	B
,	O
bronchospasm	B
,	O
throat	B
tightness	I
,	O
hypotension	B
,	O
angioedema	B
(	O
including	O
lip	B
swelling	I
,	O
periorbital	B
edema	I
,	O
and	O
face	B
edema	I
)	O
,	O
and	O
urticaria	B
,	O
have	O
occurred	O
in	O
some	O
patients	O
during	O
and	O
after	O
alglucosidase	O
alfa	O
infusions	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
hematologic	B
abnormalities	I
for	O
both	O
indications	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
lymphopenia	B
,	O
anemia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
,	O
and	O
neutropenia	B
.	O
	
A	O
placebo-controlled	O
trial	O
with	O
another	O
LABA	O
(	O
salmeterol	O
)	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
.	O
	
The	O
major	O
hemorrhagic	B
events	I
of	O
gastric	B
hemorrhage	I
occurred	O
in	O
5	O
%	O
(	O
3/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
none	O
of	O
the	O
53	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
(	O
excluding	O
hypoglycemia	B
)	O
associated	O
with	O
the	O
use	O
of	O
JARDIANCE	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.2	O
%	O
.	O
	
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
occurred	O
in	O
3.7	O
%	O
(	O
7/187	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
in	O
none	O
of	O
the	O
59	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
No	O
patient	O
required	O
dose	O
reduction	O
or	O
permanent	O
discontinuation	O
of	O
TAFINLAR	O
or	O
trametinib	O
for	O
skin	O
toxicity	O
.	O
	
Tables	O
1	O
and	O
2	O
show	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=3	O
%	O
)	O
in	O
adults	O
and	O
children	O
respectively	O
who	O
received	O
the	O
6-dose	O
regimen	O
of	O
Coartem	O
Tablets	O
.	O
	
Most	O
hypersensitivity	O
reactions	O
to	O
EOVIST	O
have	O
occurred	O
within	O
half	O
an	O
hour	O
after	O
administration	O
.	O
	
CIMZIA	O
has	O
not	O
been	O
formally	O
studied	O
in	O
patients	O
with	O
CHF	O
;	O
however	O
,	O
in	O
clinical	O
studies	O
in	O
patients	O
with	O
CHF	O
with	O
another	O
TNF	O
blocker	O
,	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
increased	B
mortality	I
due	O
to	O
CHF	B
were	O
observed	O
.	O
	
Dysphagia	B
was	O
reported	O
in	O
0.2	O
%	O
and	O
0	O
%	O
(	O
1/572	O
,	O
0/379	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5-10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
as	O
compared	O
to	O
0	O
%	O
(	O
0/378	O
,	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
in	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
adult	O
trials	O
,	O
respectively	O
.	O
	
Overall	O
,	O
312	O
patients	O
(	O
95	O
%	O
)	O
received	O
HSV	O
and	O
VZV	O
prophylaxis	O
with	O
a	O
median	O
duration	O
of	O
11.1	O
months	O
(	O
range	O
,	O
0-20	O
)	O
and	O
319	O
patients	O
(	O
98	O
%	O
)	O
received	O
PCP	O
prophylaxis	O
with	O
a	O
median	O
duration	O
of	O
6.5	O
months	O
(	O
range	O
,	O
0-20	O
)	O
.	O
	
In	O
patients	O
with	O
abnormally	O
high	O
(	O
>	O
3	O
mg/dL	O
)	O
serum	O
bilirubin	O
,	O
reduced	O
hepatic	O
contrast	O
was	O
observed	O
.	O
	
This	O
is	O
approximately	O
2-fold	O
higher	O
than	O
expected	O
in	O
the	O
general	O
population	O
.	O
	
In	O
addition	O
,	O
women	O
taking	O
DUAVEE	O
should	O
be	O
advised	O
to	O
move	O
about	O
periodically	O
during	O
travel	O
involving	O
prolonged	O
immobilization	O
.	O
	
CDAD	O
must	O
be	O
considered	O
in	O
all	O
patients	O
who	O
present	O
with	O
diarrhea	O
following	O
antibiotic	O
use	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
golimumab	O
exposure	O
.	O
	
In	O
AVERROES	O
,	O
the	O
mean	O
duration	O
of	O
exposure	O
was	O
approximately	O
59	O
weeks	O
(	O
>	O
3000	O
patient-years	O
)	O
.	O
	
5.9	O
Blood	O
Pressure	O
Effects	O
In	O
MS	O
controlled	O
clinical	O
trials	O
,	O
patients	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
had	O
an	O
average	O
increase	B
over	I
placebo	I
of	I
approximately	I
3	I
mmHg	I
in	I
systolic	I
pressure	I
,	O
first	O
detected	O
after	O
approximately	O
1	O
month	O
of	O
treatment	O
initiation	O
,	O
and	O
persisting	O
with	O
continued	O
treatment	O
.	O
	
There	O
were	O
suicides	B
in	O
the	O
adult	O
studies	O
,	O
but	O
the	O
number	O
was	O
not	O
sufficient	O
to	O
reach	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	O
.	O
	
No	O
complications	O
attributable	O
to	O
leukocytosis	B
were	O
reported	O
in	O
clinical	O
studies	O
.	O
	
S	O
Intracranial	O
,	O
intraspinal	O
,	O
intraocular	O
,	O
pericardial	O
,	O
an	O
operated	O
joint	O
requiring	O
re-operation	O
or	O
intervention	O
,	O
intramuscular	O
with	O
compartment	O
syndrome	O
,	O
or	O
retroperitoneal	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
dose	O
reduction	O
in	O
the	O
patients	O
treated	O
with	O
GILOTRIF	O
were	O
diarrhea	B
(	O
20	O
%	O
)	O
,	O
rash/acne	O
(	O
19	O
%	O
)	O
,	O
paronychia	B
(	O
14	O
%	O
)	O
,	O
and	O
stomatitis	B
(	O
10	O
%	O
)	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Treat	O
hypothyroidism	O
and	O
hyperthyroidism	O
according	O
to	O
standard	O
medical	O
practice	O
to	O
maintain	O
euthyroid	O
state	O
.	O
	
POTIGA	O
was	O
administered	O
as	O
adjunctive	O
therapy	O
to	O
1,365	O
patients	O
with	O
epilepsy	O
in	O
all	O
controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
during	O
the	O
premarketing	O
development	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reactions	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.4	O
Fluid	O
Retention	O
Fluid	B
retention	I
occurs	O
with	O
BOSULIF	O
and	O
may	O
manifest	O
as	O
pericardial	B
effusion	I
,	O
pleural	B
effusion	I
,	O
pulmonary	B
edema	I
,	O
and/or	O
peripheral	B
edema	I
.	O
	
Table	O
6	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Increased	O
Mortality	O
An	O
increased	O
risk	O
of	O
death	B
was	O
seen	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
(	O
9/79	O
,	O
11.4	O
%	O
)	O
compared	O
to	O
the	O
placebo	O
treatment	O
group	O
(	O
2/81	O
,	O
2.5	O
%	O
)	O
in	O
one	O
placebo-controlled	O
trial	O
(	O
based	O
on	O
the	O
120-week	O
visit	O
window	O
)	O
.	O
	
*	O
Hematologic	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Infection	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Tumor	B
Lysis	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Gastrointestinal	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
observed	O
in	O
the	O
trial	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
treated	O
with	O
Beleodaq	O
were	O
nausea	B
,	O
fatigue	B
,	O
pyrexia	B
,	O
anemia	B
,	O
and	O
vomiting	B
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Hypocalcemia	B
(	O
serum	O
calcium	O
<	O
8.4	O
mg/dL	O
)	O
was	O
reported	O
only	O
in	O
Prolia-treated	O
patients	O
(	O
2.4	O
%	O
vs.	O
0	O
%	O
)	O
at	O
the	O
month	O
1	O
visit	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
serious	O
hypersensitivity	B
reactions	I
in	O
patients	O
treated	O
with	O
NESINA	O
.	O
	
Ibrutinib	O
caused	O
malformations	B
in	O
rats	O
at	O
exposures	O
14	O
times	O
those	O
reported	O
in	O
patients	O
with	O
MCL	O
and	O
20	O
times	O
those	O
reported	O
in	O
patients	O
with	O
CLL	O
or	O
WM	O
,	O
receiving	O
the	O
ibrutinib	O
dose	O
of	O
560	O
mg	O
per	O
day	O
and	O
420	O
mg	O
per	O
day	O
,	O
respectively	O
.	O
	
These	O
effects	O
were	O
dose-related	O
and	O
generally	O
appeared	O
within	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
(	O
as	O
early	O
as	O
after	O
3	O
days	O
)	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bayer	O
HealthCare	O
Pharmaceuticals	O
Inc.	O
at	O
1-888-842-2937	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Abdominal	B
pain	I
Vomiting	B
2520201513	O
0	O
<	O
1120	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Pyrexia	B
Peripheral	B
edema	I
Fatigue	B
Chills	B
Chest	B
pain	I
6225171511	O
7	O
<	O
1101	O
Immune	O
system	O
disorders	O
Cytokine	B
release	I
syndrome	I
11	O
1	O
Infections	O
and	O
infestations	O
Other	O
pathogen	O
infections	B
Bacterial	B
infections	I
Fungal	B
infections	I
Viral	B
infections	I
Pneumonia	B
Sepsis	B
4419151397	O
25127486	O
Investigations	O
Increased	B
alanine	I
aminotransferase	I
Increased	B
aspartate	I
aminotransferase	I
Increased	B
weight	I
121111	O
640	O
Metabolism	O
and	O
nutrition	O
disorders	O
Hypokalemia	B
Hypomagnesemia	B
Hyperglycemia	B
Decreased	B
appetite	I
Hypophosphatemia	B
231211106	O
60735	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Back	B
pain	I
Pain	B
in	I
extremity	I
Bone	B
pain	I
Arthralgia	B
14121110	O
2132	O
Nervous	O
system	O
disorders	O
Headache	B
TremorTremor	O
includes	O
the	O
following	O
terms	O
:	O
resting	B
tremor	I
and	O
tremor	B
.	O
	
5.2	O
Growth	O
of	O
Resistant	O
Organisms	O
with	O
Prolonged	O
Use	O
As	O
with	O
other	O
anti-infectives	O
,	O
prolonged	O
use	O
of	O
Besivance	O
(	O
besifloxacin	O
ophthalmic	O
suspension	O
)	O
0.6	O
%	O
may	O
result	O
in	O
overgrowth	B
of	I
non-susceptible	I
organisms	I
.	O
	
The	O
overall	O
percentage	O
of	O
antibody	O
positive	O
patients	O
was	O
8	O
%	O
in	O
patients	O
continuously	O
exposed	O
to	O
CIMZIA	O
,	O
approximately	O
6	O
%	O
were	O
neutralizing	O
in	O
vitro	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
Trials	O
Reported	O
in	O
>	O
=5	O
%	O
of	O
TRULICITY-Treated	O
Patients	O
a	O
Includes	O
diarrhea	B
,	O
fecal	B
volume	I
increased	I
,	O
frequent	B
bowel	I
movements	I
.	O
	
Monitor	O
lipase	O
and	O
amylase	O
prior	O
to	O
the	O
start	O
of	O
ZYKADIA	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Macular	O
Edema	O
Following	O
Retinal	O
Vein	O
Occlusion	O
(	O
RVO	O
)	O
The	O
data	O
described	O
below	O
reflect	O
6	O
months	O
exposure	O
to	O
EYLEA	O
with	O
a	O
monthly	O
2	O
mg	O
dose	O
in	O
218	O
patients	O
following	O
CRVO	O
in	O
2	O
clinical	O
studies	O
(	O
COPERNICUS	O
and	O
GALILEO	O
)	O
and	O
91	O
patients	O
following	O
BRVO	O
in	O
one	O
clinical	O
study	O
(	O
VIBRANT	O
)	O
[	O
seeClinical	O
Studies	O
(	O
14.2	O
)	O
,	O
(	O
14.3	O
)	O
]	O
.	O
	
In	O
general	O
,	O
adverse	O
events	O
reported	O
by	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
were	O
similar	O
to	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
without	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
.	O
	
There	O
was	O
a	O
6-fold	O
increase	O
in	O
the	O
risk	O
of	O
CTCAE	O
Grade	O
3-4	O
hyperglycemia	B
in	O
patients	O
with	O
diabetes	O
or	O
glucose	O
intolerance	O
and	O
a	O
2-fold	O
increase	O
in	O
patients	O
taking	O
corticosteroids	O
.	O
	
Diarrhea	B
due	O
to	O
Zydelig	O
responds	O
poorly	O
to	O
antimotility	O
agents	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
and	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
Comparisons	O
between	O
placebo	O
and	O
SIMPONI	O
ARIA	O
were	O
based	O
on	O
the	O
first	O
24	O
weeks	O
of	O
exposure	O
.	O
	
POTIGA	O
was	O
discontinued	O
in	O
3	O
of	O
the	O
5	O
patients	O
who	O
required	O
catheterization	O
,	O
and	O
all	O
were	O
able	O
to	O
void	O
spontaneously	O
;	O
however	O
,	O
1	O
of	O
the	O
3	O
patients	O
continued	O
intermittent	O
self-catheterization	O
.	O
	
Steroids	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
glaucoma	O
.	O
	
S	O
A	O
medically	O
important	O
event	O
that	O
may	O
be	O
life-threatening	O
or	O
result	O
in	O
death	B
or	O
hospitalization	O
or	O
prolongation	O
of	O
existing	O
hospitalization	O
.	O
	
Tuberculosis	B
and	O
herpes	B
infections	I
were	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
NULOJIX	O
than	O
cyclosporine	O
.	O
	
Orthostatic	B
hypotension	I
was	O
reported	O
in	O
5	O
%	O
of	O
patients	O
given	O
20	O
to	O
24	O
mg/day	O
,	O
3	O
%	O
of	O
patients	O
given	O
10	O
to	O
16	O
mg/day	O
,	O
and	O
1	O
%	O
of	O
patients	O
given	O
placebo	O
.	O
	
In	O
this	O
study	O
13	O
patients	O
experienced	O
bone	B
fractures	I
for	O
treatment	O
durations	O
up	O
to	O
104	O
weeks	O
.	O
	
The	O
rate	O
of	O
withdrawals	O
due	O
to	O
adverse	O
events	O
in	O
placebo-controlled	O
monotherapy	O
and	O
combination	O
therapy	O
trials	O
was	O
2.4	O
%	O
(	O
19/801	O
)	O
for	O
placebo	O
,	O
2.2	O
%	O
(	O
24/1072	O
)	O
for	O
Edarbi	O
40	O
mg	O
,	O
and	O
2.7	O
%	O
(	O
29/1074	O
)	O
for	O
Edarbi	O
80	O
mg	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pharmacyclics	O
at	O
1-877-877-3536	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
role	O
of	O
lymphopenia	B
in	O
this	O
case	O
is	O
unknown	O
.	O
	
In	O
the	O
clinical	O
study	O
of	O
7808	O
postmenopausal	O
women	O
with	O
osteoporosis	O
,	O
the	O
incidence	O
of	O
infections	B
resulting	O
in	O
death	B
was	O
0.2	O
%	O
in	O
both	O
placebo	O
and	O
Prolia	O
treatment	O
groups	O
.	O
	
Increases	O
in	O
Serum	O
Magnesium	O
Dose-related	O
increases	B
in	I
serum	I
magnesium	I
were	O
observed	O
early	O
after	O
initiation	O
of	O
INVOKANA	O
(	O
within	O
6	O
weeks	O
)	O
and	O
remained	O
elevated	O
throughout	O
treatment	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
16	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
After	O
the	O
Cleansing	O
Gel	O
has	O
been	O
wiped	O
off	O
,	O
wash	O
the	O
area	O
with	O
soap	O
and	O
water	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
antidiarrheals	O
,	O
antiemetics	O
,	O
and	O
fluid	O
replacement	O
.	O
	
Tables	O
3	O
and	O
4	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
in	O
XALKORI-treated	O
patients	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
,	O
0.8	O
%	O
,	O
4.0	O
%	O
,	O
and	O
2.7	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
had	O
hemoglobin	B
above	I
the	I
upper	I
limit	I
of	I
normal	I
.	O
	
Other	O
adverse	O
reactions	O
reported	O
in	O
patients	O
receiving	O
Besivance	O
occurring	O
in	O
approximately	O
1-2	O
%	O
of	O
patients	O
included	O
:	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
eye	B
irritation	I
,	O
eye	B
pruritus	I
and	O
headache	B
.	O
	
Monitor	O
LDL-C	O
and	O
treat	O
if	O
appropriate	O
after	O
initiating	O
INVOKANA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
The	O
potency	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
units	O
of	O
biological	O
activity	O
of	O
DYSPORT	O
(	O
r	O
)	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
(	O
5.1	O
)	O
*	O
Recommended	O
dose	O
and	O
frequency	O
of	O
administration	O
should	O
not	O
be	O
exceeded	O
(	O
5.4	O
)	O
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
swallowing	B
difficulties	I
(	O
5.3	O
)	O
*	O
Concomitant	O
neuromuscular	O
disorder	O
may	O
exacerbate	O
clinical	O
effects	O
of	O
treatment	O
(	O
5.5	O
)	O
*	O
DYSPORT	O
(	O
r	O
)	O
contains	O
human	O
albumin	O
.	O
	
NMS	B
is	O
an	O
uncommon	O
but	O
life-threatening	O
syndrome	O
characterized	O
by	O
fever	B
or	O
hyperthermia	B
,	O
muscle	B
rigidity	I
,	O
involuntary	B
movements	I
,	O
altered	B
consciousness	I
,	O
and	O
mental	B
status	I
changes	I
.	O
	
6.3	O
Postmarketing	O
Experience	O
Similar	O
adverse	O
reactions	O
have	O
been	O
observed	O
in	O
postmarketing	O
use	O
as	O
compared	O
to	O
the	O
clinical	O
trials	O
.	O
	
5.7	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Pancreatic	O
and	O
Gastric	O
Anastomoses	O
ENTEREG	O
has	O
not	O
been	O
studied	O
in	O
patients	O
having	O
pancreatic	O
or	O
gastric	O
anastomosis	O
.	O
	
Table	O
4	O
displays	O
the	O
mean	O
changes	O
in	O
serum	O
creatinine	O
and	O
eGFR	O
levels	O
at	O
Week	O
144	O
and	O
the	O
percentage	O
of	O
subjects	O
with	O
elevations	B
in	I
serum	I
creatinine	I
(	O
All	O
Grades	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
1	O
%	O
and	O
more	O
common	O
than	O
with	O
placebo	O
)	O
:	O
ocular	B
irritation	I
,	O
application	B
site	I
irritation	I
,	O
and	O
application	B
site	I
anesthesia	I
.	O
	
The	O
proportion	O
of	O
subjects	O
with	O
psoriasis	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
was	O
6.1	O
%	O
for	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
and	O
4.1	O
%	O
for	O
placebo-treated	O
subjects	O
.	O
	
It	O
is	O
recommended	O
that	O
patients	O
being	O
considered	O
for	O
FANAPT	O
treatment	O
who	O
are	O
at	O
risk	O
for	O
significant	O
electrolyte	O
disturbances	O
have	O
baseline	O
serum	O
potassium	O
and	O
magnesium	O
measurements	O
with	O
periodic	O
monitoring	O
.	O
	
5.4	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Severe	O
Hepatic	O
Impairment	O
Patients	O
with	O
severe	O
hepatic	O
impairment	O
may	O
be	O
at	O
higher	O
risk	O
of	O
serious	O
adverse	O
reactions	O
(	O
including	O
dose-related	O
serious	O
adverse	O
reactions	O
)	O
because	O
up	O
to	O
10-fold	O
higher	O
plasma	O
levels	O
of	O
drug	O
have	O
been	O
observed	O
in	O
such	O
patients	O
compared	O
with	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
PRADAXA	O
is	O
contraindicated	O
in	O
patients	O
with	O
mechanical	O
prosthetic	O
valves	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
DaTscan	O
administration	O
and	O
,	O
following	O
administration	O
,	O
observe	O
patients	O
for	O
symptoms	O
or	O
signs	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
In	O
the	O
randomized	O
trial	O
,	O
five	O
patients	O
(	O
1.3	O
%	O
)	O
experienced	O
fatal	B
infectious	B
adverse	I
events	I
(	O
sepsis	B
or	O
septic	B
shock	I
)	O
.	O
	
Liver	O
Enzyme	O
Abnormalities	O
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
experienced	O
at	O
least	O
one	O
event	O
of	O
ALT	B
)	I
increase	I
of	O
3-fold	O
or	O
greater	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
0.9	O
%	O
and	O
0.9	O
%	O
for	O
all	O
comparators	O
versus	O
TANZEUM	O
)	O
.	O
	
6.1.1	O
Safety	O
Experience	O
with	O
Kyprolis	O
in	O
Combination	O
with	O
Lenalidomide	O
and	O
Dexamethasone	O
in	O
Patients	O
with	O
Multiple	O
Myeloma	O
The	O
safety	O
of	O
Kyprolis	O
in	O
combination	O
with	O
lenalidomide	O
and	O
dexamethasone	O
(	O
KRd	O
)	O
was	O
evaluated	O
in	O
an	O
open-label	O
randomized	O
study	O
in	O
patients	O
with	O
relapsed	O
multiple	O
myeloma	O
.	O
	
*	O
Hepatitis	B
B	I
reactivation	I
-	O
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
were	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
:	O
hyperkeratosis	B
,	O
headache	B
,	O
pyrexia	B
,	O
arthralgia	B
,	O
papilloma	B
,	O
alopecia	B
,	O
and	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
.	O
	
How	O
do	O
I	O
store	O
DUAVEE	O
?	O
	
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
is	O
associated	O
with	O
an	O
additional	B
decrease	I
in	I
hemoglobin	I
concentrations	I
.	O
	
5.4	O
Cataracts	O
In	O
the	O
three	O
controlled	O
clinical	O
trials	O
in	O
adults	O
with	O
chronic	O
ITP	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
15	O
(	O
7	O
%	O
)	O
patients	O
who	O
received	O
50	O
mg	O
of	O
PROMACTA	O
daily	O
and	O
8	O
(	O
7	O
%	O
)	O
placebo-group	O
patients	O
.	O
	
In	O
a	O
trial	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
frequency	O
of	O
such	O
gastrointestinal	B
reactions	I
increased	O
as	O
renal	B
function	I
declined	I
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
requiring	O
intervention	O
in	O
clinical	O
trials	O
were	O
hypersensitivity	B
reactions	I
,	O
occurring	O
in	O
20	O
of	O
39	O
(	O
51	O
%	O
)	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
,	O
and	O
included	O
rash	B
,	O
pyrexia	B
,	O
urticaria	B
,	O
flushing	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
cough	B
,	O
tachypnea	B
,	O
tachycardia	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
vomiting	B
,	O
cyanosis	B
,	O
agitation	B
,	O
and	O
tremor	B
.	O
	
A	O
specific	O
antidote	O
for	O
ELIQUIS	O
is	O
not	O
available	O
.	O
	
(	O
5.3	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
.	O
	
STENDRA	O
should	O
be	O
used	O
with	O
caution	O
,	O
and	O
only	O
when	O
the	O
anticipated	O
benefits	O
outweigh	O
the	O
risks	O
,	O
in	O
patients	O
with	O
a	O
history	O
of	O
NAION	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
such	O
as	O
corticosteroids	O
or	O
methotrexate	O
may	O
be	O
at	O
greater	O
risk	O
of	O
infection	O
.	O
	
*	O
Cardiac	B
arrest	I
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
*	O
Hypersensitivity	B
reactions	I
(	O
anaphylactic	B
shock	I
,	O
circulatory	B
collapse	I
,	O
respiratory	B
arrest	I
,	O
pulmonary	B
edema	I
,	O
bronchospasm	B
,	O
cyanosis	B
,	O
oropharyngeal	B
swelling	I
,	O
laryngeal	B
edema	I
,	O
blood	B
pressure	I
increased	I
,	O
chest	B
pain	I
,	O
angioedema	B
,	O
conjunctivitis	B
,	O
hyperhidrosis	B
,	O
cough	B
,	O
sneezing	B
,	O
burning	B
sensation	I
,	O
and	O
pallor	B
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
If	O
such	O
an	O
acute	O
reaction	O
occurs	O
,	O
combination	O
therapy	O
should	O
be	O
discontinued	O
and	O
appropriate	O
medical	O
therapy	O
immediately	O
instituted	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Monitor	O
platelet	O
counts	O
regularly	O
.	O
	
Monitor	O
closely	O
.	O
	
(	O
5.2	O
)	O
*	O
?	O
	
Uveitis	B
(	O
including	O
iritis	B
)	O
occurred	O
in	O
1	O
%	O
(	O
6/586	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
uveitis	B
occurred	O
in	O
1	O
%	O
(	O
2/202	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
long-term	O
consequences	O
of	O
the	O
degree	O
of	O
suppression	B
of	I
bone	I
remodeling	I
observed	O
with	O
Prolia	O
may	O
contribute	O
to	O
adverse	O
outcomes	O
such	O
as	O
osteonecrosis	B
of	I
the	I
jaw	I
,	O
atypical	B
fractures	I
,	O
and	O
delayed	B
fracture	I
healing	I
.	O
	
(	O
5.8	O
)	O
5.1	O
Post-Transplant	O
Lymphoproliferative	O
Disorder	O
NULOJIX-treated	O
patients	O
have	O
an	O
increased	O
risk	O
for	O
developing	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
,	O
predominantly	O
involving	O
the	O
CNS	O
,	O
compared	O
to	O
patients	O
on	O
a	O
cyclosporine-based	O
regimen	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Table	O
2	O
]	O
.	O
	
*	O
Renal	B
failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
A	O
dose-dependent	O
increase	O
in	O
the	O
risk	O
of	O
macular	B
edema	I
occurred	O
in	O
the	O
GILENYA	O
clinical	O
development	O
program	O
.	O
	
Therefore	O
,	O
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
5.5	O
Pre-existing	O
Neuromuscular	O
Disorders	O
and	O
other	O
Special	O
Populations	O
Individuals	O
with	O
peripheral	O
motor	O
neuropathic	O
diseases	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
or	O
neuromuscular	O
junctional	O
disorders	O
(	O
e.g.	O
,	O
myasthenia	O
gravis	O
or	O
Lambert-Eaton	O
syndrome	O
)	O
should	O
be	O
monitored	O
particularly	O
closely	O
when	O
given	O
botulinum	O
toxin	O
.	O
	
5	O
(	O
tartrazine	O
)	O
which	O
may	O
cause	O
allergic-type	B
reactions	I
(	O
including	O
bronchial	B
asthma	I
)	O
in	O
certain	O
susceptible	O
persons	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
occurring	O
in	O
at	O
least	O
3	O
%	O
of	O
patients	O
with	O
SLE	O
who	O
received	O
BENLYSTA	O
10	O
mg/kg	O
and	O
at	O
an	O
incidence	O
at	O
least	O
1	O
%	O
greater	O
than	O
that	O
observed	O
with	O
placebo	O
in	O
the	O
3	O
controlled	O
studies	O
.	O
	
Monitor	O
for	O
evidence	O
of	O
TLS	O
during	O
treatment	O
and	O
manage	O
promptly	O
including	O
interruption	O
of	O
Kyprolis	O
until	O
TLS	O
is	O
resolved	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
In	O
several	O
exploratory	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
the	O
treatment	O
of	O
CHF	O
,	O
there	O
were	O
greater	O
proportions	O
of	O
TNF-blocker	O
treated	O
patients	O
who	O
had	O
CHF	B
exacerbations	I
requiring	O
hospitalization	O
or	O
increased	B
mortality	I
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
.	O
	
(	O
5.1	O
)	O
*	O
venous	B
thrombotic	I
events	I
have	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	B
QT	I
prolongation	I
.	O
	
Approximately	O
80	O
%	O
of	O
these	O
patients	O
had	O
>	O
10	O
weeks	O
exposure	O
to	O
Toviaz	O
in	O
these	O
trials	O
.	O
	
5.4	O
Application	O
Associated	O
Pain	O
Even	O
following	O
use	O
of	O
a	O
local	O
anesthetic	O
prior	O
to	O
administration	O
of	O
Qutenza	O
,	O
patients	O
may	O
experience	O
substantial	O
procedural	B
pain	I
.	O
	
Decreases	O
in	O
Bone	O
Mineral	O
Density	O
Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
was	O
measured	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
in	O
a	O
clinical	O
trial	O
of	O
714	O
older	O
adults	O
(	O
mean	O
age	O
64	O
years	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
the	O
mean	O
percent	O
change	B
in	I
serum	I
magnesium	I
levels	I
was	O
8.1	O
%	O
and	O
9.3	O
%	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
compared	O
to	O
-0.6	O
%	O
with	O
placebo	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
the	O
WM	O
trial	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
rash	B
,	O
nausea	B
,	O
muscle	B
spasms	I
,	O
and	O
fatigue	B
.	O
	
The	O
use	O
of	O
NESINA	O
as	O
add-on	O
therapy	O
to	O
glyburide	O
or	O
insulin	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
hypoglycemia	B
compared	O
to	O
placebo	O
.	O
	
Of	O
the	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
,	O
5	O
%	O
(	O
14/304	O
)	O
developed	O
NODAT	B
by	O
the	O
end	O
of	O
one	O
year	O
compared	O
to	O
10	O
%	O
(	O
27/280	O
)	O
of	O
patients	O
on	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
25	O
%	O
)	O
were	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
lymphopenia	B
,	O
increased	B
ALP	I
,	O
hypocalcemia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
hypophosphatemia	B
,	O
and	O
hyperbilirubinemia	B
.	O
	
In	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
across	O
various	O
patient	O
populations	O
,	O
more	O
than	O
2,300	O
patients	O
have	O
received	O
HORIZANT	O
orally	O
in	O
daily	O
doses	O
ranging	O
from	O
600	O
to	O
3,600	O
mg	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
CIMZIA-treated	O
patients	O
,	O
and	O
with	O
a	O
higher	O
incidence	O
compared	O
to	O
placebo	O
)	O
in	O
controlled	O
clinical	O
studies	O
with	O
CIMZIA	O
were	O
upper	B
respiratory	I
infections	I
(	O
e.g	O
.	O
	
The	O
ophthalmologic	O
monitoring	O
program	O
should	O
include	O
visual	O
acuity	O
testing	O
and	O
dilated	O
fundus	O
photography	O
.	O
	
Treatment	O
with	O
Edarbi	O
was	O
well-tolerated	O
with	O
an	O
overall	O
incidence	O
of	O
adverse	O
reactions	O
similar	O
to	O
placebo	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX-treated	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Grade	O
3	O
or	O
greater	O
thrombocytopenia	B
occurred	O
in	O
1	O
%	O
(	O
7/503	O
)	O
of	O
patients	O
.	O
	
Figure	O
1	O
Gastrointestinal	O
Adverse	O
Reactions	O
Patients	O
on	O
PRADAXA	O
150	O
mg	O
had	O
an	O
increased	O
incidence	O
of	O
gastrointestinal	B
adverse	I
reactions	I
(	O
35	O
%	O
vs.	O
24	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
,	O
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Risk	O
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Drug	O
Events	O
in	O
Drug	O
Patients/Incidencein	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
for	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
for	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
the	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
;	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
,	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
[	O
See	O
Contraindications	O
(	O
4	O
)	O
.	O
]	O
	
Other	O
Adverse	O
Reactions	O
Adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
>	O
=10	O
%	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
or	O
cyclosporine	O
control	O
regimen	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
are	O
summarized	O
by	O
preferred	O
term	O
in	O
decreasing	O
order	O
of	O
frequency	O
within	O
Table	O
4	O
.	O
	
Adverse	O
reactions	O
were	O
predominantly	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
Somnolence	B
was	O
reported	O
in	O
22	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
12	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
(	O
See	O
the	O
respective	O
package	O
inserts	O
for	O
complete	O
VZIG	O
and	O
IG	O
prescribing	O
information	O
.	O
)	O
	
The	O
conditions	O
and	O
duration	O
of	O
treatment	O
with	O
FANAPT	O
varied	O
greatly	O
and	O
included	O
(	O
in	O
overlapping	O
categories	O
)	O
,	O
open-label	O
and	O
double-blind	O
phases	O
of	O
studies	O
,	O
inpatients	O
and	O
outpatients	O
,	O
fixed-dose	O
and	O
flexible-dose	O
studies	O
,	O
and	O
short-term	O
and	O
longer-term	O
exposure	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Tendon	O
Rupture	O
or	O
Other	O
Serious	O
Injury	O
to	O
the	O
Injected	O
Finger/Hand	O
in	O
the	O
Treatment	O
of	O
Dupuytren	O
's	O
Contracture	O
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
clinical	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
,	O
flexor	B
tendon	I
ruptures	I
occurred	O
after	O
XIAFLEX	O
injection	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
PRISTIQ	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
patients	O
with	O
a	O
seizure	O
disorder	O
.	O
	
(	O
5.6	O
)	O
*	O
Preparation	O
and	O
Administration	O
Errors	O
:	O
Strictly	O
follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
.	O
	
Fatal	B
adverse	O
reactions	O
occurred	O
in	O
6	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
resulted	O
from	O
hemorrhage	B
,	O
pneumonia	B
,	O
septicemia	B
,	O
fistulas	B
,	O
cardiac	B
arrest	I
,	O
respiratory	B
failure	I
,	O
and	O
unspecified	O
death	B
.	O
	
Activation	B
of	I
mania	I
has	O
also	O
been	O
reported	O
in	O
a	O
small	O
proportion	O
of	O
patients	O
with	O
major	O
affective	O
disorder	O
who	O
were	O
treated	O
with	O
other	O
marketed	O
antidepressants	O
.	O
	
bladder	B
infection	I
,	O
bacteriuria	B
,	O
cystitis	B
)	O
in	O
7	O
%	O
of	O
CIMZIA-treated	O
patients	O
and	O
in	O
6	O
%	O
of	O
placebo-treated	O
patients	O
,	O
and	O
arthralgia	B
(	O
6	O
%	O
CIMZIA	O
,	O
4	O
%	O
placebo	O
)	O
.	O
	
If	O
liver	O
injury	O
is	O
detected	O
,	O
promptly	O
interrupt	O
NESINA	O
and	O
assess	O
patient	O
for	O
probable	O
cause	O
,	O
then	O
treat	O
cause	O
if	O
possible	O
,	O
to	O
resolution	O
or	O
stabilization	O
.	O
	
In	O
these	O
two	O
studies	O
combined	O
,	O
554	O
patients	O
received	O
Toviaz	O
4	O
mg/day	O
and	O
566	O
patients	O
received	O
Toviaz	O
8	O
mg/day	O
.	O
	
These	O
adverse	O
reactions	O
are	O
:	O
hypersensitivity	B
reactions	I
,	O
paradoxical	B
bronchospasm	I
,	O
tachycardia/heart	O
rate	B
increase/palpitations	O
,	O
pruritus/rash	O
and	O
dizziness	B
.	O
	
Male	B
patients	I
who	I
developed	I
genital	I
mycotic	I
infections	I
on	O
INVOKANA	O
were	O
more	O
likely	O
to	O
experience	O
recurrent	O
infections	O
(	O
22	O
%	O
on	O
INVOKANA	O
versus	O
none	O
on	O
placebo	O
)	O
,	O
and	O
require	O
treatment	O
with	O
oral	O
or	O
topical	O
antifungal	O
agents	O
and	O
anti-microbial	O
agents	O
than	O
patients	O
on	O
comparators	O
.	O
	
Excessive	O
use	O
or	O
use	O
in	O
conjunction	O
with	O
other	O
medications	O
containing	O
LABA	O
can	O
result	O
in	O
clinically	O
significant	O
cardiovascular	B
effects	I
and	O
may	O
be	O
fatal	B
(	O
5.3	O
)	O
*	O
Immediate	O
hypersensitivity	B
reactions	I
may	O
occur	O
.	O
	
The	O
incidence	O
of	O
nonfatal	O
serious	O
adverse	O
events	O
was	O
24.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
25.0	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
DUAVEE	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
endometrial	B
hyperplasia	I
,	O
which	O
may	O
be	O
a	O
precursor	O
to	O
endometrial	O
cancer	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
were	O
hot	B
flush	I
,	O
abdominal	B
pain	I
upper	I
,	O
and	O
nausea	B
.	O
	
If	O
a	O
decision	O
is	O
made	O
to	O
administer	O
SIMPONI	O
ARIA	O
to	O
RA	O
patients	O
with	O
CHF	O
,	O
these	O
patients	O
should	O
be	O
closely	O
monitored	O
during	O
therapy	O
,	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
discontinued	O
if	O
new	O
or	O
worsening	O
symptoms	O
of	O
CHF	O
appear	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
the	O
planned	O
number	O
of	O
doses	O
of	O
ERWINAZE	O
ranged	O
from	O
3	O
to	O
48	O
doses	O
.	O
	
Limited	O
safety	O
data	O
are	O
available	O
in	O
patients	O
with	O
predisposing	O
factors	O
for	O
seizure	O
because	O
these	O
patients	O
were	O
generally	O
excluded	O
from	O
the	O
trials	O
.	O
	
The	O
effects	O
of	O
XEOMIN	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	O
produce	O
symptoms	O
consistent	O
with	O
botulinum	O
toxin	B
effects	I
.	O
	
(	O
1	O
,	O
5.2	O
,	O
7.1	O
,	O
7.3	O
,	O
12.3	O
)	O
*	O
Neuroleptic	B
Malignant	I
Syndrome	I
:	O
Manage	O
with	O
immediate	O
discontinuation	O
of	O
drug	O
and	O
close	O
monitoring	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
Kyprolis	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
TTP/HUS	O
is	O
not	O
known	O
.	O
	
Monitor	O
CrCl	O
at	O
least	O
daily	O
in	O
patients	O
with	O
changing	O
renal	O
function	O
and	O
adjust	O
the	O
dosage	O
of	O
ZERBAXA	O
accordingly	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
No	O
new	O
safety	O
findings	O
were	O
observed	O
following	O
the	O
switch	O
to	O
4000	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
or	O
a	O
history	O
of	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
should	O
discontinue	O
FANAPT	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
65	O
%	O
of	O
patients	O
.	O
	
RPED	B
occurred	O
in	O
2	O
%	O
(	O
1/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5	O
.	O
	
SJIA	O
Study	O
2	O
was	O
a	O
two-part	O
study	O
with	O
an	O
open-label	O
,	O
single-arm	O
active	O
treatment	O
period	O
(	O
Part	O
I	O
)	O
followed	O
by	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
event-driven	O
withdrawal	O
design	O
(	O
Part	O
II	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
Do	O
not	O
start	O
SIMPONI	O
ARIA	O
during	O
an	O
active	O
infection	O
.	O
	
5.2	O
Paradoxical	O
Bronchospasm	O
Inhaled	O
medicines	O
,	O
including	O
TUDORZA	O
PRESSAIR	O
,	O
may	O
cause	O
paradoxical	B
bronchospasm	I
.	O
	
30.6	O
%	O
had	O
diabetes	O
mellitus	O
.	O
	
Congestive	O
Heart	O
Failure	O
No	O
serious	O
adverse	O
reactions	O
to	O
AdreView	O
were	O
observed	O
in	O
clinical	O
studies	O
.	O
	
Details	O
of	O
the	O
study	O
treatment	O
are	O
described	O
in	O
Section	O
14.1	O
.	O
	
Mineralization	O
Defects	O
:	O
Cases	O
of	O
osteomalacia	B
associated	O
with	O
proximal	B
renal	I
tubulopathy	I
,	O
manifested	O
as	O
bone	B
pain	I
or	O
pain	B
in	I
extremities	I
and	O
which	O
may	O
contribute	O
to	O
fractures	B
,	O
have	O
been	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
tenofovir	O
DF	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
A	O
majority	O
of	O
reported	O
events	O
occurred	O
in	O
patients	O
who	O
had	O
experienced	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
or	O
dehydration	B
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TANZEUM	O
.	O
	
The	O
adverse	O
events	O
reported	O
in	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
occurring	O
in	O
the	O
placebo-controlled	O
trials	O
of	O
3	O
to	O
6	O
months	O
.	O
	
Patients	O
with	O
thyroid	O
nodules	O
noted	O
on	O
physical	O
examination	O
or	O
neck	O
imaging	O
should	O
also	O
be	O
further	O
evaluated	O
.	O
	
Induration	O
of	O
5	O
mm	O
or	O
greater	O
with	O
tuberculin	O
skin	O
testing	O
should	O
be	O
considered	O
a	O
positive	O
test	O
result	O
when	O
assessing	O
if	O
treatment	O
for	O
latent	O
tuberculosis	O
is	O
needed	O
prior	O
to	O
initiating	O
CIMZIA	O
,	O
even	O
for	O
patients	O
previously	O
vaccinated	O
with	O
Bacille	O
Calmette-Guerin	O
(	O
BCG	O
)	O
.	O
	
Elevation	B
of	I
serum	I
iron	I
laboratory	O
values	O
were	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
after	O
administration	O
of	O
EOVIST	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
SIMPONI	O
ARIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
.	O
	
Appropriate	O
measures	O
should	O
be	O
taken	O
to	O
identify	O
causes	O
of	O
renal	O
failure	O
and	O
treat	O
aggressively	O
.	O
	
For	O
symptomatic	O
cardiomyopathy	O
or	O
persistent	O
,	O
asymptomatic	O
LV	O
dysfunction	O
that	O
does	O
not	O
resolve	O
within	O
4	O
weeks	O
,	O
permanently	O
discontinue	O
trametinib	O
and	O
withhold	O
TAFINLAR	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
bleeding	B
occurred	O
in	O
417	O
(	O
15.6	O
%	O
)	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
661	O
(	O
24.6	O
%	O
)	O
enoxaparin/warfarin-treated	O
patients	O
.	O
	
*	O
Impaired	B
wound	I
healing	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
As	O
the	O
total	O
burden	O
of	O
immunosuppression	O
is	O
a	O
risk	O
factor	O
for	O
PTLD	O
,	O
higher	O
than	O
the	O
recommended	O
doses	O
or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
and	O
higher	O
than	O
recommended	O
doses	O
of	O
concomitant	O
immunosuppressive	O
agents	O
are	O
not	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Uveitis	O
and	O
Iritis	O
:	O
Uveitis	B
and	O
iritis	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.3	O
Other	O
Malignancies	O
Patients	O
receiving	O
immunosuppressants	O
,	O
including	O
NULOJIX	O
,	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
PTLD	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
A	O
total	O
of	O
696	O
HIV-positive	O
patients	O
in	O
three	O
placebo-controlled	O
trials	O
received	O
FULYZAQ	O
for	O
a	O
mean	O
duration	O
of	O
78	O
days	O
.	O
	
*	O
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
Prior	O
to	O
administration	O
,	O
question	O
the	O
patient	O
for	O
a	O
history	O
of	O
prior	O
reactions	O
to	O
DaTscan	O
.	O
	
(	O
5.2	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
ZERBAXA	O
.	O
	
Table	O
4	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
(	O
5.8	O
)	O
*	O
Suicide	B
:	O
Close	O
supervision	O
of	O
high	O
risk	O
patients	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
(	O
irrespective	O
of	O
causality	O
)	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
14	O
%	O
and	O
3	O
%	O
for	O
the	O
AFINITOR	O
and	O
placebo	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Table	O
4	O
:	O
Clinical	O
Cure	O
Rates	O
in	O
a	O
Phase	O
3	O
Trial	O
of	O
cIAI	O
by	O
Baseline	O
Renal	O
Function	O
(	O
MITT	O
Population	O
)	O
Baseline	O
Renal	O
Function	O
ZERBAXA	O
plus	O
metronidazolen/N	O
(	O
%	O
)	O
Meropenemn/N	O
(	O
%	O
)	O
Normal/mild	O
impairment	O
(	O
CrCl	O
>	O
=50	O
mL/min	O
)	O
312/366	O
(	O
85.2	O
)	O
355/404	O
(	O
87.9	O
)	O
Moderate	O
impairment	O
(	O
CrCl	O
30	O
to	O
<	O
=50	O
mL/min	O
)	O
11/23	O
(	O
47.8	O
)	O
9/13	O
(	O
69.2	O
)	O
5.2	O
Hypersensitivity	O
Reactions	O
Serious	O
and	O
occasionally	O
fatal	B
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Some	O
of	O
these	O
events	O
have	O
been	O
fatal	B
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
re-administering	O
XTANDI	O
to	O
patients	O
who	O
experienced	O
seizure	O
.	O
	
The	O
conduction	B
abnormalities	I
were	O
usually	O
transient	O
and	O
asymptomatic	O
,	O
and	O
resolved	O
within	O
the	O
first	O
24	O
hours	O
on	O
treatment	O
,	O
but	O
they	O
occasionally	O
required	O
treatment	O
with	O
atropine	O
or	O
isoproterenol	O
.	O
	
Glabellar	O
Lines	O
(	O
5.7	O
)	O
:	O
*	O
Risk	O
of	O
ptosis	B
(	O
5.7	O
)	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
who	O
are	O
at	O
increased	O
risk	O
for	O
these	O
events	O
.	O
	
(	O
5.11	O
)	O
*	O
Thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
.	O
	
However	O
,	O
epidemiological	O
studies	O
suggest	O
an	O
increased	O
risk	O
of	O
treatment-emergent	O
hyperglycemia-related	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
the	O
atypical	O
antipsychotics	O
included	O
in	O
these	O
studies	O
.	O
	
The	O
imbalance	O
in	O
deaths	B
is	O
unexplained	O
;	O
no	O
discernible	O
pattern	O
between	O
death	B
and	O
sputum	O
conversion	O
,	O
relapse	O
,	O
sensitivity	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
,	O
HIV	O
status	O
,	O
and	O
severity	O
of	O
disease	O
was	O
observed	O
.	O
	
Of	O
the	O
176	O
patients	O
,	O
65	O
%	O
were	O
White	O
,	O
23	O
%	O
Asian	O
,	O
3	O
%	O
Black	O
,	O
and	O
10	O
%	O
Other	O
race	O
.	O
	
Eosinophilia	O
A	O
transient	O
increase	B
in	I
mean	I
eosinophil	I
counts	I
was	O
seen	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
.	O
	
Discontinue	O
TREANDA	O
for	O
patients	O
with	O
Grade	O
4	O
infusion	O
reactions	O
.	O
	
Fifty-eight	O
percent	O
(	O
58	O
%	O
)	O
of	O
the	O
population	O
were	O
male	O
;	O
84	O
%	O
were	O
White	O
,	O
9	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
In	O
the	O
Peyronie	O
's	O
disease	O
clinical	O
studies	O
,	O
at	O
6	O
weeks	O
after	O
the	O
first	O
treatment	O
cycle	O
of	O
XIAFLEX	O
0.58	O
mg	O
,	O
approximately	O
75	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
approximately	O
55	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-II	O
.	O
	
Elevated	B
ALT	I
(	O
5.3	O
)	O
,	O
Decreased	B
plasma	I
zinc	I
concentrations	I
(	O
5.3	O
)	O
.	O
	
All	O
of	O
these	O
patients	O
who	O
received	O
FANAPT	O
were	O
participating	O
in	O
multiple-dose	O
clinical	O
trials	O
.	O
	
Placebo	O
plus	O
prednisone	O
5	O
mg	O
twice	O
daily	O
was	O
given	O
to	O
control	O
patients	O
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
penile	O
injury	O
should	O
be	O
promptly	O
evaluated	O
to	O
assess	O
for	O
corporal	O
rupture	O
or	O
severe	O
penile	O
hematoma	O
which	O
may	O
require	O
surgical	O
intervention	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Mineralocorticoid	B
excess	I
:	O
Use	O
ZYTIGA	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiovascular	O
disease	O
.	O
	
Patients	O
were	O
not	O
eligible	O
if	O
AST	O
and/or	O
ALT	O
>	O
=2.5*	O
ULN	O
in	O
the	O
absence	O
of	O
liver	O
metastases	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Cleviprex	O
clinical	O
development	O
included	O
19	O
studies	O
,	O
with	O
99	O
healthy	O
subjects	O
and	O
1307	O
hypertensive	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
clevidipine	O
(	O
1406	O
total	O
exposures	O
)	O
.	O
	
5.4	O
Neuropsychiatric	O
Symptoms	O
Confusional	B
state	I
,	O
psychotic	B
symptoms	I
,	O
and	O
hallucinations	B
were	O
reported	O
more	O
frequently	O
as	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
POTIGA	O
than	O
in	O
those	O
treated	O
with	O
placebo	O
in	O
placebo-controlled	O
epilepsy	O
trials	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
epistaxis	B
,	O
hemoptysis	B
,	O
pulmonary	B
embolism	I
.	O
	
Do	O
not	O
use	O
NULOJIX	O
in	O
transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
or	O
with	O
unknown	O
EBV	O
serostatus	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Sustained	O
blood	B
pressure	I
increases	I
could	O
have	O
adverse	O
consequences	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
permanent	O
discontinuation	O
in	O
patients	O
treated	O
with	O
COMETRIQ	O
were	O
:	O
hypocalcemia	B
,	O
increased	B
lipase	I
,	O
PPES	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
hypertension	B
,	O
nausea	B
,	O
pancreatitis	B
,	O
tracheal	B
fistula	I
formation	I
and	O
vomiting	B
.	O
	
Sustained	O
decreases	O
in	O
eGFR	O
were	O
seen	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Across	O
all	O
short-	O
and	O
long-term	O
studies	O
,	O
the	O
overall	O
mean	O
change	O
from	O
baseline	O
at	O
endpoint	O
was	O
2.1	O
kg	O
.	O
	
(	O
5.6	O
)	O
}	O
}	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Alcon	O
Laboratories	O
,	O
Inc.	O
at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
1	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
the	O
placebo-controlled	O
trial	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
in	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
in	O
the	O
placebo-treated	O
patients	O
.	O
	
The	O
following	O
risks	O
,	O
including	O
appropriate	O
action	O
to	O
be	O
taken	O
,	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1-5.13	O
)	O
]	O
:	O
hypertension	B
,	O
arterial	B
thromboembolic	I
events	I
,	O
venous	B
thromboembolic	I
events	I
,	O
hemorrhage	B
,	O
cardiac	B
failure	I
,	O
gastrointestinal	B
perforation	I
and	O
fistula	B
formation	I
,	O
thyroid	B
dysfunction	I
,	O
wound	B
healing	I
complications	I
,	O
RPLS	B
,	O
proteinuria	B
,	O
elevation	B
of	I
liver	I
enzymes	I
,	O
hepatic	B
impairment	I
and	O
fetal	O
development	O
.	O
	
Approximately	O
1162	O
patients	O
have	O
received	O
more	O
than	O
2	O
years	O
of	O
treatment	O
with	O
TECFIDERA	O
.	O
	
Laboratory	O
and	O
Imaging	O
Tests	O
Increases	O
in	O
Serum	O
Potassium	O
In	O
a	O
pooled	O
population	O
of	O
patients	O
(	O
N=723	O
)	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
45	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
increases	B
in	I
serum	I
potassium	I
to	O
greater	O
than	O
5.4	O
mEq/L	O
and	O
15	O
%	O
above	O
baseline	O
occurred	O
in	O
5.3	O
%	O
,	O
5.0	O
%	O
,	O
and	O
8.8	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
A	O
total	O
of	O
3876	O
women	O
were	O
exposed	O
to	O
placebo	O
and	O
3886	O
women	O
were	O
exposed	O
to	O
Prolia	O
administered	O
subcutaneously	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
dose	O
.	O
	
S	O
Includes	O
patients	O
treated	O
with	O
flexible	O
dose	O
of	O
SAPHRIS	O
5	O
or	O
10	O
mg	O
twice	O
daily	O
(	O
N=90	O
)	O
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
serum	B
magnesium	I
levels	I
increased	I
by	O
0.2	O
%	O
,	O
9.2	O
%	O
,	O
and	O
14.8	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
No	O
deaths	B
,	O
intubations	O
,	O
or	O
serious	O
adverse	O
reactions	O
related	O
to	O
asthma	B
exacerbation	I
were	O
reported	O
in	O
this	O
trial	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Seizure	O
In	O
Study	O
1	O
,	O
which	O
enrolled	O
patients	O
who	O
previously	O
received	O
docetaxel	O
,	O
7	O
of	O
800	O
(	O
0.9	O
%	O
)	O
patients	O
treated	O
with	O
XTANDI	O
experienced	O
a	O
seizure	B
and	O
no	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
Prescribers	O
should	O
exercise	O
caution	O
in	O
considering	O
the	O
use	O
of	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
in	O
patients	O
with	O
central	O
or	O
peripheral	O
nervous	O
system	O
demyelinating	O
disorders	O
.	O
	
Three	O
additional	O
subjects	O
tested	O
positive	O
for	O
binding	O
antibodies	O
after	O
receiving	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
.	O
	
*	O
Screen	O
patients	O
for	O
acute	O
kidney	O
injury	O
and	O
other	O
conditions	O
that	O
may	O
reduce	O
renal	O
function	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
,	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
The	O
most	O
common	O
key	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
and	O
elevated	B
partial	I
thromboplastin	I
time	I
.	O
	
In	O
Study	O
1	O
,	O
all	O
Grades	O
of	O
adverse	O
events	O
were	O
reported	O
for	O
the	O
following	O
adverse	O
events	O
of	O
special	O
interest	O
:	O
allergy	B
,	O
pancreatitis	B
,	O
coagulopathy	B
(	O
hemorrhage	B
,	O
thrombosis	B
or	O
infarct	B
)	O
,	O
hyperbilirubinemia	B
,	O
hyperglycemia	B
,	O
hyperlipidemia	B
,	O
ketoacidosis	B
,	O
and	O
CNS	B
events	I
,	O
and	O
cerebral	B
venous	I
thrombosis	I
)	O
and	O
only	O
Grade	O
3	O
and	O
4	O
events	O
were	O
reported	O
for	O
other	O
adverse	O
events	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
more	O
frequently	O
reported	O
in	O
women	O
treated	O
with	O
DUAVEE	O
than	O
placebo	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
Patients	O
treated	O
with	O
botulinum	O
toxin	O
may	O
require	O
immediate	O
medical	O
attention	O
should	O
they	O
develop	O
problems	O
with	O
swallowing	O
,	O
speech	O
or	O
respiratory	O
disorders	O
.	O
	
5.2	O
Concomitant	O
Use	O
with	O
CYP3A	O
Inducers	O
Use	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
,	O
such	O
as	O
rifampin	O
,	O
substantially	O
decreases	O
the	O
exposure	O
of	O
ivacaftor	O
,	O
which	O
may	O
reduce	O
the	O
therapeutic	O
effectiveness	O
of	O
KALYDECO	O
.	O
	
All	O
subjects	O
were	O
queried	O
about	O
the	O
presence	O
of	O
skin	O
and	O
scalp	O
symptoms	O
;	O
the	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O
	
6-Month	O
Trials	O
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
in	O
Table	O
1	O
is	O
based	O
on	O
2	O
placebo-controlled	O
,	O
6-month	O
clinical	O
trials	O
(	O
Trials	O
1	O
and	O
2	O
;	O
n	O
=	O
1,224	O
and	O
n	O
=	O
1,030	O
,	O
respectively	O
)	O
.	O
	
6.3	O
Immunogenicity	O
A	O
biosensor	O
binding	O
assay	O
or	O
a	O
bridging	O
immunoassay	O
was	O
used	O
to	O
detect	O
antibodies	O
directed	O
against	O
canakinumab	O
in	O
patients	O
who	O
received	O
ILARIS	O
.	O
	
Presence	O
of	O
antibody	O
did	O
not	O
correlate	O
with	O
reduced	O
efficacy	O
as	O
measured	O
by	O
HbA1c	O
and	O
fasting	O
plasma	O
glucose	O
or	O
specific	O
adverse	O
reactions	O
.	O
	
Withhold	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
for	O
uncomplicated	O
DVT	O
or	O
PE	O
;	O
if	O
improved	O
within	O
3	O
weeks	O
,	O
trametinib	O
may	O
be	O
resumed	O
at	O
a	O
lower	O
dose	O
level	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
*	O
Renal	B
failure	I
,	O
including	O
cases	O
with	O
fatal	B
outcomes	O
,	O
has	O
been	O
reported	O
.	O
	
(	O
5.2	O
)	O
*	O
Development	O
of	O
drug-resistant	O
bacteria	O
:	O
Only	O
use	O
DIFICID	O
for	O
infection	O
proven	O
or	O
strongly	O
suspected	O
to	O
be	O
caused	O
by	O
C.	O
difficile	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
(	O
5.12	O
)	O
.	O
	
Consider	O
discontinuing	O
use	O
if	O
severe	O
symptoms	O
develop	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.8	O
)	O
]	O
.	O
	
This	O
proteinuria	B
was	O
not	O
associated	O
with	O
increases	B
in	I
BUN	I
and	O
was	O
generally	O
transient	O
.	O
	
Consider	O
these	O
risks	O
when	O
scheduling	O
patients	O
for	O
spinal	O
procedures	O
.	O
	
Table	O
3	O
presents	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
study	O
.	O
	
Ear	O
and	O
Labyrinth	O
Disorders	O
:	O
deafness	B
,	O
tinnitus	B
,	O
vertigo	B
.	O
	
Antiemetic	O
prophylaxis	O
is	O
recommended	O
.	O
	
The	O
population	O
exposed	O
to	O
TAFINLAR	O
was	O
60	O
%	O
male	O
,	O
99	O
%	O
white	O
,	O
and	O
had	O
a	O
median	O
age	O
of	O
53	O
years	O
.	O
	
Tests	O
for	O
latent	O
tuberculosis	O
infection	O
may	O
also	O
be	O
falsely	O
negative	O
while	O
on	O
therapy	O
with	O
CIMZIA	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
SIMPONI	O
ARIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Peripheral	B
neuropathy	I
:	O
Monitor	O
patients	O
for	O
neuropathy	O
and	O
institute	O
dose	O
modifications	O
accordingly	O
(	O
5.1	O
)	O
.	O
	
5.3	O
Hepatic	O
Effects	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
more	O
DALVANCE-	O
than	O
comparator-treated	O
subjects	O
with	O
normal	O
baseline	O
transaminase	O
levels	O
had	O
post-baseline	O
ALT	B
)	I
elevation	I
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thyroid	B
C-cell	I
Tumors	I
:	O
See	O
Boxed	O
Warning	O
.	O
	
This	O
is	O
supplemented	O
with	O
information	O
on	O
adverse	O
drug	O
reactions	O
in	O
1326	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
who	O
received	O
XALKORI	O
250	O
mg	O
twice	O
daily	O
across	O
clinical	O
trials	O
,	O
for	O
a	O
total	O
of	O
1669	O
patients	O
across	O
all	O
clinical	O
studies	O
.	O
	
5.9	O
Suppression	O
of	O
Bone	O
Turnover	O
In	O
clinical	O
trials	O
in	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
treatment	O
with	O
Prolia	O
resulted	O
in	O
significant	O
suppression	B
of	I
bone	I
remodeling	I
as	O
evidenced	O
by	O
markers	O
of	O
bone	O
turnover	O
and	O
bone	O
histomorphometry	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
5.7	O
Laboratory	O
Tests	O
HCV-RNA	O
levels	O
should	O
be	O
monitored	O
at	O
Treatment	O
Weeks	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
,	O
at	O
the	O
end	O
of	O
treatment	O
,	O
during	O
treatment	O
follow-up	O
,	O
and	O
for	O
other	O
time	O
points	O
as	O
clinically	O
indicated	O
.	O
	
Identify	O
cause	O
and	O
manage	O
aggressively	O
.	O
	
(	O
5.6	O
)	O
*	O
Orthostatic	B
hypotension	I
:	O
Dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
can	O
occur	O
with	O
standing	O
.	O
	
(	O
5.3	O
)	O
*	O
Suicidal	B
thoughts	I
:	O
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
an	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=5	O
%	O
of	O
GD1	O
Patients	O
Switching	O
from	O
Enzyme	O
Replacement	O
Therapy	O
to	O
CERDELGA	O
and	O
More	O
Frequently	O
than	O
Imiglucerase	O
(	O
Trial	O
2	O
)	O
Trial	O
2	O
was	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
CERDELGA	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
If	O
keratitis	O
is	O
diagnosed	O
,	O
the	O
benefits	O
and	O
risks	O
of	O
continuing	O
treatment	O
should	O
be	O
carefully	O
considered	O
.	O
	
5	O
(	O
tartrazine	O
)	O
sensitivity	O
in	O
the	O
general	O
population	O
is	O
low	O
,	O
it	O
is	O
frequently	O
seen	O
in	O
patients	O
who	O
also	O
have	O
aspirin	O
hypersensitivity	O
.	O
	
5.12	O
Thrombotic	O
Thrombocytopenic	O
Purpura/Hemolytic	O
Uremic	O
Syndrome	O
Cases	O
of	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
including	O
fatal	B
outcome	O
have	O
been	O
reported	O
in	O
patients	O
who	O
received	O
Kyprolis	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.3	O
%	O
(	O
4/1441	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
or	O
depressed	B
mood	I
compared	O
with	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
Key	O
observed	O
laboratory	O
abnormalities	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
ENTEREG	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
taken	O
therapeutic	O
doses	O
of	O
opioids	O
for	O
more	O
than	O
7	O
consecutive	O
days	O
immediately	O
prior	O
to	O
taking	O
ENTEREG	O
.	O
	
(	O
5.12	O
)	O
*	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
:	O
Consider	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
for	O
onset	O
of	O
visual	O
or	O
neurological	O
symptoms	O
;	O
discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
5.7	O
Bone	O
Fracture	O
An	O
increased	O
risk	O
of	O
bone	B
fracture	I
,	O
occurring	O
as	O
early	O
as	O
12	O
weeks	O
after	O
treatment	O
initiation	O
,	O
was	O
observed	O
in	O
patients	O
using	O
INVOKANA	O
.	O
	
Perform	O
appropriate	O
monitoring	O
and	O
treat	O
hyperglycemia	O
with	O
insulin	O
,	O
as	O
necessary	O
(	O
5.3	O
)	O
*	O
Thrombosis	B
,	O
hemorrhage	B
:	O
discontinue	O
ERWINAZE	O
until	O
resolved	O
(	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Grade	O
3	O
and	O
4	O
hypersensitivity	B
reactions	I
after	O
the	O
use	O
of	O
ERWINAZE	O
have	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
risk	O
of	O
the	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
and	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
Seizure	B
occurred	O
from	O
31	O
to	O
603	O
days	O
after	O
initiation	O
of	O
XTANDI	O
.	O
	
Table	O
10	O
compares	O
the	O
incidence	O
of	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
occurring	O
more	O
frequently	O
with	O
AFINITOR	O
than	O
with	O
placebo	O
.	O
	
Discontinuation	O
of	O
SIMPONI	O
ARIA	O
should	O
be	O
considered	O
if	O
these	O
disorders	O
develop	O
.	O
	
The	O
adult	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
SAPHRIS	O
consisting	O
of	O
over	O
4565	O
patients	O
and/or	O
healthy	O
subjects	O
exposed	O
to	O
one	O
or	O
more	O
sublingual	O
doses	O
of	O
SAPHRIS	O
.	O
	
Serious	O
Adverse	O
Reactions	O
and	O
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
Serious	O
adverse	O
reactions	O
occurred	O
in	O
109/1778	O
(	O
6.1	O
%	O
)	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
in	O
80/1224	O
(	O
6.5	O
%	O
)	O
of	O
patients	O
treated	O
with	O
comparator	O
.	O
	
Of	O
these	O
,	O
two	O
studies	O
were	O
randomized	O
,	O
double-blind	O
,	O
single	O
treatment	O
,	O
placebo	O
controlled	O
studies	O
with	O
subsequent	O
optional	O
open	O
label	O
treatment	O
in	O
which	O
dose	O
optimization	O
(	O
250	O
to	O
1000	O
Units	O
per	O
treatment	O
)	O
over	O
the	O
course	O
of	O
5	O
treatment	O
cycles	O
was	O
allowed	O
.	O
	
Anaphylaxis	B
,	O
presenting	O
as	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
retching	B
,	O
and	O
vomiting	B
)	O
in	O
conjunction	O
with	O
urticaria	B
,	O
have	O
been	O
reported	O
to	O
occur	O
during	O
Vimizim	O
infusions	O
,	O
regardless	O
of	O
duration	O
of	O
the	O
course	O
of	O
treatment	O
.	O
	
After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
endpoint	O
in	O
weight	O
z-score	O
for	O
SAPHRS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
was	O
0.11	O
,	O
0.08	O
and	O
0.09	O
SD	O
versus	O
0.02	O
SD	O
for	O
placebo	O
,	O
respectively	O
.	O
	
Volume	O
Depletion	O
FARXIGA	O
causes	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
reductions	B
in	I
intravascular	I
volume	I
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
and	O
Syncope	O
FANAPT	O
can	O
induce	O
orthostatic	B
hypotension	I
associated	O
with	O
dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
.	O
	
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
(	O
5.5	O
)	O
.	O
	
Bleeding	B
events	O
related	O
to	O
SSRIs	O
and	O
SNRIs	O
have	O
ranged	O
from	O
ecchymosis	B
,	O
hematoma	B
,	O
epistaxis	B
,	O
and	O
petechiae	B
to	O
life-threatening	O
hemorrhages	B
.	O
	
Recipients	O
without	O
immunity	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
are	O
at	O
a	O
particularly	O
increased	O
risk	O
;	O
therefore	O
,	O
use	O
in	O
EBV	O
seropositive	O
patients	O
only	O
.	O
	
5.9	O
Preparation	O
and	O
Administration	O
Errors	O
Preparation	O
and	O
administration	O
errors	O
have	O
occurred	O
with	O
BLINCYTO	O
treatment	O
.	O
	
Cytopenias	O
:	O
Grade	O
3	O
neutropenia	B
occurred	O
in	O
28	O
%	O
(	O
143/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
in	O
Study	O
1	O
,	O
and	O
29	O
%	O
(	O
144/503	O
)	O
of	O
patients	O
experienced	O
Grade	O
4	O
neutropenia	B
.	O
	
Because	O
most	O
trials	O
included	O
in	O
the	O
analysis	O
did	O
not	O
extend	O
beyond	O
24	O
weeks	O
,	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
beyond	O
24	O
weeks	O
could	O
not	O
be	O
assessed	O
.	O
	
Skin	O
,	O
subcutaneous	O
tissue	O
disorders	O
:	O
hyperhidrosis	B
,	O
periorbital	B
edema	I
,	O
photosensitivity	B
reaction	I
,	O
pruritis	B
,	O
urticaria	B
,	O
rash	B
,	O
Henoch-Schonlein	B
purpura	I
.	O
	
Safe	O
handling	O
should	O
be	O
ensured	O
to	O
minimize	O
radiation	O
exposure	O
to	O
the	O
patient	O
and	O
health	O
care	O
workers	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
.	O
	
The	O
most	O
serious	O
adverse	O
reaction	O
reported	O
in	O
clinical	O
trials	O
with	O
Ferriprox	O
was	O
agranulocytosis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
73	O
(	O
50	O
%	O
)	O
subjects	O
.	O
	
Six	O
weeks	O
after	O
the	O
eighth	O
injection	O
(	O
fourth	O
treatment	O
cycle	O
)	O
of	O
XIAFLEX	O
,	O
>	O
99	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
high	O
titers	O
of	O
antibodies	O
to	O
both	O
AUX-I	O
and	O
AUX-II	O
.	O
	
Patients	O
received	O
5-10	O
days	O
of	O
an	O
approved	O
parenteral	O
anticoagulant	O
therapy	O
followed	O
by	O
6	O
months	O
,	O
with	O
mean	O
exposure	O
of	O
164	O
days	O
,	O
of	O
oral	O
only	O
treatment	O
;	O
warfarin	O
was	O
overlapped	O
with	O
parenteral	O
therapy	O
.	O
	
Four	O
percent	O
(	O
20/503	O
)	O
of	O
patients	O
experienced	O
peripheral	B
motor	I
neuropathy	I
of	O
any	O
grade	O
and	O
2	O
%	O
(	O
8/503	O
)	O
of	O
patients	O
developed	O
Grade	O
3	O
peripheral	B
motor	I
neuropathy	I
.	O
	
Only	O
physicians	O
experienced	O
in	O
immunosuppressive	O
therapy	O
and	O
management	O
of	O
kidney	O
transplant	O
patients	O
should	O
prescribe	O
NULOJIX	O
.	O
	
Other	O
serious	O
adverse	O
reactions	O
included	O
thromboembolic	B
complications	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
rash	B
was	O
higher	O
in	O
females	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
Discontinue	O
INTELENCE	O
(	O
r	O
)	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
severe	O
skin	O
reactions	O
or	O
hypersensitivity	O
reactions	O
develop	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
severe	O
rash	O
or	O
rash	O
accompanied	O
by	O
fever	O
,	O
general	O
malaise	O
,	O
fatigue	O
,	O
muscle	O
or	O
joint	O
aches	O
,	O
blisters	O
,	O
oral	O
lesions	O
,	O
conjunctivitis	O
,	O
facial	O
edema	O
,	O
hepatitis	O
,	O
eosinophilia	O
,	O
angioedema	O
)	O
.	O
	
Major	O
bleeding	B
is	O
defined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
>	O
=2	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
a	O
fatal	B
outcome	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
AstraZeneca	O
at	O
1-800-	O
236-9933	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
AdreView	O
may	O
increase	O
release	O
of	O
norepinephrine	O
from	O
chromaffin	O
granules	O
and	O
produce	O
a	O
transient	B
episode	I
of	I
hypertension	I
,	O
although	O
this	O
was	O
not	O
observed	O
in	O
the	O
clinical	O
studies	O
.	O
	
*	O
Fatal	B
and	O
serious	O
pneumonitis	B
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
.	O
	
*	O
Hypersensitivity	B
Reactions	O
:	O
Discontinue	O
TRULICITY	O
if	O
suspected	O
.	O
	
(	O
N	O
for	O
males	O
:	O
Placebo=716	O
,	O
FARXIGA	O
5	O
mg=564	O
,	O
FARXIGA	O
10	O
mg=595	O
)	O
.	O
	
Patients	O
who	O
develop	O
symptoms	O
of	O
hyperglycemia	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
should	O
undergo	O
fasting	O
blood	O
glucose	O
testing	O
.	O
	
The	O
abnormalities	O
seen	O
in	O
patients	O
treated	O
with	O
POTIGA	O
have	O
funduscopic	B
features	I
similar	I
to	I
those	I
seen	I
in	I
retinal	I
pigment	I
dystrophies	I
that	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Severe	O
Diarrhea	B
or	O
Colitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Pneumonitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Intestinal	B
Perforation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Cutaneous	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=20	O
%	O
)	O
are	O
diarrhea	B
,	O
pyrexia	B
,	O
fatigue	B
,	O
nausea	B
,	O
cough	B
,	O
pneumonia	B
,	O
abdominal	B
pain	I
,	O
chills	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
Six	O
patients	O
out	O
of	O
the	O
403	O
who	O
were	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
in	O
Studies	O
1	O
and	O
2	O
(	O
1.5	O
%	O
)	O
were	O
reported	O
to	O
have	O
developed	O
CNS	B
infections	I
,	O
including	O
2	O
cases	O
of	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
Chagas	B
encephalitis	I
with	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
cerebral	B
aspergillosis	I
,	O
one	O
case	O
of	O
West	B
Nile	I
encephalitis	I
,	O
and	O
one	O
case	O
of	O
PML	B
(	O
discussed	O
above	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Arbor	O
Pharmaceuticals	O
,	O
LLC	O
at	O
1-866-516-4950	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Other	O
Adverse	O
Reactions	O
Other	O
infrequent	O
adverse	O
reactions	O
(	O
occurring	O
in	O
less	O
than	O
3	O
%	O
of	O
RA	O
patients	O
)	O
were	O
similar	O
to	O
those	O
seen	O
in	O
Crohn	O
's	O
disease	O
patients	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
clinical	O
development	O
program	O
excluded	O
patients	O
with	O
active	O
autoimmune	O
disease	O
or	O
those	O
receiving	O
systemic	O
immunosuppression	O
for	O
organ	O
transplantation	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
[	O
see	O
Contraindications	O
(	O
4.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Risk	O
of	O
Suicidal	B
Thoughts	I
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Events	O
in	O
Drug	O
Patients/Incidence	O
in	O
Placebo	O
Patients	O
Risk	O
Differences	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
median	O
duration	O
of	O
treatment	O
was	O
6.4	O
months	O
(	O
range	O
0.03	O
to	O
22.0	O
)	O
for	O
patients	O
who	O
received	O
INLYTA	O
and	O
5.0	O
months	O
(	O
range	O
0.03	O
to	O
20.1	O
)	O
for	O
patients	O
who	O
received	O
sorafenib	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Acute	B
pancreatitis	I
:	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
pancreatitis	I
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Ipsen	O
Biopharmaceuticals	O
,	O
Inc.	O
at	O
877-397-7671	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
TAFINLAR	O
was	O
studied	O
in	O
open-label	O
,	O
single-arm	O
trials	O
and	O
in	O
an	O
open-label	O
,	O
randomized	O
,	O
active-controlled	O
trial	O
.	O
	
In	O
non-clinical	O
studies	O
in	O
rats	O
and	O
rabbits	O
,	O
cabazitaxel	O
was	O
embryotoxic	B
,	O
fetotoxic	B
,	O
and	O
abortifacient	B
at	O
exposures	O
significantly	O
lower	O
than	O
those	O
expected	O
at	O
the	O
recommended	O
human	O
dose	O
level	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
one	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
the	O
same	O
or	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-877-900-6479	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
EXCERPT	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
In	O
a	O
3-week	O
monotherapy	O
trial	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
in	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
treated	O
with	O
SAPHRIS	O
were	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
and	O
increased	B
weight	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
frequently	O
reported	O
adverse	O
events	O
(	O
>	O
=4	O
%	O
)	O
for	O
Toviaz	O
were	O
:	O
dry	B
mouth	I
(	O
placebo	O
,	O
7	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
19	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
35	O
%	O
)	O
and	O
constipation	B
(	O
placebo	O
,	O
2	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
4	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
6	O
%	O
)	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
Chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73	O
m2	O
)	O
,	O
orAcute	O
kidney	O
injury	O
.	O
	
Because	O
the	O
elimination	O
of	O
fingolimod	O
after	O
discontinuation	O
may	O
take	O
up	O
to	O
2	O
months	O
,	O
continue	O
monitoring	O
for	O
infections	O
throughout	O
this	O
period	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
52	O
weeks	O
(	O
range	O
24	O
to	O
89	O
weeks	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
47	O
weeks	O
(	O
range	O
14	O
to	O
88	O
weeks	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
Monitor	O
for	O
hypertension	O
and	O
treat	O
as	O
needed	O
.	O
	
Cases	O
of	O
central	B
demyelination	I
,	O
MS	B
,	O
optic	B
neuritis	I
,	O
and	O
peripheral	B
demyelinating	I
polyneuropathy	I
have	O
rarely	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
If	O
a	O
serious	O
hypersensitivity	O
reaction	O
occurs	O
,	O
discontinue	O
ERWINAZE	O
and	O
initiate	O
appropriate	O
therapy	O
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
,	O
and	O
in	O
approved	O
indications	O
,	O
cases	O
of	O
spread	O
of	O
effect	O
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Due	O
to	O
the	O
low	O
rate	O
of	O
events	O
in	O
both	O
groups	O
,	O
it	O
is	O
not	O
possible	O
to	O
conclude	O
that	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
with	O
DUAVEE	O
is	O
different	O
from	O
that	O
seen	O
with	O
other	O
estrogen	O
therapies	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Although	O
other	O
risk	O
factors	O
were	O
present	O
in	O
some	O
cases	O
(	O
such	O
as	O
corticosteroid	O
use	O
and/or	O
exposure	O
to	O
radiation	O
)	O
,	O
a	O
possible	O
risk	O
attributable	O
to	O
KALYDECO	O
can	O
not	O
be	O
excluded	O
.	O
	
Discontinue	O
GILOTRIF	O
in	O
patients	O
who	O
develop	O
life-threatening	O
bullous	O
,	O
blistering	O
,	O
or	O
exfoliating	O
lesions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
In	O
one	O
trial	O
INVOKANA	O
was	O
used	O
as	O
monotherapy	O
and	O
in	O
three	O
trials	O
INVOKANA	O
was	O
used	O
as	O
add-on	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
*	O
Flushing	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
The	O
assay	O
should	O
have	O
a	O
lower	O
limit	O
of	O
HCV-RNA	O
quantification	O
of	O
equal	O
to	O
or	O
less	O
than	O
25	O
IU	O
per	O
mL	O
,	O
and	O
a	O
limit	O
of	O
HCV-RNA	O
detection	O
of	O
approximately	O
10	O
to	O
15	O
IU	O
per	O
mL	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Not	O
for	O
Systemic	O
Infections	O
Since	O
there	O
is	O
minimal	O
systemic	O
absorption	O
of	O
fidaxomicin	O
,	O
DIFICID	O
is	O
not	O
effective	O
for	O
treatment	O
of	O
systemic	O
infections	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
Pancreatitis	B
(	O
including	O
fatal	B
outcomes	O
)	O
.	O
	
Before	O
using	O
DALVANCE	O
,	O
inquire	O
carefully	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
glycopeptides	O
,	O
and	O
due	O
to	O
the	O
possibility	O
of	O
cross-sensitivity	O
,	O
exercise	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
glycopeptide	O
allergy	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
dose	O
modifications	O
(	O
generally	O
of	O
PegIntron/REBETOL	O
)	O
due	O
to	O
anemia	B
occurred	O
twice	O
as	O
often	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
(	O
26	O
%	O
)	O
compared	O
to	O
PegIntron/REBETOL	O
(	O
13	O
%	O
)	O
.	O
	
If	O
the	O
QTc	O
Bazett	O
interval	O
is	O
>	O
=500	O
ms	O
,	O
discontinue	O
MULTAQ	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
It	O
may	O
harm	O
them	O
.	O
	
5.3	O
Neutropenia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
seven	O
percent	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
had	O
neutrophil	B
counts	I
of	I
less	I
than	I
0.5	I
*	I
10	I
9	I
per	I
L	I
compared	O
to	O
4	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Opportunistic	B
infections	I
organisms	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
,	O
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF-blockers	O
.	O
	
Discontinue	O
PROMACTA	O
if	O
ALT	O
levels	O
increase	O
to	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
ULN	O
in	O
patients	O
with	O
normal	O
liver	O
function	O
or	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
baseline	O
in	O
patients	O
with	O
pre-treatment	O
elevations	O
in	O
transaminases	O
and	O
are	O
:	O
*	O
progressively	O
increasing	O
,	O
or	O
*	O
persistent	O
for	O
greater	O
than	O
or	O
equal	O
to	O
4	O
weeks	O
,	O
or	O
*	O
accompanied	O
by	O
increased	O
direct	O
bilirubin	O
,	O
or	O
*	O
accompanied	O
by	O
clinical	O
symptoms	O
of	O
liver	O
injury	O
or	O
evidence	O
for	O
hepatic	O
decompensation	O
.	O
	
This	O
Patient	O
Information	O
summarizes	O
the	O
most	O
important	O
information	O
about	O
DUAVEE	O
.	O
	
Overall	O
,	O
abnormalities	B
in	I
liver	I
tests	I
(	I
ALT	I
)	O
were	O
reported	O
with	O
similar	O
frequency	O
in	O
the	O
DALVANCE	O
and	O
comparator	O
arms	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
study	O
drug	O
due	O
to	O
anemia	B
was	O
1	O
%	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
1	O
%	O
in	O
subjects	O
who	O
received	O
PegIntron/REBETOL	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
Teflaro	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
If	O
pancreatitis	O
is	O
confirmed	O
,	O
TANZEUM	O
should	O
not	O
be	O
restarted	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
If	O
an	O
allergic	O
reaction	O
occurs	O
,	O
treatment	O
with	O
DALVANCE	O
should	O
be	O
discontinued	O
.	O
	
Failure	O
to	O
block	O
thyroid	O
uptake	O
of	O
iodine	O
123	O
may	O
result	O
in	O
an	O
increased	O
long	O
term	O
risk	O
for	O
thyroid	O
neoplasia	O
.	O
	
Twenty-five	O
of	O
these	O
121	O
patients	O
(	O
21	O
%	O
)	O
had	O
detectable	O
anti-glucarpidase	O
antibodies	O
following	O
VORAXAZE	O
administration	O
,	O
of	O
which	O
19	O
received	O
a	O
single	O
dose	O
of	O
VORAXAZE	O
and	O
6	O
received	O
two	O
doses	O
of	O
VORAXAZE	O
.	O
	
Table	O
1	O
summarizes	O
adverse	O
reactions	O
reported	O
at	O
a	O
rate	O
of	O
at	O
least	O
1	O
%	O
in	O
ULORIC	O
treatment	O
groups	O
and	O
at	O
least	O
0.5	O
%	O
greater	O
than	O
placebo	O
.	O
	
EBV	O
Serostatus	O
The	O
risk	O
of	O
PTLD	B
was	O
higher	O
in	O
EBV	O
seronegative	O
patients	O
compared	O
to	O
EBV	O
seropositive	O
patients	O
.	O
	
The	O
principal	O
efficacy	O
study	O
evaluating	O
the	O
efficacy	O
and	O
safety	O
of	O
HORIZANT	O
in	O
the	O
management	O
of	O
PHN	O
was	O
a	O
12-week	O
,	O
double-blind	O
,	O
multicenter	O
study	O
comparing	O
1,200	O
mg/day	O
,	O
2,400	O
mg/day	O
and	O
3,600	O
mg/day	O
to	O
placebo	O
.	O
	
Reduce	O
or	O
discontinue	O
NORTHERA	O
if	O
supine	O
hypertension	O
persists	O
.	O
	
The	O
study	O
population	O
included	O
34	O
males	O
and	O
26	O
females	O
(	O
n=60	O
)	O
in	O
the	O
alglucosidase	O
alfa	O
group	O
and	O
11	O
males	O
and	O
19	O
females	O
(	O
n=30	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
*	O
Corrugator	O
injections	O
should	O
be	O
placed	O
at	O
least	O
1	O
cm	O
above	O
the	O
bony	O
supraorbital	O
ridge	O
.	O
	
Carefully	O
weigh	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
OTEZLA	O
in	O
patients	O
with	O
a	O
history	O
of	O
depression	O
and/or	O
suicidal	O
thoughts	O
or	O
behavior	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Mortality	O
There	O
were	O
more	O
deaths	B
reported	O
with	O
BENLYSTA	O
than	O
with	O
placebo	O
during	O
the	O
controlled	O
period	O
of	O
the	O
clinical	O
trials	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	B
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	B
weakness	I
on	I
one	I
side	I
of	I
the	I
body	I
or	O
clumsiness	B
of	I
limbs	I
,	O
disturbance	B
of	I
vision	I
,	O
and	O
changes	B
in	I
thinking	I
leading	O
to	O
confusion	B
and	O
personality	B
changes	I
.	O
	
The	O
rates	O
of	O
adverse	O
reactions	O
below	O
were	O
derived	O
from	O
two	O
randomized	O
,	O
multi-center	O
,	O
vehicle-controlled	O
clinical	O
trials	O
and	O
one	O
open-label	O
study	O
in	O
subjects	O
with	O
head	O
lice	O
infestation	O
.	O
	
Because	O
of	O
its	O
anticholinergic	O
effects	O
,	O
XEOMIN	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
of	O
developing	O
narrow	O
angle	O
glaucoma	O
.	O
	
There	O
is	O
no	O
known	O
treatment	O
for	O
established	O
cases	O
of	O
tardive	O
dyskinesia	O
,	O
although	O
the	O
syndrome	O
may	O
remit	O
,	O
partially	O
or	O
completely	O
,	O
if	O
antipsychotic	O
treatment	O
is	O
withdrawn	O
.	O
	
The	O
most	O
frequently	O
reported	O
ADR	O
at	O
least	O
Grade	O
2	O
in	O
severity	O
was	O
rash	B
(	O
10.0	O
%	O
)	O
.	O
	
The	O
duration	O
of	O
Prolia	O
exposure	O
to	O
time	O
of	O
atypical	B
femoral	I
fracture	I
diagnosis	O
was	O
as	O
early	O
as	O
21/2	O
years	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
The	O
causes	O
of	O
death	B
in	O
the	O
remaining	O
subjects	O
varied	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
associated	O
with	O
TREANDA	O
treatment	O
has	O
occurred	O
in	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
NESINA	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
anaphylactic	B
shock	I
(	O
fatal	B
)	O
,	O
urticaria	B
,	O
and	O
angioedema	B
have	O
been	O
reported	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	O
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	O
weakness	O
on	O
one	O
side	O
of	O
the	O
body	O
or	O
clumsiness	O
of	O
limbs	O
,	O
disturbance	O
of	O
vision	O
,	O
and	O
changes	O
in	O
thinking	O
,	O
memory	O
,	O
and	O
orientation	O
leading	O
to	O
confusion	O
and	O
personality	O
changes	O
.	O
	
Local	B
skin	I
reactions	I
typically	O
occurred	O
within	O
1	O
day	O
of	O
treatment	O
initiation	O
,	O
peaked	O
in	O
intensity	O
up	O
to	O
1	O
week	O
following	O
completion	O
of	O
treatment	O
,	O
and	O
resolved	O
within	O
2	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
face	O
and	O
scalp	O
,	O
and	O
within	O
4	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
trunk	O
and	O
extremities	O
.	O
	
Psoriatic	O
Arthritis	O
Clinical	O
Study	O
CIMZIA	O
has	O
been	O
studied	O
in	O
409	O
patients	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
in	O
a	O
placebo-controlled	O
trial	O
.	O
	
*	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
All	O
infections	B
#	O
27	O
(	O
7	O
)	O
26	O
(	O
6	O
)	O
55	O
(	O
14	O
)	O
46	O
(	O
11	O
)	O
Tuberculosis	B
2	O
(	O
1	O
)	O
1	O
(	O
<	O
1	O
)	O
6	O
(	O
2	O
)	O
1	O
(	O
<	O
1	O
)	O
Infections	O
Reported	O
in	O
the	O
CNS	O
Following	O
three	O
years	O
of	O
treatment	O
in	O
Studies	O
1	O
and	O
2	O
,	O
cryptococcal	B
meningitis	I
was	O
reported	O
in	O
one	O
patient	O
out	O
of	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
(	O
0.2	O
%	O
)	O
and	O
one	O
patient	O
out	O
of	O
the	O
405	O
treated	O
with	O
the	O
cyclosporine	O
control	O
(	O
0.2	O
%	O
)	O
.	O
	
(	O
5.5	O
)	O
item	O
{	O
Fungal	O
infections-	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
The	O
median	O
number	O
of	O
dosing	O
delays	O
was	O
one	O
in	O
patients	O
receiving	O
COMETRIQ	O
compared	O
to	O
none	O
in	O
patients	O
receiving	O
placebo	O
.	O
	
5.4	O
Abnormal	O
Bleeding	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	B
events	O
.	O
	
In	O
the	O
patients	O
who	O
developed	O
antibodies	O
during	O
treatment	O
,	O
the	O
median	O
titer	O
(	O
by	O
dilution	O
method	O
)	O
was	O
8	O
,	O
with	O
a	O
range	O
of	O
5	O
to	O
80	O
.	O
	
Prior	O
to	O
AdreView	O
administration	O
,	O
ensure	O
emergency	O
cardiac	O
and	O
anti-hypertensive	O
treatments	O
are	O
readily	O
available	O
.	O
	
Effects	O
of	O
fluticasone	O
furoate	O
on	O
the	O
HPA	O
axis	O
are	O
not	O
observed	O
with	O
the	O
therapeutic	O
doses	O
of	O
BREO	O
ELLIPTA	O
.	O
	
In	O
addition	O
,	O
no	O
clinical	O
safety	O
concerns	O
related	O
to	O
the	O
inhibition	O
of	O
endogenous	O
MMPs	O
have	O
been	O
observed	O
.	O
	
5.10	O
Pulmonary	O
Toxicity	O
Events	O
of	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
acute	B
respiratory	I
distress	I
syndrome	I
(	O
ARDS	B
)	O
,	O
some	O
with	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
on	O
the	O
ZYTIGA	O
arm	O
in	O
Study	O
1	O
that	O
occurred	O
with	O
a	O
>	O
=2	O
%	O
absolute	O
increase	O
in	O
frequency	O
compared	O
to	O
placebo	O
or	O
were	O
events	O
of	O
special	O
interest	O
.	O
